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Executive summary 
Introduction 
Health problem 
The anterior cruciate ligament (ACL) and posterior cruciate ligament (PCL) 
are crucial structures for providing stability in the knee joint during functio-
nal and sporting activities. The main role of the ACL is to provide restraint 
against the forward translation of the tibia on the femur and secondary con-
straint against tibial rotation and valgus and varus stress [1]. 
Patients with ruptures of the ACL/PCL, re-ruptures of the ACL/PCL or mul-
ti-ligament knee injuries can be treated using arthroscopic surgery. Yet, con-
troversy exists regarding the adequate treatment, as conservative management 
can also be an adequate treatment option depending, inter alia, on the specif-
ic health condition, and factors such as stability and activity level [2]. Based 
on the aforementioned health conditions, patients who are candidates for one 
of the following ligament reconstructions were selected as indications in this 
assessment: 
 Anterior Cruciate Ligament Reconstruction (ACLR), 
 Posterior Cruciate Ligament Reconstruction (PCLR), 
 Revision ACLR, 
 Revision PCLR or 
 Cruciate ligament reconstructions in mutli-ligament knee injuries. 
Approximately 31-37 ACL ruptures occur per 100,000 persons annually in 
Germany [2]. Similarly and according to data from the United States (US), the 
incidence of ACL ruptures in the general population is 1 in 3,500 persons [3]. 
PCL injuries are less common compared to ACL injuries – approximately 
only 1 to 44 percent of all knee injuries are PCL injuries based on data from 
the US [4, 5]. Yet, relevant data on the incidence of PCL injuries by hand-
searching was not found. Similarly, we were unable to find any relevant in-
cidence data on ACL or PCL re-ruptures and mutli-ligament knee injuries. 
Description of technology 
When reconstructing a cruciate ligament, the torn anterior cruciate ligament 
(ACL) or posterior cruciate ligament (PCL) is replaced using a graft – typi-
cally using tendons from the patient’s body (autograft) or from another exter-
nal source (allograft) [6-8]. 
Allografts to be used for ACLR or PCLR are the technology under investiga-
tion in this assessment. Allografts are reconstructive natural materials; they 
are processed cadaveric fascia lata or acellular dermal matrices of human do-
nors [9]. Allografts are taken from a cadaver Achilles tendon, a semitendi-
nosus, a gracilis, or a posterior tibialis tendon [10]. 
Both graft types are associated with benefits and harms: when using auto-
grafts, for instance, donor site morbidities and associated complications may 
be present. In theory, allografts offer a solution to donor site morbidities and 
may also lead to shorter operative time [9, 11]. Disadvantages of allografts 
may include potential disease transmission, immunologic reactions, slower 
remodelling and integration, as well as costs [7]. 
vordere und hintere 
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Research question 
Is allograft cruciate ligament reconstruction in comparison to other techniques 
of cruciate ligament reconstruction or conservative management in patients 
undergoing ACLR, PCLR, revision ACLR/PCLR or ligament reconstruction 
in multi-ligamentous injuries of the knee more effective and safe concerning 
function, activity level and symptoms, knee stability, graft failure, and com-
plications?  
 
Methods 
A systematic search for relevant publications was carried out in 4 databases 
(Medline, Embase, the Cochrane Library, and the University of York Centre 
for Reviews and Dissemination). Primary studies on allografts to be used for 
ACLR, PCLR, revision surgery or reconstructions in patients with multi-liga-
ment knee injuries were searched from inception to 19 December 2018. The 
study selection was conducted by three authors (GG, CdV, SGG). Two au-
thors (GG, SGG) screened the abstracts. The full-text screening and the ap-
praisal of the quality of the respective studies was conducted by GG and CdV. 
The risk of bias assessment of the included studies was conducted using ad-
equate tools: the Cochrane Risk of Bias Tool [12] was utilised for randomised 
controlled studies, while the Newcastle-Ottawa Scale (NOS) was applied for 
assessing the risk of bias for cohort studies [13]. Data extraction was con-
ducted by one researcher (GG) and verified by another researcher (CdV).  
A qualitative evidence synthesis was chosen. Based on the data extraction ta-
bles, data on each selected outcome category were synthesised across studies 
according to GRADE (Grading of Recommendations, Assessment, Develop-
ment and Evaluation) [14].  
In case of disagreement, a third researcher (SGG) was consulted to resolve 
disagreements. 
Clinical effectiveness 
The crucial outcomes used as evidence to derive a recommendation on the 
relative effectiveness of allografts to be used for cruciate ligament reconstruc-
tion are patient-reported function, activity level and symptoms. Included are 
the following scores: Lysholm score, Tegner score, Cincinnati Knee score, 
SANE score, IKDC score (subjective), KOOS, and the Marx activity score. 
In addition, 3 further outcomes were selected, yet only judged as important, 
but not crucial, to derive a recommendation: clinical knee stability, quality 
of life, patient satisfaction. 
Safety 
The crucial outcomes used as evidence to derive a recommendation on the 
relative safety of allografts to be used for cruciate ligament reconstruction 
included: graft failure, re-ruptures, re-operations, revisions, and other com-
plications. 
 
Allograft wirksamer und 
sicherer als autograft, 
konservatives 
Management bei 
Kreuzbandriss 
systematische 
Übersichtsarbeit 
Systematische Suche in 
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2 WissenschafterInnen  
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und Symptome 
wesentliche 
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Results 
Available evidence 
Overall, 9 studies [15-23] were eligible to be included in this assessment. All 
of these studies compared allografts to autografts in cruciate ligament recon-
struction. Of the included studies, 8 were randomised controlled trials [15, 
17-23] with unclear-high risk of bias (mainly due to the lack of blinding and 
potential selective outcome reporting), and one further comparative cohort 
study [16] with a moderate risk of bias.  
Clinical effectiveness and safety 
When assessing the relative effectiveness of allograft cruciate ligament re-
construction in comparison to autograft cruciate ligament reconstruction, the 
following evidence was found for the selected indications: 
 Anterior cruciate ligament reconstruction (ACLR): Low to moderate 
quality evidence indicating comparable effectiveness based on the cru-
cial outcome of patient-reported function, activity level and symptoms. 
Moderate certainty evidence was found indicating the inferiority of 
allografts with regard to graft failure. Yet, with regard to the other se-
lected crucial safety outcomes, the evidence was insufficient to clearly 
prove the inferiority of allografts when compared to autografts (evi-
dence base: 6 RCTs [15, 17, 19-22] with high RoB). 
 Posterior cruciate ligament reconstruction (PCLR): Very low to low 
quality evidence indicating comparable effectiveness based on the cru-
cial outcome of patient-reported function, activity level and symptoms. 
Insufficient evidence to indicate superiority or inferiority on the basis 
of comparative safety (evidence base: 2 RCTs [18, 23] with unclear-
high RoB). 
 Revision ACLR: Insufficient evidence to support or to refute that al-
lografts are superior or inferior on the basis of the selected effective-
ness and safety outcomes (evidence base: 1 comparative cohort study 
[16] with moderate RoB). 
 Revision PCLR: No evidence to support or to refute that allografts are 
superior or inferior on the basis of the selected effectiveness and safe-
ty outcomes. 
 ACLR/PCLR in multi-ligament knee injuries: No evidence to support 
or to refute that allografts are superior or inferior on the basis of the 
selected effectiveness and safety outcomes. 
No evidence was found comparing allograft cruciate ligament reconstruction 
to conservative management. 
Anterior cruciate ligament reconstruction (ACLR) 
The scientific evidence indicates that allografts are equally effective when 
compared to autografts based on the outcome of patient-reported function, 
activity level and symptoms (crucial outcome; certainty: low-moderate; evi-
dence base: 6 RCTs [15, 17, 19-22] with high RoB).  
In addition, very low to moderate quality evidence was found indicating com-
parable effectiveness based on the outcome of clinical knee stability (impor-
tant outcome; certainty: very low to moderate; evidence base: 4 RCTs [19-22] 
with high RoB). Yet, 1 study [22] found a statistically significant difference 
favouring autografts based on the Lachman test and Pivot shift test (4 studies 
reported on these outcomes, with the remaining studies [19-21] having not  
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found any statistically significant difference), and 2 studies [19, 22] found a 
statistically significant difference favouring autografts when comparing side-
to-side differences between treatment groups. No further studies that report-
ed on this outcome [20, 21] found a statistically significant difference in side-
to-side difference (measured instrumentally) and none of the studies that 
reported on an objective IKDC score [19-22] found a statistically significant 
difference of this score result between treatment groups. In addition, there is 
low-quality evidence that patient satisfaction is comparable between the al-
lograft and autograft groups (important outcome; evidence base: 1 RCT [17] 
with high RoB). No evidence was found for the important outcome of HRQoL. 
Concerning comparative safety for ACLR, moderate quality evidence was 
found suggesting that allografts may be less safe compared to autografts with 
regard to graft failures (evidence base: 2 RCTs [15, 22] with high RoB). Yet, 
with regard to the other selected crucial safety outcomes, the evidence was 
insufficient to clearly prove the inferiority of allografts when compared to 
autografts (evidence base: 6 RCTs [15, 17, 19-22] with high RoB). 
Posterior cruciate ligament reconstruction (PCLR) 
The scientific evidence indicates that allografts are equally effective as auto-
grafts for PCLR based on the outcome of patient-reported function, activity 
level and symptoms (crucial outcome; certainty: very low to low; evidence 
base: 2 RCTs [18, 23] with unclear to high RoB). Moreover, very low-quality 
evidence was found for the outcome of clinical knee stability measured with 
the KT-arthrometer that may favour autografts. Yet, a statistically significant 
difference was only seen in 1 study [18] (mean difference: 3.5 ±1.1 vs. 2.1 ±1), 
while the other study [23] did not find a statistically significant difference of 
side-to-side differences between treatment groups. The other sub-outcomes 
measuring knee stability with clinical tests did not find any statistically sig-
nificant differences between allografts and autografts (certainty: low to mod-
erate; evidence base: 2 RCTs [18, 23] with unclear to high RoB). No evidence 
was found for the important outcomes patient satisfaction and HRQoL. 
Concerning comparative safety for PCLR, insufficient scientific evidence was 
found for overall (long-term) comparative safety of allografts in comparison 
to autografts in PCLR (evidence base 2 RCTs [18, 23] with unclear to high 
RoB). There is low-quality evidence that allografts lead to fewer complica-
tions related to infections, donor site pain, and reflex sympathetic dystrophy 
in comparison to autografts. Yet, only 1 study [23] reported on an overall 
complication rate (without statistical testing), and it appears that the report-
ed complications are related to graft harvesting and infection for autografts. 
As a result, the evidence was insufficient for the overall comparative safety. 
Revision ACLR 
One included observational study [16] conducted a logistic regression analy-
sis and found results from some subscales that were in favour of autografts 
(e.g., sports function and some further patient-reported outcomes, re-rup-
tures) in comparison to allografts. In the absence of evidence derived from 
randomised controlled trials, the evidence is insufficient to prove superiori-
ty/inferiority of allografts regarding clinical effectiveness and safety when 
compared to autografts in revision ACLR (evidence base: 1 comparative ob-
servational study with moderate RoB). 
 
andere 
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Upcoming evidence 
Overall, 7 ongoing clinical trials that investigated the use of allografts for 
cruciate ligament reconstruction were identified (ACLR: 3 ongoing studies; 
PCLR: 1 ongoing study; multi-ligament knee injury: 1 ongoing study; revi-
sion reconstruction: 2 ongoing studies).  
Surprisingly, only 2 of these 7 ongoing studies were RCTs comparing allo-
grafts to autografts or a new treatment modality (Z-lig anterior cruciate liga-
ment reconstruction). The sample size of the RCTs is 40 in one ongoing study 
comparing allografts to autografts, and 60 in another ongoing study compar-
ing allografts to Z-ligs. The primary completion date of these studies already 
passed in 2015 and 2014, respectively. In addition, the primary outcomes were 
X-ray, CT-scan, and KT-1000 in one study, and KT-1000 only in the other 
study. The remaining 5 ongoing studies were uncontrolled, with a maximum 
sample size of 100 enrolled patients.  
As a result, it is not expected that the evidence will change considerably ac-
cording to the upcoming results of the identified ongoing studies. 
Yet and according to information from the manufacturers, 2 studies (incl. 1 
RCT) are currently being conducted in Austria. However, study protocols are 
not publicly available. 
Reimbursement 
In the Austrian catalogue of benefits, there is a generic code for the recon-
struction of the anterior and/or posterior cruciate ligament already included 
in the Austrian hospital benefit catalogue [24], but not a separate/specific 
code for the use of allografts for reconstruction/replenishment (of the cruci-
ate ligament). 
 
Discussion 
The evidence found in this systematic review indicates that allografts may 
be equally effective but less safe in ACLR with regard to graft failures. Re-
garding PCLR, effectiveness may be comparable, yet insufficient evidence 
was found for the comparative safety of allografts when compared to auto-
grafts in PCLR. The evidence is insufficient for revision ACLR, and no evi-
dence was found for the remaining indications. 
The main limitations of the evidence base were in relation to the high risk of 
bias of the primary studies and the poor reporting on complications (e.g., dif-
ferences were often reported narratively, and statistical testing was not always 
conducted). In addition, one further main limitation of this work, as evident 
with all studies investigating ACLR or PCLR, is the lack of an objective as-
sessment of numerous outcomes (e.g., rotational knee stability, knee function, 
etc.). 
Further research should focus on more high quality randomised controlled 
trials with comprehensive safety reporting. In addition, questions regarding 
differences between types of allografts should be addressed. Evidence-based 
guidelines should clearly state the role of allografts in the management of 
cruciate ligament reconstruction. 
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Recommendation 
On the basis of the evidence identified in this assessment, the inclusion in the 
catalogue of benefits is currently not recommended. 
In the absence of ongoing randomised controlled trials that could provide an 
answer to the question chosen in this assessment, it is unlikely that the evi-
dence will change. A re-evaluation is therefore not recommended for the pre-
sent. 
A re-evaluation is necessary as soon as results of new RCTs are available. 
According to information from the manufacturers, 2 studies (incl. 1 RCT) are 
currently being conducted in Austria. However, study protocols are not pub-
licly available. 
  
Erstattung derzeit  
nicht empfohlen 
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LBI-HTA | 2019 13 
Zusammenfassung 
Einleitung 
Indikation und therapeutisches Ziel 
Das vordere Kreuzband (engl. anterior cruciate ligament = ACL) und das 
hintere Kreuzband (engl. posterior cruciate ligament = PCL) sind entschei-
dende Strukturen für die Stabilisierung des Kniegelenks bei funktionellen 
und sportlichen Aktivitäten. Die Hauptaufgabe des ACL besteht darin, gegen 
die Vorwärtsverschiebung der Tibia am Femur und die sekundäre Zwangs-
lage gegen die Tibia-Rotation und den Valgus- und Varus-Stress Einhalt zu 
leisten [1]. 
PatientInnen mit Rupturen des ACL/PCL, Re-Ruptur des ACL/PCL oder 
Multi-Ligament-Knieverletzungen können mit einer arthroskopischen Ope-
ration behandelt werden. Kontroversen bestehen jedoch hinsichtlich der adä-
quaten Behandlung, da auch die konservative Behandlung unter gewissen 
Bedingungen eine angemesseneBehandlungsoption darstellen kann [2]. Die 
in diesem Assessment gewählten Indikationen sind bei PatientInnen, die 
aufgrund der oben beschriebenen Verletzungen KanditatInnen für eine der 
5 Operationen sind: 
 Rekonstruktion des vorderen Kreuzbandes  
(engl. Anterior Cruciate ligament reconstruction = ACLR), 
 Rekonstruktion des hinteren Kreuzbandes  
(engl. Posterior Cruciate Ligament Reconstruction = PCLR), 
 Revisionsrekonstruktionen des vorderen Kreuzbandes  
(engl. revision ACLR): 
 Revisionsrekonstruktion des hinteren Kreuzbandes  
(engl. revision PCLR oder 
 ACLR und/oder PCLR bei multi-ligamentären Knieverletzungen 
Die jährliche Inzidenz der vorderen Kreuzbandrisse liegt in Deutschland bei 
etwa 31-37 pro 100.000 Personen [2]. In den Vereinigten Staaten treten die 
Risse der ACL in ähnlichem Ausmaß auf: Die diesbezügliche Inzidenz liegt 
hierbei bei 1 von 3.500 Personen [3]. Hintere Kreuzbandverletzungen treten 
weniger häufig auf und umfassen in etwa 1 bis 44 Prozent aller Knieverlet-
zungen in den Vereinigten Staaten [4, 5]. Zu den anderen Indikationen wur-
den keine relevanten Daten zur Inzidenz gefunden. 
Beschreibung der Technologie & Komparatoren 
Bei allogenen Bandersätzen handelt es sich um natürliche, rekonstruktive Ma-
teralien (Allografts); also um kadaverartige fascia lata oder azelluläre derma-
le Matrizen menschlicher Spender [9].  
Als Alternativen zu allogenen Bandersätzen können autogene Bandersätze 
(Autografts) zum Einsatz kommen. Invasive operative Eingriffe sind jedoch 
bei Kreuzbandverletzungen nicht immer notwendig [10]: Die konservative 
Therapie (inkl. Physiotherapie) wurde daher ebenfalls als Komparator ge-
wählt. 
Bei Kreuzbandrekonstruktionen sind die Transplantattypen mit Vor- und 
Nachteilen verbunden: Autogene Bandersätze sind beispielsweise mit Ent-
nahmemorbiditäten und diesbezüglichen etwaigen Komplikationen verbun-
vorderes und hinteres 
Kreuzband wichtig  
für Stabilität des 
Kniegelenks 
5 Indikationen  
zu Kreuzbandrisse in 
Assessment gewählt 
allogene Bandersätze  
als mögliche Alternative 
zu autogenen 
Bandersätzen 
Allograft for anterior and posterior cruciate ligament reconstruction 
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den. Allogene Bandersätze bieten eine Lösung für diese – mit der Entnahme 
des Transplantats verbundenen – Komplikationen. Zudem ist eine kürzere 
Operationsdauer für betroffene PatientInnen zu verzeichnen [9, 11]. Allogene 
Bandersätze können jedoch auch mit Nachteilen verbunden sein: langsamere 
Remodellierung und Integration des Transplatats, potenzielle Übertragung 
von Krankheiten, immunologische Reaktionen sowie erhöhte Kosten [7].  
Wissenschaftliche Forschungsfrage 
Sind allogene Kreuzbandrekonstruktionen im Vergleich zu Kreuzbandrekons-
truktionen mittels anderer Transplantate (insb. Autografts) oder im Ver-
gleich zur konservativen Behandlung bei PatientInnen mit Kreuzbandriss 
(bei denen ACLR, PCLR, Revision ACLR/PCLR, oder Kreuzbandrekons-
truktionen bei multi-ligamentären Knieverletzungen indiziert ist) wirksamer 
und sicherer in Bezug auf Funktion, Aktivitätsniveau und Symptome sowie 
Kniestabilität, Transplantatversagen und Komplikationen? 
 
Methoden 
Es wurde eine systematische Suche nach relevanten Publikationen in 4 Da-
tenbanken durchgeführt (Medline, Embase, Cochrane Library und Univer-
sity of York Center for Reviews und Dissemination). Drei AutorInnen (GG, 
CdV, SGG) führten die Studienauswahl unabhängig voneinander durch. Das 
Abstract-Screening wurde von GG und SGG, und die Voll-Text-Auswahl und 
die Qualitätsbewertung der Studien wurde von GG und CdV durchgeführt. 
Das Verzerrungspotential (Risk of Bias) der eingeschlossenen Studien wurde 
mit geeigneten Instrumenten bewertet: Das Cochrane Risk of Bias Tool [12] 
wurde für randomisierte kontrollierte Studien verwendet, während die New-
castle-Ottawa-Skala (NOS) zur Bewertung des Verzerrungsrisikos für Ko-
hortenstudien verwendet wurde [13]. Datenextraktion wurde von einer Per-
son (GG) durchgeführt und von einer anderen Person (CdV) verifiziert. Die 
GRADE-Methode [14] kam im Zuge der qualitativen Evidenzsynthese zum 
Einsatz. 
Im Falle von Meinungsverschiedenheiten wurde eine dritte Forscherin (SGG) 
konsultiert, um einen Konsens zu finden. 
Wirksamkeit 
Es wurden in diesem Assessment folgende wesentliche Wirksamkeitsend-
punkte gewählt: „Funktion, Aktivität und Symptome“. Folgende Instrumente 
wurden dabei herangezogen: Lysholm Score, Tegner Score, Cincinnati Knee 
Score, SANE Score, IKDC Score (subjektiv), KOOS und der Marx-Aktivitäts-
wert. Darüber hinaus wurden 3 weitere Wirksamkeitsendpunkte gewählt, die 
jedoch nicht wesentlich für die Ableitung einer Empfehlung eingestuft wur-
den: klinische Kniestabilität, Lebensqualität, PatientInnenzufriedenheit. 
Sicherheit 
Zur Evaluierung der Sicherheit wurden folgende wesentliche Endpunkte ge-
wählt: Transplantatversagen, Re-Rupturen, Re-Operationen, Revisionen und 
andere Komplikationen. 
 
Allograft wirksamer und 
sicherer als Autograft 
oder konservatives 
Management bei 
Kreuzbandriss? 
systematische 
Übersichtsarbeit, 
systematische Suche in 
4 Datenbanken, 
alle Arbeitsschritte 
durch  
2 WissenschafterInnen  
wesentliche 
Wirksamkeitsendpunkte: 
Funktion, Aktivität  
und Symptome 
wesentliche 
Sicherheitsendpunkte:  
Komplikationen, 
Transplantversagen, etc. 
Zusammenfassung 
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Ergebnisse 
Verfügbare Evidenz 
Insgesamt wurden 9 Studien [15-23] in dieser Literaturübersicht eingeschlos-
sen. Alle eingeschlossenen Studien verglichen allogene Kreuzbandrekonstruk-
tionen mit autogenen Kreuzbandrekonstruktionen. Von den eingeschlossenen 
Studien waren 8 randomisierte kontrollierte Studien [15, 17-23] mit einem 
unklaren bis hohen Verzerrungspotenzial (Risk of Bias) – hauptsächlich auf-
grund von fehlender Verblindung und der selektiven Berichterstattung. Eine 
weitere vergleichende Kohortenstudie [16] mit moderatem Verzerrungspo-
tenzial erfüllte die Einschlusskriterien für die Indikation der Revisionsre-
konstruktion des vorderen Kreuzbandes. 
Klinische Wirksamkeit und Sicherheit 
Bei den gewählten Indikationen konnte folgende Evidenz hinsichtlich Über-
legenheit/Unterlegenheit der allogenen Bandersätze im Vergleich zu autoge-
nen Kreuzbandrekonstruktionen gefunden werden: 
 Rekonstruktion des vorderen Kreuzbandes (ACLR): Es wurde Evi-
denz auf niedrig bis moderatem Qualitätsniveau gefunden, die – auf 
Basis des in diesem Assessment gewählten wesentlichen Wirksamkeits-
Endpunktes „Funktion, Aktivität und Symptome“ – eine vergleichba-
re Wirksamkeit nahelegt. Es besteht moderate Stärke der Evidenz, 
die auf Unterlegenheit der Allografts im Vergleich zu Autografts hin-
sichtlich des Endpunktes Transplantatversagen (graft failure) hinweist. 
Die Evidenz war jedoch unzureichend für die Evaluation der verglei-
chenden Sicherheit auf Basis der anderen gewählten wesentlichen Si-
cherheitsendpunkte (Evidenzbasis: 6 RCTs mit hohem RoB).  
 Rekonstruktion des hinteren Kreuzbandes (PCLR): Es wurde Evidenz 
auf sehr niedrigem bis niedrigem Qualitätsniveautsniveau gefunden, 
die – auf Basis des in diesem Assessment gewählten wesentlichen Wirk-
samkeits-Endpunktes „Funktion, Aktivität und Symptome“ – eine ver-
gleichbare Wirksamkeit nahelegt. Es wurde unzureichende Evidenz 
zur vergleichenden Sicherheit gefunden (Evidenzbasis: 2 RCTs mit un-
klarem-hohem RoB). 
 Revisionsrekonstruktionen des vorderen Kreuzbandes (revision   
ACLR): unzureichende Evidenz, die eine Überlegenheit oder Unter-
legenheit der Allografts im Vergleich zu Autografts nahelegt (Evidenz-
basis: 1 komparative Kohortenstudie mit moderatem RoB). 
 Revisionsrekonstruktion des hinteren Kreuzbandes (revision PCLR): 
keine Evidenz, die eine Überlegenheit oder Unterlegenheit der Allo-
grafts im Vergleich zu Autografts nahelegt 
 ACLR und/oder PCLR bei mutli-ligamentären Knieverletzungen:   
keine Evidenz, die eine Überlegenheit oder Unterlegenheit der Allo-
grafts im Vergleich zu Autografts nahelegt. 
Rekonstruktion des vorderen Kreuzbandes (ACLR) 
Die Evidenz weist – auf Basis des in diesem Assessment gewählten wesentli-
chen Wirksamkeits-Endpunktes „Funktion, Aktivität und Symptome“ – auf 
eine vergleichbare Wirksamkeit hin (wesentlicher Endpunkt, Stärke der Evi-
denz: niedrig bis moderat; Evidenzbasis: 6 RCTs [15, 17, 19-22] mit hohem 
RoB). 
Evidenz: 9 Studien 
6 RCTs zu ACLR 
2 RCTs zu PCLR 
1 Kohortenstudie  
zu Revisions-ACLR 
ACLR:  
Wirksamkeit: 
vergleichbar; 
Sicherheit: moderate 
Evidenz: höheres Risiko 
für graft failure bei 
Allografts; 
andere 
Sicherheitsendpunkte: 
unzureichende Evidenz 
PCLR:  
vergleichbare 
Wirksamkeit & 
unzureichende Evidenz 
zu Sicherheit 
Revisions-ACLR: 
unzureichende Evidenz 
Revisions-PCLR:  
keine Evidenz 
keine Evidenz  
bei multi-ligament 
Knieverletzungen 
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Auch auf Basis des Wirksamkeitsendpunktes der klinischen Kniestabilität 
weist die Evidenz eher auf eine vergleichbare Wirksamkeit hin (Evidenzba-
sis: 4 RCTs [19-22] mit hohem RoB). Es ist hierbei aber darauf hinzuweisen, 
dass eine Studie [22] einen statistisch signifikanten Unterschied zu Unguns-
ten der allogenen Bandersätze auf Basis der Resultate des Lachman Tests und 
des Pivot-Shift Tests fand. Die anderen Studien, die diese Endpunkte gemes-
sen haben [19-21], konnten jedoch keine statistisch signifikante Unterschie-
de dieser klinischen Tests finden. Darüber hinaus fanden 2 Studien [19, 22] 
einen statistisch signifikanten Unterschied zu Ungunsten der allogenen Band-
ersätze bei Messung der “side-to-side” Differenzen mit Hilfe des KT-Arthro-
meters. Die anderen Studien, die diesen Endpunkt gemessen haben [20, 21], 
fanden keinen statistisch signifikanten Unterschied der Resultate dieses End-
punktes zwischen Allografts und Autografts. Der objektive IKDC Score wur-
de von 4 Studien als Messung der Kniestabilität herangezogen und keine 
dieser Studien konnte einen statistisch signifikanten Unterschied zwischen 
Allografts und Autografts finden [19-22]. 
PatientInnenzufriedenheit wurde lediglich von einer Studie gemessen und 
es konnte Evidenz gefunden werden, die auf vergleichbare Zufriedenheit zwi-
schen PatientInnen mit allogenen Bandersätzen versus autogenen Bander-
sätzen hinweist. Genaue Angaben der Messung dieser Zufriedenheit fehlten 
jedoch in der Studie, wodurch die Stärke der Evidenz in diesem Endpunkt 
als niedrig einzustufen ist (Evidenzbasis: 1 RCT [17] mit hohem RoB). Es 
wurde keine Evidenz hinsichtlich der vergleichenden gesundheitsbezogenen 
Lebensqualität gefunden.  
Im Hinblick auf die vergleichende Sicherheit bei ACLR konnte Evidenz mit 
moderater Stärke gefunden werden, die darauf hinweist, dass allogene Band-
ersätze weniger sicher sind als autogene Bandersätze. Diese Evidenz, die auf 
Unterlegenheit der Allografts hinweist, basiert auf dem Endpunkt Transplan-
tatversagen (graft failure). Die Evidenz war jedoch unzureichend für die Eva-
luation der vergleichenden Sicherheit auf Basis der anderen gewählten we-
sentlichen Sicherheitsendpunkte (Evidenzbasis: 6 RCTs [15, 17, 19-22] mit 
hohem RoB).  
Posterior cruciate ligament reconstruction (PCLR) 
Es wurde Evidenz auf sehr niedrigem bis niedrigem Qualitätsniveau gefun-
den, die – auf Basis des in diesem Assessment gewählten wesentlichen Wirk-
samkeits-Endpunktes „Funktion, Aktivität und Symptome“ – eine vergleich-
bare Wirksamkeit nahelegt (Evidenzbasis: 2 RCTs [18, 23] mit unklarem bis 
hohem RoB). 
Darüber hinaus wurde Evidenz auf sehr niedrigem Qualitätsniveau gefun-
den, die darauf hinweist, dass Resultate der KT-Arthrometer Testung (Knie-
stabilität) bei Verwendung der allogenen Bandersätze im Vergleich zur Ver-
wendung von autogenen Bandersätzen schlechter sind. Ein statistisch signi-
fikanter Unterschied der „side-to-side“ Differenzen konnte jedoch lediglich 
von einer Studie gefunden werden [18]. Die andere eingeschlossene Studie 
[23] konnte in diesem Zusammenhang keinen statistisch signifikanten Un-
terschied finden. Keine der eingeschlossenen Studien [18, 23] konnte einen 
statistisch signifikanten Unterschied bei Endpunkten, die Kniestabilität mes-
sen (Lachman Test, Pivot-Shift Test & objektiver IKDC Test), nachweisen. 
Daher weist diese Evidenz eher auf eine vergleichbare Kniestabilität hin 
(Stärke: niedrig bis moderat; Evidenzbasis 2 RCTs [18, 23] mit unklarem bis 
hohem RoB). Hinsichtlich PatientInnenzufriedenheit und gesundheitsbezo-
gener Lebensqualität wurde keine Evidenz gefunden. 
PCLR:  
Evidenz weist auf 
vergleichbare 
Wirksamkeit hin, 
unzureichende Evidenz 
zur vergleichenden 
Sicherheit 
Zusammenfassung 
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Es wurde unzureichende Evidenz zur vergleichenden Sicherheit bei PCLR 
gefunden (Evidenzbasis: 2 RCTs [18, 23] mit unklarem-hohem RoB). 
Revision ACLR 
Zur Evaluierung der vergleichenden Wirksamkeit und Sicherheit der allo-
genen Bandersätze bei Revisions-ACLR wurde eine Beobachtungsstudie ein-
geschlossen: Die prospektive komparative Kohortenstudie [16] führte eine 
Regressionsanalyse durch und verglich dabei wesentliche Wirksamkeits- und 
Sicherheitsendpunkte bei Verwendung von Allografts im Vergleich zu Auto-
grafts in einer großen Kohorte (n=1205). Die Studie präsentierte Ergebnisse 
zu Ungunsten von allogenen Bandersätzen bei einigen Sub-Scales (z. B. bei 
„sportliche Funktionalität“ oder Re-rupturen). In Ermangelung an randomi-
sierten Kontrollstudien ist die Evidenz jedoch unzureichend, um Überlegen-
heit oder Unterlegenheit der allogenen Bandersätzen im Vergleich zu auto-
genen Bandersätzen beurteilen zu können (Evidenzbasis: 1 komparative Be-
obachtungsstudie mit moderatem RoB). 
Es wurde keine Evidenz gefunden, die allogene Bandersätze mit konservati-
vem Management verglich. 
Laufende Studien 
Insgesamt wurden 7 laufende klinische Studien identifiziert, die den Einsatz 
von Allografts bei Rekonstruktionen des Kreuzbandes untersuchen (ACLR: 
3 laufende Studien; PCLR: 1 laufende Studie; Multi-Ligament-Knieverlet-
zung: 1 laufende Studie; Revisionsrekonstruktion: 2 laufende Studien). 
Allerdings sind nur zwei dieser sieben laufenden Studien RCTs, die Allo-
grafts entweder mit Autografts (1 Studie) oder mit einer anderen neuen Be-
handlungsmodalität (Z-lig anteriorer Cructiat-Ligment-Rekonstruktion; 1 
laufende Studie) vergleichen. Die Stichprobengröße der RCTs beträgt 40 Pa-
tientInnen in einer laufenden Studie (Vergleich: Allograft vs. Autograft) und 
60 PatientInnen in einer weiteren laufenden Studie (Vergleich Allograft vs. 
Z-Ligs). Der Zeitpunkt des voraussichtlichen Abschlusses dieser beiden Stu-
dien ist bereits verstrichen (in 2015 und 2014). Darüber hinaus ist kein in 
diesem Assessment wesentlicher Endpunkt in den laufenden Studien als pri-
märer Endpunkt definiert. Die Studien betrachten insbesondere Endpunkte 
wie etwa Röntgen, CT-Scan und KT1000. Die restlichen 5 laufenden Studien 
sind unkontrolliert mit einer maximalen Stichprobengröße von 100 einge-
schriebenen PatientInnen. 
Es ist daher nicht zu erwarten, dass die Ergebnisse dieser Studien einen we-
sentlichen Einfluss auf die Wirksamkeit und Sicherheit von Allografts im 
Vergleich zu Autografts bei Kreuzbandrekonstruktionen haben werden.  
Nach Angaben der Hersteller werden derzeit jedoch noch 2 Studien (davon 
1 RCT) in Österreich durchgeführt. Die Studienprotokolle sind nicht öffent-
lich einsehbar und daher kann das Vorliegen der Ergebnisse zeitlich nicht 
abgeschätzt werden. 
Kostenerstattung 
Im österreichischen Leistungskatalog gibt es einen generischen Code für die 
Rekonstruktion des vorderen und/oder hinteren Kreuzbandes, nicht jedoch 
einen separaten/spezifischen Code für die Verwendung von allogenen Band-
ersätzen bei Kreuzbandrekonstruktionen. 
 
Revisions-ACLR: 
unzureichende Evidenz 
Keine Evidenz: 
Allografts vs. 
konservatives 
Management 
 
7 laufende Studien: 
Nur 2 RCTs  
mit geringer Fallzahl  
 
5 laufende 
Beobachtungsstudien 
ohne Vergleich 
Kreuzband-
rekonstruktionen im 
Leistungskatalog, 
jedoch nicht mittels 
Allografts 
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Diskussion 
Die in dieser systematischen Übersichtsarbeit gefundene Evidenz weist da-
rauf hin, dass Allograft bei ACLR gleichermaßen wirksam, jedoch womög-
lich weniger sicher sein könnte. Die Evidenz legt überdies nahe, dass die 
Wirksamkeit der Allografts im Vergleich zu Autografts bei PCLR vergleich-
bar sein könnte, es wurde jedoch keine ausreichende Evidenz für die ver-
gleichende Sicherheit bei PCLR gefunden. Des Weiteren wurde unzureichen-
de Evidenz gefunden, die die Wirksamkeit und Sicherheit der Allografts bei 
ACLR-Revisionsrekonstruktionen beurteilen könnte. Für die verbleibenden 
Indikationen (PCLR-Revisionsrekonstruktionen und Banderätze bei mutli-
ligamentären Knieverletzungen) wurden keine wissenschaftlichen Nachwei-
se der komparativen Wirksamkeit oder Sicherheit gefunden. 
Eine wesentliche Einschränkung der Evidenzbasis bestand in Bezug auf das 
hohe Verzerrungspotenzial der Primärstudien und auf schlechte Berichter-
stattung der Komplikationen (z. B. wurden Unterschiede häufig nur narrativ 
berichtet und statistische Tests wurden nicht immer durchgeführt). Wie bei 
allen Studien, die sich mit ACLR oder PCLR befassen, ist eine weitere we-
sentliche Einschränkung dieser Arbeit das Fehlen einer möglichen objektiven 
Messung zahlreicher Endpunkte (z. B. Rotationsstabilität des Kniegelenkes, 
Funktion usw.) in der Primärforschung. 
Randomisierte kontrollierte Studien von hoher Qualität und geringem Ver-
zerrungspotential sind zukünftig wesentlich, um eine valide wissenschaftli-
che Grundlage zu schaffen, die es ermöglicht, den Einsatz von Allografts bei 
Kreuzbandrekonstruktionen umfassend zu evaluieren. 
 
Empfehlung  
Auf Basis der vorliegenden Evidenz wird eine Aufnahme in den Leistungs-
katalog derzeit nicht empfohlen. 
In Ermangelung laufender randomisierter Kontrollstudien, die eine Antwort 
auf die in dieser Bewertung gewählte Fragestellung geben können, kann der-
zeit kein genauer Zeitpunkt einer Re-Evaluierung empfohlen werden.  
Eine Re-Evaluierung wird empfohlen, wenn Ergebnisse neuer, randomisierter 
Kontrollstudien vorliegen.  
 
 
Wirksamkeit: 
vergleichbar bei ACLR & 
PCLR, unzureichend bei 
Revisions-ACLR 
 
Sicherheit:  
weniger sicher bei ACLR 
(graft failure), sonst 
unzureichende Evidenz 
Limitationen:  
erhöhtes RoB der RCTs 
und unvollständige 
Berichterstattung 
 
weitere Forschung 
wesentlich, um Vor- und 
Nachteile der Allografts 
weiter überprüfen zu 
können  
Erstattung derzeit  
nicht empfohlen  
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1 Scope 
1.1 PICO question 
Is allograft cruciate ligament reconstruction in comparison to other techniques 
of cruciate ligament reconstruction or conservative management in patients 
undergoing anterior cruciate ligament reconstruction (ACLR), posterior 
cruciate ligament reconstruction (PCLR), revision ACLR/PCLR or cruciate 
ligament reconstruction in multi-ligamentous injuries of the knee, more ef-
fective and safe concerning the outcomes listed in Table 1-1?  
 
 
1.2 Inclusion criteria 
Inclusion criteria for relevant studies are summarised in Table 1-1. 
Table 1-1: Inclusion criteria 
Population Patients who are – as a result of ruptures in the anterior and/or posterior cruciate 
ligament, (incl. re-ruptures) or multi-ligament knee injuries – candidates for one of the 
following ligament reconstructions: 
 Anterior Cruciate Ligament Reconstruction (ACLR) 
 Posterior Cruciate Ligament Reconstruction (PCLR) 
 Revision ACLR 
 Revision PCLR 
 Cruciate ligament reconstructions in mutli-ligament knee injuries 
International classification of diseases (ICD)-10-CM code: M23.60, M23.61, M23.62,  
S83.53, S83.54 
MeSH terms: “Anterior Cruciate Ligament Injuries” [C26.558.554.213]; 
“Posterior Cruciate Ligament/injuries” [A02.513.514.600, A02.835.583.512.600, 
A10.165.669.514.600]; “Knee Injuries” [C26.558.554] 
Intervention  Allograft cruciate ligament reconstruction  
 Product names: not applicable 
 MeSH terms: (“Allografts” [ A01.941.500]) AND/OR (“Anterior Cruciate Ligament 
Reconstruction” [E04.555.110.026, E04.680.101.026] OR “Posterior Cruciate Ligament 
Reconstruction” [E02.718.688, E04.555.110.557, E04.680.101.557]) 
Control  Other techniques of cruciate ligament reconstruction (autograft, synthetic graft, etc.) 
 Conservative management 
Rationale: Both other types of cruciate ligament reconstruction and conservative 
management were set as control interventions since surgery may not always be  
required [25]. 
 
PIKO-Frage 
Einschlusskriterien  
für relevante Studien 
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Outcomes  
Efficacy Relevant efficacy outcomes include (crucial outcomes are highlighted in bold): 
 Patient-reported function, activity level and symptoms measured using a validated 
instrument (e.g., Lysholm score, Tegner score, IKDC scores) 
 Clinical knee stability measured using a validated instrument (e.g., KT-1000/2000 
arthrometer, the Lachman test or Pivot shift test) 
 Health-related Quality of Life measured using a validated instrument 
 Patient satisfaction measured using a validated instrument 
Rationale: Appropriate clinical outcomes have been informed by one identified guideline 
on the management of ACL injuries [25], a meta-analysis [26], and the EUnetHTA 
guidelines [27]. 
Safety Relevant safety outcomes include (crucial outcomes are highlighted in bold): 
 Graft failure 
 Re-ruptures, re-operations and revisions 
 Complications 
 Procedure-related mortality 
Rationale: Appropriate clinical outcomes have been informed by one identified guideline 
on the management of ACL injuries [25] and a meta-analysis [26]. 
Study design  
Efficacy ACLR: Randomised controlled trials. If more than 10 RCTs identified,  
restriction to RCTs with mean FU of 5 years and more than 50 patients. 
PCLR: Randomised controlled trials. If more than 10 RCTs identified,  
restriction to RCTs with mean FU of 5 years and more than 50 patients. 
For revision ACLR/PCLR or ligament reconstructions in multi-ligament knee injury: 
Randomised controlled trials, if no RCTs available: prospective comparative studies. 
Safety ACLR: Randomised controlled trials. If more than 10 RCTs identified,  
restriction to RCTs with mean FU of 5 years and more than 50 patients. 
PCLR: Randomised controlled trials. If more than 10 RCTs identified,  
restriction to RCTs with mean FU of 5 years and more than 50 patients. 
For revision ACLR/PCLR or ligament reconstructions in multi-ligament knee injury: 
Randomised controlled trials, if no RCTs available: prospective (comparative) studies. 
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2 Methods 
The study was undertaken in accordance with the PRISMA statement [28, 29]. 
 
 
2.1 Research questions 
Description of the technology 
Element ID Research question 
B0001 What is the technology and the comparator(s)? 
A0020 For which indications has the technology received marketing authorisation or CE marking? 
B0002 What is the claimed benefit of the technology in relation to the comparators? 
B0003 What is the phase of development and implementation of the technology and  
the comparator(s)? 
B0004 Who administers the technology and the comparators and in what context and  
level of care are they provided? 
B0008 What kind of special premises are needed to use the technology and the comparator(s)? 
B0009 What supplies are needed to use the technology and the comparator(s)? 
A0021 What is the reimbursement status of the technology? 
 
Health problem and current use 
Element ID Research question 
A0001 For which health conditions, and for what purposes is the technology used? 
A0002 What is the disease or health condition in the scope of this assessment? 
A0003 What are the known risk factors for the disease or health condition? 
A0004 What is the natural course of the disease or health condition? 
A0005 What is the burden of disease for the patients with the disease or health condition? 
A0006 What are the consequences of the disease or health condition for the society? 
A0024 How is the disease or health condition currently diagnosed according to published guidelines 
and in practice? 
A0025 How is the disease or health condition currently managed according to published guidelines 
and in practice? 
A0007 What is the target population in this assessment?  
A0023 How many people belong to the target population? 
A0011 How much are the technologies utilised? 
 
Clinical effectiveness 
Element ID Research question 
D0001 What is the expected beneficial effect of the technology on mortality? 
D0003 What is the effect of the technology on the mortality due to causes other  
than the target disease? 
D0005 How does the technology affect symptoms and findings (severity, frequency)  
of the disease or health condition? 
D0006 How does the technology affect progression (or recurrence) of the disease or health condition? 
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Clinical effectiveness 
Element ID Research question 
D0011 What is the effect of the technology on patients’ body functions? 
D0016 How does the use of technology affect activities of daily living? 
D0012 What is the effect of the technology on generic health-related quality of life? 
D0013 What is the effect of the technology on disease-specific quality of life? 
D0017 Was the use of the technology worthwhile? 
 
Safety 
Element ID Research question 
C0008 How safe is the technology in comparison to the comparator(s)? 
C0002 Are the harms related to dosage or frequency of applying the technology? 
C0004 How does the frequency or severity of harms change over time or in different settings? 
C0005 What are the susceptible patient groups that are more likely to be harmed through the use of 
the technology? 
C0007 Are the technology and comparator(s) associated with user-dependent harms? 
B0010 What kind of data/records and/or registry is needed to monitor the use of the technology and 
the comparator? 
 
 
2.2 Sources 
Description of the technology 
 Deximed (https://deximed.de/intro) 
 UpToDate (https://www.uptodate.com/home) 
 Clinical practice guidelines identified by hand searching databases 
(Guidelines International Network) 
 Hand search in PubMed, and the websites of the manufacturer 
 Background publications identified in database search: see Section 2.3 
Health problem and current use 
 Deximed (https://deximed.de/intro) 
 UpToDate (https://www.uptodate.com/home) 
 Background publications identified in database search: see Section 2.3 
 Documentation provided by the manufacturer 
For the domains of clinical effectiveness and safety, a systematic literature 
search and hand search, described in detail in the following chapter (see Sec-
tion 2.3), were conducted. 
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2.3 Systematic literature search 
The systematic literature search was conducted on the  
18th and 19th of December 2018 in the following databases:  
 Medline via Ovid 
 Embase  
 The Cochrane Library 
 CRD (DARE, NHS-EED, HTA) 
The systematic search was limited to clinical trials and to articles published 
in English or German. No further filters applied. After deduplication, a total 
of 492 citations were included. The specific search strategy employed can be 
found in the Appendix.  
Before the systematic search was conducted, 7 systematic reviews/meta-anal-
yses [26, 30-35] were identified through a hand search in PubMed. The ref-
erence lists of these publications were hand-searched to identify relevant ran-
domised controlled trials, resulting in 13 relevant hits. The results of the hand 
search assisted and strengthened the systematic search: all of the potentially 
relevant hits were also included in the records identified through the system-
atic search. 
Furthermore, to identify ongoing and unpublished studies, a search in three 
clinical trials registries (ClinicalTrials.gov; WHO-ICTRP; EU Clinical Trials) 
was conducted on the 17th of January 2019, resulting in 17 potential relevant 
hits. 
No additional hits were found through hand search, leading to a result of 492 
identified publications overall. 
 
 
2.4 Flow chart of study selection 
Overall, 492 hits were identified. The abstracts were screened by two inde-
pendent researchers (GG, SGG), and the full texts were screened by GG and 
CdV. In case of disagreement, a third researcher (SGG) was involved to solve 
the differences. The selection process is displayed in Figure 2-1. 
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Figure 2-1: Flow chart of study selection (PRISMA Flow Diagram)1 
  
                                                             
1 More than 10 RCTs were identified for ACLR. Therefore, the stricter inclusion cri-
teria applied: min. mean FU of 5 years and at least 50 enrolled patients. No RCT, 
or other, at least prospective studies were identified for cruciate ligament recons-
tructions in patients with multi-ligament knee injuries. 
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2.5 Analysis 
Relevant data from the eligible studies were systematically extracted into da-
ta extraction tables. The single-data extraction method with verification by 
another researcher was used: One researcher (GG) extracted the data, and 
one further researcher (CdV) controlled the extracted data. 
Two independent researchers (GG, CdV) systematically assessed the quality 
of the evidence. The risk of bias assessment of the included studies was con-
ducted using adequate tools: the Cochrane Risk of Bias Tool [12] was uti-
lised for randomised controlled studies, while the Newcastle-Ottawa Scale 
(NOS) was applied for assessing the risk of bias for cohort studies [13].  
 
 
2.6 Synthesis 
The questions were answered in plain text format with reference to GRADE 
evidence tables included in the Appendix, and the results were summarised 
in Table 7-1, Table 7-2, and Table 7-3. 
No inferential statistical analysis was conducted. A qualitative evidence syn-
thesis was chosen. Based on the data extraction tables, data on each selected 
outcome category were synthesised across studies according to GRADE (Grad-
ing of Recommendations, Assessment, Development and Evaluation) [14].  
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3 Description and technical 
characteristics of technology 
Features of the technology and comparators 
B0001 – What is allograft cruciate ligament reconstruction, autograft 
cruciate ligament reconstruction and conservative management? 
Allograft Cruciate Ligament Reconstruction  
Cruciate ligaments belong to structures providing support and stability in the 
knee. The anterior cruciate ligament (ACL) and posterior cruciate ligament 
(PCL) provide stability for both anterior and posterior movements, as well 
as with flexion and extension. Furthermore, there are medial and lateral col-
lateral ligaments that provide support in their respective planes [36]. 
ACL and/or PCL ruptures are common sports injuries and may require sur-
gical treatment. The reconstruction is generally performed with arthroscopy 
using a graft for the replacement of the ruptured ligament. Currently, there is 
a debate regarding graft selection among orthopaedic surgeons. The source 
of the grafts can be the patient’s body (autologous) or from a donor body (al-
logenic) [6-8] 
Allografts are reconstructive natural materials. They are processed cadaveric 
fascia lata or acellular dermal matrices of human donors [9]. Allografts are 
taken from a cadaver Achilles tendon, a semitendinosus, a gracilis, or a pos-
terior tibialis tendon [10]. 
Comparators of allograft cruciate ligament reconstruction 
Due to the existing controversy regarding the appropriate management of cru-
ciate ligament tears [7, 8], there is also a broad variety of different compara-
tors. In this assessment, the following comparators were used: 
 Autograft cruciate ligament reconstruction and 
 Conservative management.  
Within surgery, the following graft types are common when using autografts 
for cruciate ligament reconstruction [10]: 
 patellar tendon autograft, 
 hamstring tendon autograft, or 
 quadriceps tendon autograft. 
In the 1970s and 1980s, the use of artificial ligaments (e.g., Gore-Tex and Pro-
plast) in cruciate ligament reconstructions was promoted. However, the expe-
rience with these non-tissue substitutes was poor, leading surgeons to choose 
other, natural, graft materials [37].  
In the past decades, a newer synthetic graft choice that can be used for cruci-
ate ligament reconstructions was developed – the Ligament Augmentation and 
Reconstruction System (LARS). According to an advice document from the 
National Institute for Health and Care Excellence (NICE), however, LARS 
should only be used in cruciate ligament procedures after non-synthetic al-
ternatives (e.g., autograft and allograft) have been considered as a possible 
treatment option by the clinician and the patient [38]. 
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Nonsurgical treatment (conservative management) consists of progressive 
physiotherapy and rehabilitation. The aim of conservative management is to 
restore the knee to a condition close to its pre-injury state and provide the 
patient with the necessary knowledge on how to prevent instability. Supple-
mentarily, a hinged knee brace may also be used [10].  
Synthetic graft types were only set as a secondary comparator of less interest 
for the purpose of this assessment. 
Conservative management vs. surgery 
For ACL tears, a conservative or surgical treatment may be used depending 
on the severity of the tear and the preferences of the respective patient [2].  
In ACL tears, conservative management may be indicated in patients with: 
 low stability, 
 low level of activity, 
 existing arhthrosis, and/or 
 a general contra-indication for an operation [2]. 
The age of the patient may be a further indicator for the decision whether 
surgery should be indicated. 
The surgical reconstruction of the ACL may be indicated if patients [2]: 
 are athletes,  
 have a physically demanding occupation,  
 have high demands of the knee function in the future, 
 suffer simultaneously from repairable meniscal injury  
or another ligament injury, 
 suffer from a complex capsule ligament injury, and/or 
 have chronic instability. 
However, and lastly, it must be evaluated individually whether conservative 
management or surgery fits most to the needs of the patient [2]. In this con-
text and contrary to these potential indications for an ACLR, a randomised 
controlled trial [39] showed that in young, active adults with acute ACL tears, 
a strategy of rehabilitation plus early ACLR was not superior to a strategy of 
rehabilitation plus optional delayed ACLR. In addition, the latter strategy 
substantially reduced the frequency of surgical reconstructions. 
The success rate of nonsurgical treatment differs significantly for ACL versus 
PCL ruptures. For PCL tears, controversy exists regarding the appropriate 
management. Based on limited evidence, it appears that good subjective and 
functional results can be achieved when using a non-operative management. 
Yet, it is not clear, whether conservative treatment or a surgical cruciate lig-
ament reconstruction is the best approach to treatment for PCL ruptures [8]. 
Contrary to single ligament tears, surgery is often performed soon after the 
injury in patients with multi-ligamentous knee injuries [40]. 
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A0020 – For which indications has allograft cruciate ligament 
reconstruction received marketing authorisation or CE marking? 
Human allografts for the use of cruciate ligament reconstruction are not clas-
sified as medical devices. Therefore, they are not subject to CE marking. 
Human tissue donation is regulated by the European Union under the EU 
Tissue and Cells Directive (EUTCD) that was adopted in 2004 (Directive 
2004/23/EC). The EUTCD outlines the legal framework for the supply of hu-
man tissues and cells within the EU, aiming at ensuring safety and quality 
standards of the biological samples [41, 42]. Therefore, suppliers of tissues are 
able to distribute allografts within the EU if they have the licence to do so. 
The Austrian legal regulation on tissue and organ donation is positioned in 
the “Bundesgesetz über die Transplantation von menschlichen Organen” (Or-
gantransplantationsgesetz – OTPG) [43]. 
B0002 – What is the claimed benefit of allograft cruciate ligament 
reconstruction in relation to autograft cruciate ligament reconstruction 
and conservative treatment? 
In surgery, the use of allografts as a reconstructive material eliminates donor 
site morbidity associated with autologous fascia harvest [9, 11]. More pre-
cisely, pain – caused by obtaining the graft from the patient – and the sur-
gery time may be reduced. The latter may also lead to smaller incisions [10]. 
Quick recovery of muscle strength and no increased risk of patellar fracture 
may be described as further advantages of allografts [11]. 
In addition, the clinical expert who reviewed this report stated that not only 
pain is reduced using allografts, but also potential weakness of the joint’s 
range of motion due to injured tendons of the ipsi- or contralateral knee. 
Disadvantages of allografts may include potential disease transmission, im-
munologic reactions, slower remodelling and integration, as well as costs [7]. 
Allografts may bear a risk of disease transmission, e.g., HIV and Hepatitis C 
[10, 11]. Yet, the risk of infection when using an allograft is considered as 
extremely low [7]. 
Furthermore, and according to the submitting hospital, allografts are espe-
cially useful when surgery using autografts is not feasible anymore due to re-
ruptures or multi-ligament knee injuries. 
B0003 – What is the phase of development and implementation of 
allograft and autograft cruciate ligament reconstruction? 
Cruciate ligament reconstruction is, technically speaking, not a novel proce-
dure and has been conducted since the early 20th century. However, changes 
in the used surgical procedure were notable. When looking at graft types, for 
instance, autologous fascia lata, the hamstring graft, patellar tendon grafts 
were introduced within the first half of the 20th century, with documented 
procedures using those graft types in 1912, 1934, and 1935, respectively. Lat-
er in the same century, the surgical technique using bone-patellar tendon-
bone grafts (BPTB) was described in a publication in 1963. In the 1970s and 
1980s, experiments with synthetic graft types followed [44]. However, the ex-
perience with these non-tissue substitutes was poor [37], with complications 
such as synovitis occurring in patients having undergone ACL reconstruction 
using synthetic graft types [44]. 
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In the 1980s, increasing interest in using allografts for cruciate ligament re-
construction was notable [44]. Since then, allografts have been the subject of 
research and are now considered to be a viable alternative to autografts for 
reconstructing a cruciate ligament [7]. 
Besides changes in graft type selection, there was also notable progress when 
looking at the arthroscopic procedure as such [45]. 
 
Administration, Investments, personnel and tools required  
to use the technology and the comparator(s) 
B0004 – Who administers allograft and autograft cruciate ligament 
reconstruction and in what context and level of care are they provided? 
B0008 – What kind of special premises are needed to use allograft  
and autograft cruciate ligament reconstruction? 
B0009 – What supplies are needed to use allograft and autograft  
cruciate ligament reconstruction? 
Allograft cruciate ligament reconstruction is performed by an orthopaedic 
surgeon and assisted by qualified personnel. In addition, required structural 
conditions further include a surgery room and an anaesthesia work station 
(Information provided by the submitting hospitals). 
In Europe, LifeNetHealth® [46] and Arthrex® [47] provide allografts to be 
used for ACLR or PCLR. Different products that may vary, inter alia, accord-
ing to graft type used and sterilisation method are offered. 
 
Regulatory & reimbursement status  
A0021 – What is the reimbursement status of allograft  
cruciate ligament reconstruction? 
A generic code for the reconstruction of the anterior and/or posterior cruci-
ate ligament is already included in the Austrian hospital benefit catalogue2 
[24], but not a separate/specific code for the use of allografts for reconstruc-
tion/replenishment (of the cruciate ligament). In addition, a similar benefit 
is included in this catalogue: defect replenishment is reimbursed using ho-
mologous bone or substitute materials (PA040) [24]. According to the infor-
mation of the submitting hospitals, this code is not applicable in this context.  
 
 
                                                             
2 „NF050 Rekonstruktion des vorderen Kreuzbandes – arthroskopisch (LE=je Seite)“, 
„NF060 Rekonstruktion des hinteren Kreuzbandes – arthroskopisch (LE=je Seite)“ 
[24].  
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4 Health problem and current use 
Overview of the disease or health condition 
A0001 – For which health conditions, and for what purposes  
is allograft cruciate ligament reconstruction used? 
A0002 – What is the disease or health condition in the scope  
of this assessment?  
The anterior cruciate ligament (ACL) and posterior cruciate ligament (PCL) 
are crucial structures for providing stability in the knee joint during function-
al and sporting activities. The main role of the ACL is to provide restraint 
against the forward translation of the tibia on the femur, and secondary con-
straint against tibial rotation and valgus and varus stress [1]. The PCL pri-
marily provides constraint against the posterior translation of the tibia in re-
lation to the femur, and secondary constraint against external rotation, and 
protects the knee from varus and valgus stresses in extension. 
ACL injuries occur as a result of high energy trauma or low energy contact 
or non-contact sports injuries. Non-contact injuries such as sudden decelera-
tion with cutting or change in direction, pivoting or landing from a jump ac-
count for 72% [48] of ACL injuries, with most of the injuries occurring with 
the knee in valgus, almost fully extended, and with internal rotation of the 
tibia.  
Most PCL injuries occur as a result of high energy trauma such as motor 
traffic accidents [49-51], where a posterior shearing force is applied with the 
knee in a flexed position. It usually manifests as multi-ligament injuries [5], 
including the posterior lateral corner, ACL, and the medial collateral liga-
ments. Isolated PCL injuries are more common with low energy, sporting ac-
tivities where the patient falls on a flexed knee with the foot in plantar flex-
ion or a direct force on the front of the knee [8]. The PCL and posterior cap-
sule can also be injured during varus or valgus stress on the knee or with hy-
perextension or hyperflexion positions with or without a posterior force. 
Ligament injuries can be surgically or conservatively managed [7]. The deci-
sion to proceed with surgery is multi-factorial and should consider the pa-
tients’ level of activity, functional demands on the knee, and any other asso-
ciated meniscal or ligament injuries. Allograft or autograft ligament recon-
structions are performed arthroscopically to repair the damaged ligaments 
and restore stability of the knee joint. Autografts are usually harvested from 
the hamstring (semitendinosis and gracilis) and patellar tendon or quadriceps 
tendons [7]. Allografts are typically from the Achilles tendon or patellar ten-
don [7], but could also be from other sources. Currently, there is controversy 
about the superiority/inferiority of choosing one graft over another [52]. 
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A0003 – What are the known risk factors for anterior  
or posterior cruciate ligament rupture? 
A previous history of an ACL injury is a strong indicator for a non-contact 
ACL injury [53]. 70% of ACL injuries occur due to non-contact sports inju-
ries [48, 54] and may be due to the contribution of environmental, anatomi-
cal, hormonal, neuromuscular, and biomechanical factors. Neuromuscular 
factors include hamstring and core muscle weakness during pivoting, land-
ing and deceleration activities, with a higher risk of ACL injuries in female 
athletes [55-57].  
Biomechanical factors such as dynamic knee valgus, hip internal rotation and 
adduction, tibial rotation and anterior translation, and ankle eversion also in-
crease the risk of ACL injuries, in particular for female athletes [58, 59].  
Gender-related differences are therefore risk factors, with females two to eight 
times more likely than males participating in the same sport to sustain non-
contact ACL injuries [54, 60]. 
Trauma and high energy injuries are risk factors for multi-ligament and PCL 
injuries. It may also be associated with dislocation, vascular injuries, notice-
able instability, and loss of range of knee motion [8]. 
There is a 6-25% ipsilateral re-rupture risk after reconstruction and a similar 
contralateral re-rupture risk of 2-25% [53]. 
A0004 What is the natural course of anterior or posterior cruciate 
ligament rupture? 
The natural course of anterior or posterior cruciate ligament ruptures is ex-
plained in A0005 and A0006. 
 
Effects of the disease or health condition  
on the individual and society 
A0005 – What is the burden of disease for patients with anterior  
or posterior cruciate ligament rupture? 
A0006 – What are the consequences of anterior or posterior  
cruciate ligament rupture for the society? 
The short-term impact for younger, active patients who sustained a knee lig-
ament injury is that they are often unable to return to sports or activities that 
place a high demand on the knee. ACL deficiency is associated with an in-
creased risk of meniscal injuries, articular cartilage and chronic knee pain [7]. 
ACL deficiency is also associated with a higher long-term risk of the inci-
dence of osteoarthritis (OA) [26, 60-62]. Concurrent meniscal injuries with 
ACL injuries are risk factors for OA after ACL injury, with a 3.54-fold in-
crease in the incidence of OA post ACL injury [63].  
It is uncertain whether the absent ACL and subsequent knee joint instability 
or the initial extent and degree of the joint damage during the ACL injury 
increase the risk of developing OA. It is most likely a combination of factors, 
including the severity of the initial ACL injury, the extent of the meniscal in-
jury, the biomechanics of the knee, and the activity level of the patient [64]. 
The prevalence of knee OA was estimated between 0-13% in patients with iso-
lated ACL injuries [65], and between 28-41% in patients with an ACL rup-
ture and other injuries such as meniscal injuries [66]. Some studies suggest 
the occurrence of OA regardless of a surgical or conservative treatment ap-
proach after ligament injuries, and others found a higher incidence of OA in 
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the injured, unrepaired knee [7]. The short time frame of reported studies 
and the inability to account for functional levels after the injury might ac-
count for the conflicting results [7].  
There is more uncertainty about the long-term complications after an isolat-
ed PCL injury. On the one hand, there is an accelerated risk of OA post PCL 
injury reported, justifying a PCL surgical repair. On the other hand, OA af-
ter a PCL repair is similar or worse compared to a conservative PCL rehabil-
itation, questioning the benefit of a repair [7].  
The global burden of disease indicated hip and knee OA as the 11th highest 
contributor to global disability [67]. Health services might face an increase 
in demand of care sought in relation to hip and knee OA as a result of the 
ageing population and obesity [67].  
 
Current clinical management of the disease or health condition 
A0024 – How is anterior or posterior cruciate ligament rupture currently 
diagnosed according to published guidelines and in practice? 
An ACL rupture is best diagnosed via Magnetic Resonance Imaging (MRI) 
[7]. Information in regard to any other possible ligament, meniscal and ar-
ticular cartilage injuries may also be diagnosed with an MRI scan. Diagnos-
tic studies, particular arthroscopy as the standard of care, report a sensitivity 
of 92 to 100% and a specificity of 95 to 100% for ACL diagnoses [68]. 
The examination should evaluate the timing and mechanism of the injury, 
any joint swelling, instability and functional inability, such as walking and 
descending stairs [7, 26]. This is followed by a lower limb, physical, muscu-
loskeletal examination in comparison to the non-injured knee by a health-
care professional.  
The MRI scan demonstrates an almost 100% sensitivity and specificity for 
accurately diagnosing an acute PCL injury [8] compared to arthroscopy as 
standard care. A provisional acute PCL injury can be diagnosed according to 
the mechanism of the injury and a physical examination using the posterior 
drawer test, the posterior sag sign, and the quadriceps active test. Confirma-
tion of the diagnosis is with an MRI scan or arthroscopy. The latter (arthros-
copy) can also be used for the reconstruction of a cruciate ligament as such. 
In chronic PCL injuries, MRI and arthroscopy might not accurately diag-
nose the injury, as the PCL rupture might heal over time and the PCL view 
is often obscured by the ACL [8]. 
A0025 – How are anterior or posterior cruciate ligament ruptures 
currently managed according to published guidelines and in practice? 
Only one relevant clinical practice guideline (CPG) was identified. The CPG 
was published in 2015 by the American Academy of Orthopaedic Surgeons 
(AAOS) and focused on the management of ACL injuries [25]. The AAOS re-
commends, inter alia, the following regarding the adequate treatment of ACL 
injuries: 
 moderate evidence supporting surgical reconstruction in active  
young adult patients,  
 limited evidence in skeletally immature patients, with ACL tears,  
 limited evidence supporting conservative management  
(non-surgical therapy) for less active patients with less laxity, 
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 moderate evidence supporting neuromuscular training programs  
to reduce the risk of further ACL injuries. 
According to information from the consulted clinical expert, the appropriate-
ness of early surgical reconstruction in active young adult patients may be 
questioned. In this context, he referred to a randomised controlled trial [39] 
that showed that in young, active adults with acute ACL tears, a strategy of 
rehabilitation plus early ACLR was not superior to a strategy of rehabilitation 
plus optional delayed ACL reconstruction. In addition, the latter strategy sub-
stantially reduced the frequency of surgical reconstructions. This shows that 
controversy may exist regarding the appropriate management of ACL tears. 
Regarding graft type selection, the AAOS [25] suggests that there is strong 
evidence to either use autografts or allografts in patients undergoing ACL 
reconstruction. The AAOS states that allograft and autograft ACL reconstruc-
tion leads to similar measured outcomes based on their systematic review con-
ducted in 2013. 
In practice, acute ACL injuries are managed with protection, rest, ice, com-
pression, and elevation. Ruptures may be managed conservatively or surgi-
cally, depending on the extent of the injury, patient activity levels, patient 
characteristics, and available resources [7]. Surgical management should take 
the patients’ functional level, physical demands placed on the knee, and oth-
er potential injuries to the meniscus or other ligaments into consideration [7]. 
This option is mainly exercised by the active and younger patients or the 
high-level elite athletes [7] who participate in sports which require cutting, 
jumping, pivoting, and rapid deceleration. A significant subjective history of 
instability, where the knee gives way while descending stairs or during other 
single leg activities, would also justify a surgical management approach [7]. 
Acute PCL injuries are referred for immediate surgical opinion from an ex-
perienced orthopaedic surgeon if a multi-ligament injury is suspected after a 
traumatic incident or there is severe instability of the knee. This is due to the 
higher incidence of morbidity for multi-ligament injuries compared to iso-
lated PCL injuries [8]. 
If an isolated PCL injury is diagnosed and no immediate referral is neces-
sary, the standard of care should include the management of pain and disa-
bility with walking aids and braces according to the PRICE-M (protection, 
rest, ice, compression, elevation, and medication) principle and conservative 
rehabilitation [8]. 
 
Target population 
A0007 – What is the target population in this assessment? 
A0023 – How many people belong to the target population?  
A0011 – How much are allograft cruciate ligament reconstructions 
utilised? 
The target population in this assessment includes all patients who are can-
didates for anterior cruciate ligament reconstruction (ACLR), posterior cru-
ciate ligament reconstruction (PCLR), revision ACLR, revision PCLR, or cru-
ciate ligament reconstructions in patients with multi-ligament knee injuries. 
According to information retrieved from DexiMed [2], 31-37 per 100,000 ACL 
ruptures occur annually in Germany. According to data from the US, nearly 
250,000 ACL ruptures occur annually [58, 69], and there is an annual inci-
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dence in the general population of 1 in 3,500 [3]. PCL injuries are less com-
mon compared to ACL injuries – approximately 1 to 44 percent of all knee 
injuries are PCL injuries based on data from the United States [4, 5]. How-
ever, we did not identify relevant data on the incidence of PCL injuries by 
hand-searching. Similarly, we were unable to find any relevant incidence da-
ta on ACL or PCL re-ruptures and mutli-ligament knee injuries. 
The reader must be aware that the presented incidence data do not necessari-
ly reflect the actual target population, given that a reconstruction is not always 
necessary in cruciate ligament ruptures [2]. 
In Austria, the estimated overall annual utilisation of allograft cruciate liga-
ment reconstructions is approximately 900-920 according to information re-
trieved from the submission files of the submitting hospitals. 
 
 
ca. 900-920 jährliche 
Behandlungen in Ö 
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5 Clinical effectiveness 
5.1 Outcomes 
The following outcome was defined as crucial to derive a recommendation: 
 Patient-reported function, activity level and symptoms 
Postoperative differences of patient-reported function, activity level and symp-
toms between treatment groups were defined to be crucial to formulate a re-
commendation, since they are shown to be patient-centred outcomes indicat-
ing a success after anterior cruciate ligament reconstruction [70]. The follow-
ing tools can be used for this crucial outcome:  
 Lysholm score: Scale from 0-100; higher score indicates  
fewer symptoms/disability [71].  
 Tegner score: Scale from 0-10; higher score indicates better  
activity level [72]. 
 Cincinnati Knee score: Scale from 0-100; higher score indicates better 
knee function [73] (score is calculated through a sum of questions in 
the area of pain, swelling, function, as well as activity level).  
 Single Assessment Numeric Evaluation (SANE): Scale from 0-100; 
higher score indicates better function/less disability3 [74].  
 International Knee Documentation Committee (IKDC) Subjective   
Knee Evaluation Form: Scale from 0-100: higher score indicates fewer 
symptoms/disability – a score of 100 means no limitation with daily 
sporting activities and the absence of symptoms [71]. 
 Knee Injury and Osteoarthritis Outcome Score (KOOS): This compo-
site measure consists of 5 subscales (pain, symptoms, activities of dai-
ly living, sport and recreational activities, and knee-related quality of 
life) scored seperately on a scale from 0-100 (0 means extreme prob-
lems and 100 no problems) [71].  
 Marx activity scale: Scale from 0 (low activity)  
to 16 (highest activity) [75].  
The scores of these outcomes were extracted pre- and postoperatively. How-
ever, the evidence synthesis is based on postoperative differences between 
patients receiving allografts and autografts because the studies only reported 
on the differences of the postoperative scores between groups.  
Three further outcomes were judged important, but not crucial,  
to formulating a recommendation: 
 Clinical knee stability 
 Quality of Life 
 Patient satisfaction 
 
                                                             
3 SANE is a single-question instrument that elaborates a score by asking the patient 
the following question solely: “On a scale from zero to 100, how would you rate your 
knee today (100 being normal)?” [74] 
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Clinical knee stability can be measured using different tests. The Lachman 
and the Pivot shift tests are used to measure the knee stability of patients af-
ter a cruciate ligament injury and reconstruction. Usually, those tests use 4 
grades hereby [22]: 
 grade 0 (Lachman: -1 to 2 mm, Pivot shift: equal), 
 grade 1 (Lachman: 3-5mm, Pivot shift: glide), 
 grade 2 (Lachman: 6-10mm, Pivot shift: clunk), and 
 grade 3 (Lachman: >10mm, Pivot shift: gross). 
In this assessment, the grades have been dichotomised in intact (grade 0, 
grade I) and torn (grade II-III) [76]. The number of patients with intact knees 
was hereby extracted and used for evidence synthesis. 
Similarly, the objective IKDC evaluation consists of 4 grades that are used 
to assess the stability of a patient’s knee: normal (<3mm), nearly normal (3 
to 5 mm), abnormal (6 to 10 mm), severely abnormal (>10mm) [22]. In this 
assessment, this sub-outcome was also dichotomised in normal stability (i.e., 
normal and nearly normal objective IKDC score), and abnormal (i.e., abnor-
mal and severely abnormal objective IKDC score). The number of patients 
with normal knee stability was extracted and used for evidence synthesis. 
In addition, there are certain instrumented tests that measure the outcome 
of clinical knee stability. The KT arthrometer is used to measure the side-to-
side difference. A lower side-to-side difference may indicate less knee laxity 
(and more stability), and may be a factor indicating the superiority of one 
graft over the other. 
The results of the objective outcomes (i.e., Lachman test, Pivot shift test, or 
KT arthrometer results, or objective IKDC evaluation) were only extracted 
postoperatively. 
The tools for measuring knee stability (e.g., using the Lachman or Pivot shift 
test) are discussed controversially in the literature for being subjective. A re-
cent consensus document stated that functional tests and laxity measures were 
not identified as important measures of successful outcome 1 or 2 years after 
ACL injury or reconstruction [70]. These outcomes were only considered as 
important, but not crucial, to formulating a recommendation.  
According to information from the clinical expert from Graz, the rolimeter 
[77] is used in Austrian clinical practice and may be used for research to 
measure rotational instability. Yet, none of the studies used this instrument. 
Patient satisfaction and Quality of Life are further patient-relevant outcomes 
that were defined as important, but not crucial, because this outcome appears 
to be only indirectly affected by the different graft type due to the functional 
and activity level.  
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5.2 Included studies 
In total, 9 clinical studies met the inclusion criteria for the evaluation of the 
comparative effectiveness of allografts to be used for cruciate ligament recon-
struction. All of the studies compared allografts to autografts in cruciate lig-
ament reconstructions. Six RCTs [15, 17, 19-22] were included for anterior 
cruciate ligament reconstruction (ACLR), while 2 further RCTs were includ-
ed for posterior cruciate ligament reconstruction (PCLR) [18, 23]. 1 further 
prospective comparative cohort study [16] was identified for the indication 
revision ACLR.  
Of the included studies, 2 were conducted in the United States [15, 16], 6 stud-
ies were conducted in China [17-22], and 1 further study was conducted in 
Taiwan [23]. 
No study comparing allografts to conservative management in either of the 
indications selected in this assessment was identified. 
The reader is referred to Table A-1, Table A-2, Table A-3 for more informa-
tion on study characteristics and results of included studies, and to the evi-
dence profiles according to GRADE (see Table A-7, Table A-8, and Table A-9). 
 
 
5.3 Results 
5.3.1 Use of allografts in anterior cruciate 
ligament reconstruction 
Study characteristics 
For ACLR, 6 studies met the inclusion criteria [15, 17, 19-22]. All of the stud-
ies compared allograft to autograft ACLR in patients with ruptured ACL. 
However, there were differences regarding graft type and procedure, e.g., 
whether a graft was fresh-frozen, irradiated or whether bone-patellar bone 
tendon-bone, tibialis anterior or posterior or hamstring tendons were used. 
Of the included studies, 2 of them [19, 22] used allografts that were irradiat-
ed, while the remaining studies [15, 17, 20, 21] did not use irradiation for the 
purpose of disinfecting the allografts. The source of graft differed between 
studies (e.g., hamstring tendons, bone-patellar tendons). 
Overall, the number of patients at the time of randomisation across studies 
resulted in 794 patients with an ACL deficiency that needed ACLR. Sample 
sizes at time of randomisation ranged from 99 patients to 208 patients. Of all 
enrolled patients across studies, 34 patients received hybrid grafts (a combi-
nation of allografts and autografts), and a further 69 patients were lost to fol-
low-up. One study [15] did not clearly mention the number of patients in-
cluded, as one patient underwent bilateral, simultaneous ACL reconstruc-
tions using an autograft on one side and an allograft on the other side; the 
loss to follow-up was not clearly stated; and the results refer to knees and not 
patients [15]. Therefore, we identified 352 patients who received allografts 
and 340 patients who received autografts (n=692). The reader must be aware 
that one entity in either the allograft or autograft group refers to a knee. 
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The mean follow-up across studies ranged from 5.6 to 10.5 years. Loss to fol-
low-up ranged from 3% to 22.4%. It appears that loss to follow-up in the au-
tograft groups was higher when compared to the allograft groups, with a per-
centage of patients lost to follow-up ranging from 0-25.9% in the autograft 
groups compared to 0-18.9% in the allograft groups. The mean age of the pa-
tients receiving allografts and autografts ranged from 28 to 32.8 years and 
28.9 to 31.7 years, respectively. The percentage of females within the studies 
ranged from 12.2% to 53.1% in patients receiving allografts and 14.6% to 
47.2% in patients receiving autografts.  
In 5/6 studies [15, 19-22], it was stated that most of the baseline characteris-
tics were not statistically significantly different (p<0.05) between treatment 
groups, except for Chondral pathological abnormalities of the lateral femoral 
condyle being statistically significantly different in 1 study [15], with 87.8% 
and 72.9% with grade 0 lateral compartment in the allograft and autograft 
group, respectively. Co-interventions included meniscus treatment (e.g., re-
pair, reconstruction) in 5/6 studies [15, 19-22]. The remaining study [17] nei-
ther sufficiently reported on baseline characteristics, nor on co-interventions. 
Patients received pre- or postoperative rehabilitation such as physiotherapy. 
All studies reported that the enrolled patients received the same postopera-
tive rehabilitation programme. 
In all of the included studies [15, 17, 19-22], the significance level was defined 
as p<0.05. 
The reader is referred to the data extraction table (see Table A-1), the sum-
mary of findings table (see Table 7-1), and the GRADE evidence profile (see 
Table A-7) for more information. 
 
Mortality 
D0001 – What is the expected beneficial effect  
of allograft ACLR on mortality? 
D0003 – What is the effect of allograft ACLR on the mortality  
due to causes other than the target disease? 
Due to the fact that cruciate ligament tears are not life-threatening, mortality 
was not considered to be affected. However, procedure-related mortality can 
be found in the safety domain (see Chapter 6). 
 
Morbidity 
D0005 – How does allograft ACLR affect symptoms and findings 
(severity, frequency) of the disease or health condition? 
D0006 – How does allograft ACLR affect progression (or recurrence)  
of the disease or health condition? 
Re-ruptures may be considered as a recurrence after cruciate ligament recon-
structions. In this assessment, however, this outcome was considered to be a 
safety-related one and the evidence regarding it was synthesised in Chapter 6. 
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Function 
D0011 – What is the effect of allograft ACLR on patients’ body functions? 
D0016 – How does the use of allograft ACLR affect activities  
of daily living? 
Answering these research questions can be based on the selected crucial out-
comes of patient-reported function, activity level and symptoms, as well as on 
the selected, important outcome of clinical knee stability. 
Patient-reported function, activity level and symptoms  
This outcome was measured by all studies using different validated instru-
ments. The certainty of the results of these respective instruments ranged from 
low to moderate. 
The Lysholm score was reported in 5/6 included studies [17, 19-22]. In total, 
595 patients (excluding 31 patients with hybrid grafts) were analysed hereby. 
Overall, 303 and 292 patients received an allograft and autograft, respective-
ly. None of the studies found a statistically significant difference in mean 
Lysholm scores between treatment groups postoperatively (p>0.05). Postop-
eratively, the mean Lysholm scores ranged from 86 ±9 to 91 ±6 in the allo-
graft groups, and 85.2 ±3.1 to 91.3+11.5 in the autograft groups across stud-
ies. These results reached low certainty according to GRADE. 
The Tegner score was reported in 5/6 included studies [15, 19-22]. In total, 
586 patients (excluding 31 patients with hybrid grafts) were analysed in the 
studies. Overall, 299 and 287 patients were in the allograft and autograft 
group, respectively. None of the studies found a statistically significant dif-
ference when comparing the mean Tegner score between treatment groups 
postoperatively (p>0.05). The mean postoperative Tegner scores ranged from 
4.5 ±2.2 to 7.6 ±1.9 in the allograft groups, and 4.8 ±2.3 to 7.8 ±1.2 in the 
autograft groups across studies. These results reached moderate certainty ac-
cording to GRADE. 
The Cincinnati Knee score was reported in 3/6 included studies [20-22]. In 
total, 425 patients were analysed in the studies. Of these, 218 and 207 were in 
the allograft and autograft group, respectively. None of the studies found a 
statistically significant difference when comparing the mean Cincinnati Knee 
score between treatment groups postoperatively (p>0.05). The mean postop-
erative Cincinnati Knee score ranged from 87 ±12 to 92 ±11 in the allograft 
groups, and 90 ±10 to 91 ±12 in the autograft groups across studies. These 
results reached moderate certainty according to GRADE. 
The SANE score was reported in 1 study [15]. In this study, 49 knees received 
allografts, and 48 knees received autografts4. No statistically significant dif-
ference was found in postoperative SANE scores (p>0.05). The postoperative 
mean score was 2.7 points lower in the allograft group when compared to the 
autograft group, with 78.8 ±18.8 and 81.5 ±16.4 mean SANE scores in these 
groups, respectively. The results from the SANE score reached low certainty 
according to GRADE. 
                                                             
4 The reader is reminded that the exact number of patients in these treatment groups 
was unknown, given that the study did not clarify in which group the patient with 2 
operated knees was.  
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The subjective IKDC score was reported in all 6 included studies [15, 17, 19-
22]. In total, 692 patients (excl. 31 analysed patients with hybrid grafts) were 
analysed in the studies. Of these, 352 and 340 patients received an ACLR 
with allografts and autografts, respectively. None of the studies found a sta-
tistically significant difference in mean subjective IKDC scores between 
groups postoperatively. The mean postoperative subjective IKDC scores 
ranged from 73.7 ±25.9 to 90 ±14 in the allograft groups, and 77.2 ±25.4 to 
90 ±10 in the autograft groups across studies. The results of the subjective 
IKDC score reached moderate certainty according to GRADE. 
KOOS scores (e.g., pain, symptoms) were not used by any of the included 
studies. 
The Marx activity scale was not used by any of the included studies. 
Clinical knee stability 
The outcome of clinical knee stability was measured using a variety of dif-
ferent tests. In this assessment, the Lachman test, Pivot shift test, and the 
instrumented side-to-side difference were selected for this outcome. 
The Lachman test was reported in 4/6 studies [19-22]5. In total, 489 patients 
(excluding 31 patients with hybrid graft) were analysed in the studies. Of 
these, 250 received an allograft, and 239 patients received an autograft. 1 study 
[22] found a statistically significant difference in postoperative Lachman scores 
favouring autografts. That is, worse postoperative Lachman test results were 
found in the allograft group when compared to the autograft group, with 31/ 
43 (72%) and 37/40 (93%) patients with grade 0-1 on the Lachman test in 
these groups, respectively. The remaining 3 studies [19-21] did not find any 
statistically significant differences in the postoperative Lachman test between 
treatment groups postoperatively. The proportion of patients with intact lig-
aments (grade 0-1) postoperatively according to the Lachman test across stud-
ies ranged from 31/43 patients (72%) to 74/80 patients (92.5%) in the allo-
graft groups, and 84/91 patients (92.3%) to 30/32 patients (93.8%) in the au-
tograft groups. These results reached very low certainty according to GRADE. 
The Pivot shift test was reported in 4/6 studies [19-22]6. In total, 489 patients 
(excluding 31 patients with hybrid graft) were analysed in the studies. Of 
these, 250 received an allograft, and 239 patients received an autograft. 1 study 
[22] found a statistically significant difference, with fewer patients scoring a 
grade 0-1 on the Pivot shift test in the allograft group when compared to the 
autograft group: 38/43 (88.4%) vs. 40/40 (100%). The remaining 3 studies [19-
21] did not find any statistically significant differences in the postoperative 
Pivot shift test between the two treatment groups. The proportion of patients 
with intact ligaments (grade 0-1) postoperatively according to the Pivot shift 
test across studies ranged from 38/43 patients (88.4%) to 95/95 patients 
(100%) in the allograft groups, and 32/32 patients (100%) to 91/91 patients 
(100%) in the autograft groups. These results reached very low certainty ac-
cording to GRADE. 
                                                             
5 One further study [17] stated that the Lachman test was used, yet the data was 
insufficient to calculate the number of patients with intact ligaments (grade 0-1). 
6 One further study [17] stated that the Pivot shift test was used, yet the data was 
insufficient to calculate the number of patients with intact ligaments (grade 0-1). 
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Side-to-side difference in mm was reported in 4/6 included studies [19-22]. 
In total, 489 patients (excluding 31 patients with hybrid graft) were analysed 
in the studies. Of these, 250 received an allograft, and 239 patients received 
an autograft. 2/4 studies [19, 22] found a statistically significant difference in 
instrumented knee laxity favouring autografts, while the other 2/4 studies [20, 
21] did not find any statistically significant difference in postoperative mean 
side-to-side differences measured with the KT arthrometer between treat-
ment groups. Mean side-to-side differences (in mm) ranged from 2.5 ±0.9 to 
5.5 ±1 in the allograft groups, as opposed to 2.1 ±1.6 to 2.5 ±0.7 in the au-
tograft groups. These results reached low certainty according to GRADE. 
The objective IKDC was reported in 4/6 included studies [19-22]. In total 
489 patients (excluding 31 patients with hybrid graft) were analysed in the 
studies. Of these, 250 received an allograft, and 239 patients received an au-
tograft. None of the studies found a statistically significant difference in the 
objective IKDC score between treatment groups (p>0.05). The proportion of 
normal or nearly normal scores according to the objective IKDC score across 
studies ranged from 38/43 patients (88.4%) to 75/80 patients (93.8%) in the 
allograft groups, and 29/32 patients (90.6%) to 38/40 patients (95%) in the au-
tograft groups. These results reached moderate certainty according to GRADE. 
The reader is referred to the data extraction table (see Table A-1), the sum-
mary of findings table (see Table 7-1), and the GRADE evidence profile (see 
Table A-7) for more information. 
 
Health-related quality of life 
D0012 – What is the effect of the technology on generic  
health-related quality of life? 
No evidence was found to answer the research question. 
D0013 – What is the effect of the technology on disease-specific  
quality of life? 
No evidence was found to answer the research question. 
 
Patient satisfaction 
D0017 – Was the use of allografts worthwhile? 
Only 1 out of 6 studies [17] reported on patient satisfaction and stated that 
there were no statistically significant difference between patients undergoing 
allograft ACLR (n=53) or autograft ACLR (n=53). Among the patients hav-
ing undergone allograft ACLR, 46/53 (86.8%) patients were satisfied and 7 
(13.2%) further patients were nearly satisfied. In the autograft group, 47/53 
(88.7%) patients were satisfied and the 5 further remaining patients (9.4%) 
were nearly satisfied. Overall, the result of this outcome reached low certain-
ty according to GRADE. 
However, this result must be interpreted with caution, since the instrument 
used to measure patient satisfaction was not reported. 
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5.3.2 Use of allografts in posterior 
cruciate ligament reconstruction 
Study characteristics 
For PCLR, 2 randomised controlled studies [18, 23] were included in this 
assessment. Both of the studies compared allografts to autografts, but differ-
ences in graft types were used: One study [18] included 4-stranded y-irradi-
ated tibialis anterior tendon allografts, and the other study [23] used Achil-
les tendon and anterior tibial tendons allografts. 
Overall, the number of patients at the time of randomisation across studies 
resulted in 145 patients with PCL ruptures and undergoing PCLR in the in-
cluded studies. Of these, 30 patients received hybrid grafts, and 7 further pa-
tients were lost to follow-up. As a result, there were 108 analysed patients re-
ceiving allografts (n=50) or autografts (n=58). 
The mean follow-up time was 2.8 years in one study [23], and 5.6 in the oth-
er study [18], while the mean age between the allograft and autograft groups 
was 32.2 vs. 31.3 years and 30 vs. 29 years in these studies, respectively.  
Co-interventions in these studies included treatment of meniscal tears at the 
time of the PCLR and patients received pre- or postoperative rehabilitation 
such as physiotherapy. All studies reported that patients received the same 
postoperative rehabilitation programme. 
In all of the included studies [18, 23], the significance level was defined as 
p<0.05. 
The reader is referred to the data extraction table (see Table A-2), the sum-
mary of findings table (see Table 7-2), and the GRADE evidence profile (see 
Table A-8) for more information. 
 
Mortality 
D0001 – What is the expected beneficial effect  
of allograft PCLR on mortality? 
D0003 – What is the effect of allograft PCLR on the mortality  
due to causes other than the target disease? 
Due to the fact that neither anterior and posterior cruciate ligament ruptures, 
nor multi-ligament knee injuries are life-threatening, mortality was not con-
sidered to be affected. However, procedure-related mortality can be found in 
the safety domain (see Chapter 6). 
 
Morbidity 
D0005 – How does allograft PCLR affect symptoms and findings 
(severity, frequency) of the disease or health condition? 
D0006 – How does allograft PCLR affect progression (or recurrence)  
of the disease or health condition? 
Re-ruptures may be considered as a recurrence after cruciate ligament recon-
structions. In this assessment, however, this outcome was considered to be a 
safety-related one, and the evidence regarding it was synthesised in Chapter 6. 
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Function 
D0011 – What is the effect of allograft PCLR on patients’ body functions? 
D0016 – How does the use of allograft PCLR affect activities  
of daily living? 
Answering these research questions can be based on the selected crucial out-
comes of patient-reported function, activity level and symptoms, as well as 
on the selected, important outcome of clinical knee stability. 
Patient-reported function, activity level and symptoms  
This outcome was measured by all studies using different validated instru-
ments.  
The Lysholm score was reported in 2 studies [18, 23]. In total, 108 patients 
(excluding 27 patients with hybrid grafts) receiving allografts (n=50) or au-
tografts (n=58) were analysed. None of the studies found a statistically sig-
nificant difference in the mean Lysholm score between treatment groups post-
operatively (p>0.05). In one study [18], the mean postoperative Lysholm score 
was 85.2 ±3.9 in the allograft group (n=27), and 87.8 ±3.6 in the autograft 
group (n=26). In another study [23], the mean postoperative Lysholm score 
was 92.3 ±6.8 in the allograft group (n=23), and 87.8 ±9.6 in the autograft 
group (n=32). These results reached very low certainty according to GRADE. 
The Tegner score was reported in 2 included studies [18, 23]. In total, 108 
patients (excluding 27 patients with hybrid grafts) receiving allografts (n=50) 
or autografts (n=58) were analysed. None of the studies found a statistically 
significant difference in the Tegner score between treatment groups postop-
eratively (p>0.05). In one study [18], the mean postoperative Tegner score 
was 6.2 ±1.7 in the allograft group (n=27), and 6.8 ±1.1 in the autograft 
group (n=26). In another study [23], the mean postoperative Tegner score was 
4.7 ±1.66 in the allograft group (n=23), and 4.73 ±1.66 in the autograft group 
(n=32). These results reached low certainty according to GRADE. 
The Cincinnati Knee score was not reported in the included studies. 
The SANE score was not reported in the included studies. 
The subjective IKDC score was reported in 1 of the 2 included studies [18]. 
In total, 53 patients (excluding 27 patients with hybrid grafts) in the study 
receiving allografts (n=27) and autografts (n=26) were analysed. The study 
did not find a statistically significant difference between treatment groups 
(p>0.05). Patients in the allograft and autograft groups had a mean postop-
erative subjective IKDC score of 80.2 ±6.8 and 83.5 ±6.3, respectively. These 
results reached low certainty according to GRADE. 
KOOS scores were not reported in the included studies. 
The Marx activity scale was not reported in the included study. 
Clinical knee stability  
The outcome of clinical knee stability was measured using a variety of differ-
ent tests. In this assessment, the reverse Lachman test, reverse Pivot shift test, 
and the instrumented side-to-side difference were selected for this outcome. 
The reverse Lachman test was reported in 1 out of 2 included studies [23]. 
The study analysed 55 patients, with 23 patients receiving allografts and 32 
patients receiving autografts. The study did not find a statistically significant 
difference in the reverse Lachman test postoperatively (p>0.05). The study 
Funktion, Aktivitätslevel 
und Symptome  
in 2/2 Studien 
 
 
Lysholm Score  
in 2/2 Studien: 
keine stat. signifikanten 
Unterschiede 
Tegner Score  
in 2/2 Studien: 
keine stat. signifikanten 
Unterschiede 
Cincinnati Knee Score  
& SANE Score: NR 
Subjective IKDC  
in 1/2 Studien: 
keine stat. signifikanten 
Unterschiede 
KOOS, Marx: NR 
Kniestabilität 
Lachman in 1/2 Studien: 
keine stat. signifikanten 
Unterschiede 
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only reported on the mean Lachman score: the allograft and autograft groups 
had a mean postoperative reverse Lachman test score of 0.7 ±0.56 and 0.75 
±0.67, respectively. These results reached low certainty according to GRADE. 
The reverse Pivot shift test was reported in 1 out of 2 included studies [18]. 
In total, 53 patients (excluding 27 patients with hybrid grafts) receiving allo-
grafts (n=27) and autografts (n=26) were analysed. The study did not find a 
statistically significant difference of the Pivot shift test between treatment 
groups postoperatively (p>0.05). The proportion of intact ligaments (grade 
0-1) according to the Pivot shift test was 26/27 patients (96.3%), and 26/26 
patients (100%) in the allograft and autograft group, respectively. These re-
sults reached moderate certainty according to GRADE. 
Side-to-side difference in mm was reported in the 2 included studies [18, 23]. 
In total, 108 patients (excluding 27 patients with hybrid grafts) receiving al-
lografts (n=50) or autografts (n=58) were analysed. One study [18] found a 
statistically significant difference favouring autografts, with postoperative 
side-to-side differences of 3.5 ±1.1 and 2.1 ±1 in the allograft and autograft 
group, respectively (p<0.001). The other study [23] did not find any statisti-
cally significant difference based on the postoperative side-to-side difference 
between the allograft and autograft groups (2.83 ±1.7 vs. 3.16 ±2.6; p>0.05) 
measured with an instrumented knee laxity test. These results reached very 
low certainty according to GRADE. 
The objective IKDC score was reported in the 2 included studies [18, 23]. In 
total, 108 patients (excluding 27 patients with hybrid grafts) receiving allo-
grafts (n=50) or autografts (n=58) were analysed. None of the studies found 
a statistically significant difference in the objective IKDC score between treat-
ment groups postoperatively. In one study [18], the proportion of patients 
classified as “normal” or “nearly normal” according to the objective IKDC 
score between the allograft and autograft groups was 24/27 patients (88.9%) 
and 25/26 patients (96.2%), respectively. In another study [23], the propor-
tion normal and nearly normal according to the objective IKDC score in the 
allograft and autograft groups was 14/23 patients (60.9%) and 23/32 patients 
(71.9%), respectively. The results of the objective IKDC score reached low cer-
tainty according to GRADE. 
The reader is referred to the data extraction table (see Table A-2), the sum-
mary of findings table (see Table 7-2), and the GRADE evidence profile (see 
Table A-8) for more information. 
 
Health-related quality of life 
D0012 – What is the effect of allograft PCLR on generic health-related 
quality of life? 
No evidence was found to answer the research question. 
D0013 – What is the effect of allograft PCLR on disease-specific  
quality of life? 
No evidence was found to answer the research question. 
 
Patient satisfaction 
D0017 – Was the use of allograft PCLR worthwhile? 
No evidence was found to answer the research question. 
Pivot-Shift  
in 1/2 Studien: 
keine stat. signifikanten 
Unterschiede 
Side-to-Side Diff.  
in 2/2 Studien: 
stat. signifikante 
Unterschiede zugunsten 
von Autografts  
in 1 Studie 
keine stat. signifikanten 
Unterschiede in der 
anderen Studie 
Objective IKDC  
in 2/2 Studien:  
keine stat. signifikanten 
Unterschiede 
HRQoL: keine Daten 
PatientInnenzufrieden-
heit: keine Daten 
Clinical effectiveness 
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5.3.3 Use of allografts in revision anterior cruciate 
ligament reconstruction 
For revision cruciate ligament reconstruction, only one prospective cohort 
study [16] with patients undergoing revision ACLR was identified. 
The study compared the use of allografts (various specific graft types, but all 
were fresh-frozen with minimal to no irradiation) and autografts (various spe-
cific graft types) in patients undergoing a revision of a previously failed ACLR. 
However, patients with multi-ligament knee injuries were not included in 
the study. 
Overall, the study enrolled 1,205 patients. Of these, 590 received an allograft 
and 583 received an autograft. A further 32 patients received a combination 
of these grafts. 
The median age of all patients was 26 (IQR: 20-34). 508 of all patients (42%) 
were female. 
The study followed them up after 2 years by questionnaire (989) and tele-
phone call (1,112). The loss to follow-up using these techniques was 216 
(17.9%) and 93 (7.7%), respectively.  
Prior revisions ranged from 1 to 3+. That is, 1055 patients had 1 revision, 
125 patients had 2 revisions, and 25 patients had 3+ revisions. Further pre-
vious surgery/ies included but was/were not limited to meniscus surgery. 
The pre- and postoperative rehabilitation of patients was not reported.  
The reader is referred to the data extraction table (see Table A-3), the sum-
mary of findings table (see Table 7-3), and the GRADE evidence profile 
(Table A-9) for more information. 
 
Mortality 
D0001 – What is the expected beneficial effect  
of allograft revision ACLR on mortality? 
D0003 – What is the effect of allograft revision ACLR  
on the mortality due to causes other than the target disease? 
Due to the fact that neither anterior and posterior cruciate ligament ruptures, 
nor multi-ligament knee injuries are life-threatening, mortality was not con-
sidered to be affected. However, procedure-related mortality can be found in 
the safety domain (see Chapter 6). 
 
Morbidity 
D0005 – How does allograft revision ACLR affect symptoms  
and findings (severity, frequency) of the disease or health condition? 
D0006 – How does allograft revision ACLR affect progression  
(or recurrence) of the disease or health condition? 
Re-ruptures may be considered as a recurrence after cruciate ligament recon-
structions. In this assessment, however, this outcome was considered to be a 
safety-related one, and the evidence regarding it was synthesised in Chapter 6. 
 
Revisions-ACLR:  
1 prospektive 
Kohortenstudie 
1.205 eingeschrieben 
590 pts mit Allograft 
583 pts mit Autograft 
FU: 2 Jahre 
Loss to FU 
(questionnaire): 17.9 % 
Loss to FU (telephone): 
7.7 %  
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Function 
D0011 – What is the effect of allograft revision ACLR  
on patients’ body functions? 
D0016 – How does the use of allograft revision ACLR affect  
activities of daily living? 
Answering these research questions can be based on the selected crucial out-
come of patient-reported function, activity level and symptoms, as well as on 
the selected important outcome of clinical knee stability. 
Patient-reported function, activity level and symptoms  
This outcome was measured by the included study using different validated 
instruments. The certainty of the results of these respective instruments was 
low according to GRADE. 
The Lysholm score was not reported in the included study. 
The Tegner score was not reported in the included study. 
The Cincinnati Knee score was not reported in the included study. 
The SANE score was not reported in the included study. 
The subjective IKDC score was reported in the included study [16]. The 
study only reported on the subjective IKDC score for all patients and not be-
tween allograft and autograft. The study did, however, conduct a logistic re-
gression analysis and found that graft choice proved to be a significant pre-
dictor of 2-year IKDC scores (p=0.017). The use of an autograft for revision 
reconstruction, therefore, predicted an improved score on the IKDC (p=0.045; 
OR =1.31; 95% CI: 1.01-1.70).  
KOOS scores were reported in the included study [16]. However, the respec-
tive scores between the different groups were not reported. The study con-
ducted a logistic regression analysis and stated that graft choice did not pre-
dict the KOOS symptoms score (no further data reported). KOOS pain score 
was not reported, but the study found higher scores of the KOOS sports and 
recreation in the setting of an autograft compared with an allograft for revi-
sion ACLR (p=0.037; OR: 1.33; 95%CI: 1.02-1.73). The study further report-
ed that graft choice did not predict the KOOS activities of daily living score 
(no further data reported).  
The Marx activity scale was reported in the included study [16]. Results from 
the logistic regression analysis show that graft choice was a significant pre-
dictor of the Marx activity score (p=0.012). More precisely, the use of a com-
bination of graft types (i.e., autograft and allograft) for revision reconstruc-
tion predicted improved scores on the Marx activity scale (p=0.005; OR: 3.33; 
95%CI: 1.43-7.78). No further data were reported. 
Clinical Knee stability  
The included study did not report on any of the clinical knee stability. 
 
Funktion, Aktivitätslevel 
und Symptome  
in 1/1 Studie 
Lysholm, Tegner, SANE, 
Cincinnati Knee Score: 
NR 
Subjective IKDC  
in 1 Studie: 
Autograft Prädiktor für 
verbesserten IKDC Score 
KOOS Score in 1 Studie 
 
Transplantattyp  
kein Prädiktor für 
verbesserten  
KOOS Score 
Marx Activity Scale  
in 1 Studie: Kombination 
aus Autograft und 
Allograft war Prädiktor 
für verbesserten Score 
Kniestabilität: NR 
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Health-related quality of life 
D0012 – What is the effect of allograft revision ACLR on generic health-
related quality of life (HRQoL)? 
The included study [16] reported on generic HRQoL using the KOOS quali-
ty of life scale. However, only scores for all patients were reported. Results 
from logistic regression analysis show that the use of autografts predicted im-
proved scores on the KOOS quality of life subscale (p=0.031; OR: 1.33; 95%CI: 
1.03-1.73). 
D0013 – What is the effect of allograft revision ACLR  
on disease-specific quality of life? 
No evidence was found to answer the research question. 
 
Patient satisfaction 
D0017 – Was the use of allograft revision ACLR worthwhile? 
No evidence was found to answer the research question. 
The reader is referred to the data extraction table (see Table A-3), the sum-
mary of findings table (see Table 7-3), and the GRADE evidence profile (see 
Table A-9) for more information. 
 
 
5.3.4 Use of allografts in revision posterior cruciate 
ligament reconstruction  
No evidence was identified through the systematic literature search to answer 
the research question. 
 
5.3.5 Use of allografts for ligament reconstruction 
in patients with multi-ligament knee injuries  
No evidence was identified through the systematic literature search to answer 
the research question. 
 
HRQoL in 1 Studie: 
Autograft Prädiktor  
für verbesserten  
KOOS QoL Score 
PatientInnen-
zufriedenheit:  
keine Daten 
Revisions-PCLR:  
keine Evidenz 
Multi-ligament knee 
injuries: keine Evidenz 
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6 Safety 
6.1 Outcomes 
The following outcomes were defined as crucial to derive  
a recommendation: 
 Graft failure 
 Re-ruptures 
 Re-operations 
 Revisions 
 Complications 
Graft failure was chosen as a crucial outcome for the evaluation of the safety 
of allograft cruciate ligament reconstruction, since it may require further in-
vasive surgeries and could, as a result, be an indicator for clinically inappro-
priate care. Graft failure was not defined in a standardised way by the in-
cluded studies. 
Re-ruptures, re-operations, and revisions are similar terms associated with 
graft failures. These outcomes were extracted separately and were also classi-
fied as crucial to derive a recommendation. 
Complications were defined broadly in this assessment and capture routine 
surgical complications such as infection, anaesthesia complications, et cetera, 
and complications associated with cruciate ligament surgery. The latter in-
cludes, but is not limited to, postoperative loss of motion, arthrofibrosis, and 
donor site morbidity [25]. 
In addition to the crucial outcomes, one further outcome was considered to 
be important, but not crucial, to the decision: 
 Procedure-related mortality 
Procedure-related mortality is very rare, given that neither the condition nor 
the therapeutic procedure is life-threatening. This outcome has been included 
in determining whether or not there is any procedure-related mortality risk 
associated with the use of allograft cruciate ligament reconstruction. 
 
  
wesentliche 
Sicherheitsendpunkte: 
Komplikationen, 
Transplantversagen,  
Re-Rupturen, etc. 
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6.2 Included studies 
In total, 9 clinical studies were included in this assessment. All of the studies 
compared allografts to autografts in cruciate ligament reconstructions. Six 
RCTs [15, 17, 19-22] were included for anterior cruciate ligament reconstruc-
tion (ACLR), while 2 further RCTs were included for posterior cruciate lig-
ament reconstruction (PCLR) [18, 23]. For revision reconstruction, 1 cohort 
study met the inclusion criteria [16] of patients with revision ACLR. 
Of the included studies, 2 were conducted in the United States [15, 16], 6 
studies were conducted in China [17-22], and 1 further study was conducted 
in Taiwan [23]. 
All of the included studies compared allografts to autografts in cruciate liga-
ment reconstructions. No study was identified comparing allografts to con-
servative management in either of the indications selected in this assessment. 
The reader is referred to Table A-1, Table A-2 and Table A-3 for more in-
formation on study characteristics and results of included studies, as well as 
to the evidence profiles according to GRADE (see Table A-7, Table A-8, and 
Table A-9). 
 
 
6.3 Results 
6.3.1 Use of allografts in anterior cruciate 
ligament reconstruction 
Study and patient characteristics 
For ACLR, 6 clinical studies were included [15, 17, 19-22]. All of the studies 
compared allograft to autograft ACLR in patients with ruptured ACL. How-
ever, differences regarding graft type and procedure were existent, e.g., wheth-
er a graft was fresh-frozen, irradiated or whether bone-patellar bone tendon-
bone or hamstring tendons were used. 
Of the included studies, 2 studies [19, 22] used allografts that were irradiat-
ed, while the remaining studies [15, 17, 20, 21] did not use irradiation for the 
purpose of disinfecting the allografts. The source of graft differed between 
studies (e.g., hamstring tendons, bone-patellar tendons). 
Overall, the number of patients at the time of randomisation across studies 
resulted in 794 patients with an ACL deficiency that needed ACLR being 
enrolled in the included studies. Sample sizes at the time of randomisation 
ranged from 99 to 208 patients. Of all enrolled patients across studies, 34 pa-
tients received hybrid grafts (a combination of allografts and autografts), and 
further 69 patients were lost to follow-up. One study [15] did not clearly men-
tion the number of patients included, as one patient underwent bilateral, 
simultaneous ACL reconstructions using an autograft on one side, and an al-
lograft on the other side. Moreover, the loss to follow-up was not clearly stat-
ed, and the results refer to knees and not patients [15]. Therefore, we identi-
fied 352 patients who received allografts and 340 patients who received au-
tografts (n=692). The reader must be aware that one entity in either allograft 
or autograft group refers to a knee. 
9 Studien 
eingeschlossen 
ACLR: 6 RCTs 
PCLR: 2 RCTs 
Revisions-ACLR:  
1 Kohortenstudie 
ACLR: 6 RCTs 
794 pts 
 
692 pts analysiert  
(excl. pts mit  
Hybrid Grafts) 
 
352 pts mit Allograft 
340 pts mit Autograft 
Safety 
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The mean follow-up across studies ranged from 5.6 to 10.5 years. Loss to fol-
low-up ranged from 3% to 22.4%. It appears that loss to follow-up in the au-
tograft groups was higher when compared to the allograft groups, with a per-
centage of patients lost to follow-up ranging from 0-25.9% in the autograft 
groups compared to 0-18.9% in the allograft groups. The mean age of the pa-
tients receiving allografts and autografts ranged from 28 to 32.8 years and 
28.9 to 31.7 years in the groups, respectively. The percentage of females with-
in the studies ranged from 12.2% to 53.1% in patients receiving allografts, 
and 14.6% to 47.2% in patients receiving autografts.  
In 5/6 studies [15, 19-22], it was stated that most of the baseline characteris-
tics were not statistically significant between treatment groups, except for 
lateral compartment being statistically significantly different in 1 study [15], 
with 87.8% and 72.9% with grade 0 lateral compartment in the allograft and 
autograft groups, respectively. Co-interventions included meniscus treatment 
(e.g., repair, reconstruction) in 5/6 studies [15, 19-22]. The remaining study 
[17] neither sufficiently reported on baseline characteristics, nor on co-inter-
ventions. Patients received pre- or postoperative rehabilitation such as phys-
iotherapy. All studies reported that the enrolled patients received the same 
postoperative rehabilitation programme. 
In all of the included studies [15, 17, 19-22], the significance level was defined 
as p<0.05. Yet, for safety outcomes, it appears that differences were not al-
ways statistically tested by the included studies, since the p-value was not al-
ways reported. 
The reader is referred to the data extraction table (see Table A-1), the sum-
mary of findings table (see Table 7-1), and the GRADE evidence profile (see 
Table A-7) for more information. 
 
Patient safety 
C0008 – How safe is allograft ACLR in comparison to autograft ACLR? 
Graft failure 
Graft failure was reported in 2/6 included studies [15, 22]. One study [15] 
reported on a graft failure rate of 13/49 (26.5%), and 4/48 (8.3%) knees in 
the allograft and autograft groups, respectively (p<0.05). The sample of this 
study included highly active, young patients. The other study [22] reported 
on a graft failure occurring in 13/43 (30.2%) patients in the (irradiated) al-
lograft group, and 3/40 (7.5%) in the autograft group (p<0.001). Graft fail-
ure was measured differently in the included studies. The results of this out-
come reached moderate certainty according to GRADE. This outcome was 
downgraded due to suspected applicability problems, e.g., it was unclear in 
how far these results are generalisable due to the fact that one study [15] on-
ly included highly active military (mostly) men, and the other study [22] on-
ly had irradiated allografts as their intervention. 
Re-rupture rate 
The re-rupture rate was not reported in any of the included studies. 
Re-operation rate 
The re-operation rate was not reported in any of the included studies. 
Mean FU: 5.6-10.5 J. 
Loss to FU (Allograft): 
0-25.9 % 
Loss to FU (Autograft): 
0-18.9 % 
Baseline Characteristics 
in 5/6 Studien 
ausreichend 
beschrieben: 
vergleichbar 
Transplantversagen  
in 2/6 Studien berichtet: 
1 RCT (Allo vs. Auto): 
13/49 (26.5 %) vs.  
4/48 (8.3 %), aktives 
junges Sample 
 
1 RCT (bestrahlte  
Allo vs. Auto):  
13/43 (30.2 %) vs.  
3/40 (7.5 %)  
Re-Rupturen,  
Re-Operationen: NR 
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Revisions 
The outcome of revisions was reported in 2/6 included studies [15, 19]. One 
study [15] reported on a revision ACLR rate of 13/49 knees (26.5%), and 4/48 
knees (8.3%) knees in the allograft and autograft groups, respectively. The 
sample of this study included highly active, young patients. The other study 
[19] stated that no patient needed additional surgery because of recurrent or 
residual symptoms in 32 and 32 analysed patients receiving y-irradiated al-
lografts and autografts, respectively (and an additional 31 patients receiving 
hybrid grafts). The results of this outcome reached low certainty according to 
GRADE. This outcome was downgraded because the results were not consistent, 
and due to applicability problems, e.g., it was unclear in how far these results 
are generalisable due to the fact that one study [15] only included highly active 
military (mostly) men, and the other study [19] used y-irradiated allografts. 
Overall complications 
None of the studies reported on the overall complication rate.  
Arthrofibrosis was reported in 2 studies (n=269) [21, 22]: No events occurred 
in both groups (0% vs. 0%).  
Effusion was not reported in any of the included studies.  
Tenderness was reported in 1 study [21], with 0/95 (0%) and 2/91 (2.1%) af-
fected patients in allograft and autograft groups, respectively.  
Infections were reported in 4 studies [19-22]: one study [19] stated that no 
postoperative infection occurred (0% vs. 0%), while the other studies found 
infections occurring in allograft patients (1.25-4.6%), as opposed to none in 
the autograft group (0%). No statistical testing was conducted. 
Hypoesthesia was reported in 2 studies [21, 22] and favoured allografts (0% 
vs. 3.3-7.5%). No statistical testing was conducted.  
Synovitis was not reported in any of the included studies.  
Deep venous thrombosis (DVT) was reported on by 3 studies [20-22]. Of these, 
2 [21, 22] stated that no DVTs occurred, and in another study [20], 3 cases 
with this complication occurred: 2 (2.5%) vs. 1 (1.3%). No statistical testing 
was conducted.  
Other complications were reported in the included studies: Arthritic pro-
gression was mentioned in 1 study [22] and found statistically significantly 
higher progression in the allograft group when compared to the autograft 
group, with 14 (32.6%) and 4 (10%) in these groups, respectively (p<0.05). 
Postoperative axillary fever time was reported in 1 study [20], with 2.4 days 
longer in the allograft group (mean: 6.8 days) when compared to the auto-
graft group (mean: 4.4 days; diff. s. s., with p<0.05). Two further studies [15, 
17] reported that tibial and femoral tunnel widening was lower in the auto-
graft group, yet only 1 of these studies [17] found a statistically significant 
difference (p<0.05) of tibial and femoral tunnel size widening between allo-
graft and autograft. In this study [17], the postoperative mean tibial tunnel 
size (in mm) was 7.8 ±0.4 vs. 7.61 ±0.22, and the postoperative mean femo-
ral tunnel size (in mm) was 7.64 ±0.35 vs. 7.51 ±0.42. 
Furthermore, some of the included studies specifically stated that there were 
no cases of pain when kneeling, anterior knee pain, et cetera7. 
Overall, the outcome of complications reached low certainty according to 
GRADE.  
                                                             
7 The reader is referred to the data extraction table (see Table A-1) for more information. 
Revisionsrate in  
2/6 Studien berichtet: 
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Procedure-related mortality 
None of the included studies reported on procedure-related mortality. 
C0002 – Are the harms related to dosage or frequency  
of applying allograft ACLR? 
No evidence was found to answer the research question. 
C0004 – How does the frequency or severity of harms change  
over time or in different settings? 
No evidence was found to answer the research question. 
C0005 – What are the susceptible patient groups that are more likely  
to be harmed through the use of allograft ACLR? 
No evidence was found to answer the research question. 
C0007 – Are allograft and autograft ACLR associated  
with user-dependent harms? 
No evidence was found to answer the research question. 
 
Investments and tools required 
B0010 – What kind of data/records and/or registry is needed  
to monitor the use of allograft and autograft ACLR? 
No evidence was found to answer the research question. 
 
 
6.3.2 Use of allografts in posterior cruciate 
ligament reconstruction 
Study characteristics 
For PCLR, 2 randomised controlled studies [18, 23] were included in this as-
sessment. Both of the studies compared allografts to autografts; however, dif-
ferences in graft types were used: One study [18] included 4-stranded y-irra-
diated tibialis anterior tendon allografts, and the other study [23] used Achil-
les tendon and anterior tibial tendons allografts. 
Overall, the number of patients at the time of randomisation across studies 
resulted in 145 patients with PCL ruptures and undergoing PCLR. Of these, 
30 patients received hybrid grafts, and 7 further patients were lost to follow-
up. As a result, there were 108 analysed patients receiving allografts (n=50) 
or autografts (n=58). 
The mean follow-up time was 2.8 years in one study [23] and 5.6 years in an-
other study [18]. The loss to follow-up rate was 11% (10% vs. 13%) in one 
study [18] and not reported in another study8 [23]. The mean age between 
allograft and autograft groups was 32.2 vs. 31.3 years, and 30 vs. 29 years in 
these studies, respectively.  
                                                             
8 The study did not adequately report on the enrolment process. Therefore, the loss to 
follow-up rate could not have been stated. 
PCLR: 2 RCTs 
145 pts; 
108 pts analysiert  
(excl. Hybrid Grafts):  
50 vs. 58 
Mean FU:  
2.8-5.6 Jahre 
Allograft for anterior and posterior cruciate ligament reconstruction 
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Co-interventions in the included studies included treatment of meniscal tears 
before PCLR and patients receiving pre- or postoperative rehabilitation such 
as physiotherapy. All studies reported that patients received the same post-
operative rehabilitation programme. 
In all of the included studies [18, 23], the significance level was defined as 
p<0.05. Yet, the differences in safety outcomes were not always statistically 
tested, since no p-values were reported 
The reader is referred to the data extraction table (see Table A-2) the 
summary of findings table (see Table 7-2), and the GRADE evidence profile 
(see Table A-8) for more information. 
 
Patient safety 
C0008 – How safe is allograft PCLR in comparison to autograft PCLR? 
Graft failure 
The graft failure rate was not reported in any of the included studies. 
Re-rupture rate 
The re-rupture rate was not reported in any of the included studies. 
Re-operation rate 
The re-operation rate was reported in 1 study [18], yet the information of re-
porting on this outcome was sparse and indirect. The study only stated that 
no patient needed additional surgery because of recurrent or residual poste-
rior laxity. This outcome reached low certainty according to GRADE. 
Revisions 
The outcome of revisions was not reported in any of the included studies. 
Overall complications 
1 out of the 2 included studies [23] reported on an overall complication rate. 
In the allograft group, no complications occurred (0%), as opposed to 7 com-
plications (21.9%) in the autograft group. No statistical testing was conduct-
ed, since the p-value was not reported in the study. 
Arthrofibrosis was not reported in the included studies. 
Effusion was not reported in the included studies. 
Tenderness was not reported in the included studies. 
Infections were reported in the 2 included studies [18, 23]: One study [18] 
stated that no postoperative infection occurred. Another study [23] reported 
on 2 infections (6.3%; 1 acute and 1 late infection) occurring in the autograft 
group, while no infections occurred in the allograft group. The difference was 
not statistically tested, since the p-value was not reported. 
Hypoesthesia was not reported in any of the included studies. 
Synovitis was not reported in any of the included studies. 
Deep venous thrombosis was reported in 1 study [18]: the study stated that 
no deep venous thrombosis occurred. 
Co-Interventionen: 
Meniskus-Operation 
Transplantatversagen, 
Re-Ruptur,  
Revisionen: NR 
Re-Operationen  
in 1/2 Studie berichtet: 
kein pt benötigte 
zusätzliche Operation 
wegen wiederkehrender 
oder bleibender Laxität 
Komplikationsrate  
in 1/2 Studien berichtet 
(Allo vs. Auto):  
0 % vs. 21.9 %, aber: 
nicht statistisch getestet; 
Arthrofribrose, Effusion, 
Tenderness: NR 
Infektionen  
in 2/2 Studien berichtet: 
keine postoperativen 
Infektionen in 1 Studie, 
2 Infektionen in  
Auto-Gruppe (6.3 %)  
in 1 Studie; 
Hypoesthesia,  
Synovitis: NR  
Safety 
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Further complications were reported in the included studies: One study [23] 
reported on donor site symptoms, with an occurrence of 0% and 12.5% in the 
allograft and autograft groups, respectively. Reflex sympathetic dystrophy 
was reported in the same study [23], occurring in 1/32 patients (3.1%) in the 
autograft group versus in 0/23 patients (0%) in the allograft group. The dif-
ference was not statistically tested, since the p-value was not reported. 
Moreover, 1 study [23] reported on tibial and femoral tunnel widening and 
found no statistically significant difference between the allograft and autograft 
groups.  
Regarding complications, 1 study [18] further stated that there were no cases 
of major neurovascular, infectious, vascular, or wound complications. 
Overall, the outcome of complications reached low certainty according to 
GRADE. 
Procedure-related mortality 
None of the included studies reported on procedure-related mortality. 
C0002 – Are the harms related to dosage or frequency  
of applying allograft PCLR? 
No evidence was found to answer the research question. 
C0004 – How does the frequency or severity of harms change  
over time or in different settings? 
No evidence was found to answer the research question. 
C0005 – What are the susceptible patient groups that are more likely  
to be harmed through the use of allograft PCLR? 
No evidence was found to answer the research question. 
C0007 – Are allograft and autograft PCLR associated  
with user-dependent harms? 
No evidence was found to answer the research question. 
Investments and tools required 
B0010 – What kind of data/records and/or registry is needed  
to monitor the use of allograft and autograft? 
No evidence was found to answer the research question. 
 
  
DVT in 1 Studie 
berichtet: keine DVT 
geschah; 
Spendersyndrom  
in 1 Studie berichtet:  
0 % vs. 12.5 %,  
Reflex Sympathetic 
Dystrophy in 1 Studie 
berichtet: 0 % vs. 3.1 % 
Unterschied vmtl. nicht 
statistisch getestet; 
Tibia- und Femortunnel-
erweiterung in 1 Studie 
berichtet: keine stat. 
signifikanten 
Unterschiede 
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6.3.3 Use of allografts in revision anterior cruciate 
ligament reconstruction 
Study characteristics 
For revision cruciate ligament reconstruction, only 1 prospective cohort study 
[16] with patients undergoing revision ACLR was identified. 
The study compared the use of allografts (various specific graft types, but all 
were fresh-frozen with minimal to no irradiation), and autografts in patients 
undergoing a revision of a previously failed ACLR. However, patients with 
multi-ligament knee injuries were not included in the study. 
Overall, the study enrolled 1,205 patients. Of these, 590 received an allograft 
and 583 received an autograft. A further 32 patients received a combination 
of these grafts. 
The median age of all patients was 26 (IQR: 20-34). 508 of all patients (42%) 
were female. 
The study followed the enrolled patients after 2 years by questionnaire (989) 
and telephone call (1,112). The loss to follow-up using these techniques was 
216 (17.9%) and 93 (7.7%) patients, respectively.  
Prior revisions ranged from 1 to 3+. That is, 1055 patients had 1 revision, 
125 patients had 2 revisions, and 25 patients had 3+ revisions. Further pre-
vious surgery/ies included but was/were not limited to meniscus surgery. Pre- 
and postoperative rehabilitation of patients was not reported.  
The reader is referred to the data extraction table (see Table A-3), the sum-
mary of findings table (see Table 7-3), and the GRADE evidence profile 
(Table A-9) for more information. 
 
Patient safety 
C0008 – How safe is allograft revision cruciate ligament reconstruction 
in comparison to autograft revision cruciate ligament reconstruction? 
Graft failure 
The outcome of graft failure was not reported in the included study. 
Re-rupture rate 
The outcome of re-rupture rate was reported in the included study [16]. Over-
all, a re-rupture occurred in 24 patients (4.4%) in the allograft group and 12 
(2.2%) in the autograft group. The study used a logistic regression analysis 
and revealed that patients with an autograft revision were found to be 2.78 
times less likely of sustaining a subsequent graft rupture when compared to 
the patients in the allograft group (p=0.047; 95%CI: 1.01-7.69). The results 
of this outcome reached low certainty according to GRADE. 
Re-operation rate 
The re-operation rate was reported in the included studies [16]. However, on-
ly the overall re-operation rate was reported, with 150/1112 patients (13.5%) 
needing a re-operation. In addition, a logistic regression analysis was con-
ducted in the included study, showing that graft choice was not a predictor 
of the incidence of subsequent reoperations at 2 years after revision surgery. 
The results of this outcome reached low certainty according to GRADE. 
Revisions-ACLR:  
1 prospektive 
Kohortenstudie 
1205 eingeschrieben 
590 pts mit Allograft 
583 pts mit Autograft 
FU: 2 Jahre 
Loss to FU 
(questionnaire): 17.9 % 
Loss to FU (telephone): 
7.7 %  
Transplantatversagen: 
NR 
Re-Rupture  
(Allo vs. Auto):  
4.4 % vs. 2.2 % 
stat. signifikant 
Re-Operation: 
Transplantattyp war 
kein Prädiktor für  
Re-Operation; keine 
head-to-head Daten 
berichtet 
Safety 
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Revisions 
The outcome of revisions was not reported in the included study. 
Overall Complications 
The outcome of overall complications was not reported in the included study. 
Arthrofibrosis was not reported in the included study. 
Effusion was not reported inreported in the included study. 
Tenderness was not reported inreported in the included study. 
Infections were not reported in the included study. 
Hypoesthesia was not reported in the included study. 
Synovitis was not reported in the included study. 
Deep venous thrombosis was not reported in the included study. 
Procedure-related mortality 
The outcome of procedure-related mortality was not reported in the included 
study. 
C0002 – Are the harms related to dosage or frequency  
of applying allograft revision cruciate ligament reconstruction? 
No evidence was found to answer the research question. 
C0004 – How does the frequency or severity of harms change  
over time or in different settings? 
No evidence was found to answer the research question. 
C0005 – What are the susceptible patient groups that are more likely  
to be harmed through the use of allograft revision cruciate ligament 
reconstruction? 
No evidence was found to answer the research question. 
C0007 – Are allograft and autograft revision cruciate ligament 
reconstruction associated with user-dependent harms? 
No evidence was found to answer the research question. 
 
Investments and tools required 
B0010 – What kind of data/records and/or registry is needed  
to monitor the use of allograft and autograft revision cruciate  
ligament reconstruction? 
No evidence was found to answer the research question. 
 
  
Revisionsrate, 
Komplikationsrate  
etc.: NR 
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6.3.4 Use of allografts in revision posterior cruciate 
ligament reconstruction 
No evidence was identified through the systematic literature search to answer 
the research question 
 
6.3.5 Use of allografts for cruciate cruciate ligament 
reconstruction in patients with multi-ligament 
knee injuries  
No evidence was identified through the systematic literature search to answer 
the research question 
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7 Quality of evidence 
Risk of Bias (RoB) for individual studies was assessed with the Cochrane RoB 
tool and the Newcastle-Ottawa Scale (NOS), and is presented in Table A-4, 
Table A-5 and Table A-6 in the Appendix.  
Overall, 7 RCTs had high RoB, 1 RCT had unclear RoB, and 1 cohort study 
reached moderate RoB. 
For ACLR, the 6 included studies had a high RoB, mainly due to the lack of 
blinding of the outcome assessors (attrition bias increased likelihood in 5 stud-
ies), and selective outcome reporting (high risk in 2 studies). For PCLR, the 
2 included studies had unclear to high risk of bias. The study with high risk 
of bias had substantial limitations regarding the randomisation process and 
may only be labelled as “quasi-randomised”. For revision ACLR, the included 
cohort study comparing allografts to autografts in patients undergoing revi-
sion ACLR reached a moderate RoB using the NOS scale. For revision PCLR 
and reconstruction of cruciate ligaments in patients with multi-ligament knee 
injuries, no evidence was found indicating the superiority or inferiority of 
allografts when compared to autografts. 
The strength of evidence was rated according to the GRADE (Grading of Re-
commendations Assessment, Development, and Evaluation) scheme [14] for 
each endpoint individually. Each study was rated by two independent re-
searchers (GG, CdV). In case of disagreement, a third researcher (SGG) was 
involved to solve the difference. A more detailed list of criteria applied can 
be found in the recommendations of the GRADE Working Group [14].  
GRADE uses 4 categories to rank the strength of evidence: 
 High = We are very confident that the true effect lies close to that  
of the estimate of the effect. 
 Moderate = We are moderately confident in the effect estimate: The 
true effect is likely to be close to the estimate of the effect, but there 
is a possibility that it is substantially different. 
 Low = Our confidence in the effect estimate is limited: The true 
effect may be substantially different from the estimate of the effect.  
 Very low = Evidence either is unavailable or does not permit  
a conclusion. 
The ranking according to the GRADE scheme for the research question can 
be found in the summary of findings table below, and in the evidence profile 
in Appendix (see Table A-7, Table A-8 and Table A-9) 
According to GRADE, the overall strength of evidence of the selected crucial 
outcomes is as follows: 
The strength of evidence for the effectiveness and safety of allograft ACLR in 
comparison to autograft ACLR is low.  
The strength of evidence for the effectiveness and safety of allograft PCLR 
in comparison to autograft PCLR is very low.  
The strength of evidence for the effectiveness and safety of revision allograft 
ACLR in comparison to revision autograft ACLR is low.  
For the remaining indications (e.g., revision PCLR, cruciate ligament recon-
structions in multi-ligament knee injuries), no evidence is available to assess 
the effectiveness and safety of allografts compared to autografts in cruciate 
ligament reconstruction. 
RoB  
7 RCTs mit hohem RoB, 
1 RCT mit unklarem RoB 
& 1 Kohortenstudie mit 
moderate RoB  
Qualität der Evidenz 
nach GRADE: 
ACLR: niedrig 
PCLR: sehr niedrig 
Revisions-ACLR: niedrig 
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Table 7-1: Summary of findings table of allografts for ACLR 
Outcomes 
№ of analysed 
patients Anticipated absolute effects* 
Relative 
effect 
(95% CI) 
№ of analysed 
participants9  
(studies) 
Certainty of 
the evidence 
(GRADE) 
Comments 
Allograft Autograft 
EFFECTIVENESS 
Patient-reported function, 
activity level and symptoms 
assessed with:  
Tegner score (Scale: 0-10) 
follow-up: mean ≥5 years 
299 287 None of the studies found a statistically significant difference  
when comparing the Tegner activity score between treatment  
groups postoperatively. 
Postoperative mean Tegner scores (ranges):  
4.5 ±2.2 to 7.6 ±1.9 vs. 4.8 ±2.3 to 7.8 ±1.2 
- 586 
(5 RCTs)  
[15, 19-22] 
⨁⨁⨁◯ 
MODERATE
c,d,e 
Higher scores 
indicate better 
patient-reported 
outcome. 
Patient-reported function, 
activity level and symptoms 
assessed with: Cincinnati 
Knee score (Scale: 0-100) 
follow-up: mean ≥5 years 
218 207 None of the studies found a statistically significant difference  
when comparing the Cincinnati Knee score between treatment  
groups postoperatively. 
Postoperative mean Cincinnati Knee scores (ranges):  
87 ±12 to 92 ±11 vs. 90 ±10 to 91 ±12 
- 425 
(3 RCTs)  
[20-22] 
⨁⨁⨁◯ 
MODERATE 
c,f,g 
Higher scores 
indicate better 
patient-reported 
outcome. 
Patient-reported function, 
activity level and symptoms 
assessed with:  
SANE score (Scale:0-100) 
follow-up: mean 10.5 years 
49 48 The postoperative mean score was 2.7 points lower in the  
allograft group when compared to the autograft group. 
Postoperative mean SANE score: 78.8 ±18.8 vs. 81.5 ±16.4 
- 97 
(1 RCT)  
[15] 
⨁⨁◯◯ 
LOW h,i 
Higher scores 
indicate better 
patient-reported 
outcome. 
Patient-reported function, 
activity level and symptoms 
assessed with: subjective 
IKDC score (Scale: 0-100) 
follow-up: mean ≥5 years 
352 340 None of the studies found a statistically significant difference  
in subjective IKDC scores between groups postoperatively. 
Postoperative mean subjective IKDC scores (ranges):  
73.7 ±25.9 to 90 ±14 vs. 77.2 ±25.4 to 90 ±10 
- 692 
(6 RCTs)  
[15, 17, 19-22] 
 
⨁⨁⨁◯ 
MODERATE,
c,h 
Higher scores 
indicate better 
patient-reported 
outcome. 
Patient-reported function, 
activity level and symptoms 
assessed with: KOOS score 
(Scales: 0-100) 
 - (0 studies) - Higher scores 
indicate better 
patient-
reported 
outcome. 
Patient-reported function, 
activity level and symptoms 
assessed with: Marx activity 
scale (Scale: 0-16) 
 - (0 studies) - Higher scores 
indicate better 
patient-reported 
outcome. 
                                                             
9 The Number of analysed participants only refers to the number of patients receiving either allografts or autografts. Hybrid grafts were hereby excluded.  
In addition, the reader is reminded that in Bottoni et al. the number of patients actually refers to the number of knees. 
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Outcomes 
№ of analysed 
patients Anticipated absolute effects* 
Relative 
effect 
(95% CI) 
№ of analysed 
participants9  
(studies) 
Certainty of 
the evidence 
(GRADE) 
Comments 
Allograft Autograft 
Clinical knee stability  
assessed with:  
Lachman test (Grade 0-1) 
250 239 s. s. difference in Lachman scores (grade 0-1) in 1 study [22]:  
31/43 (72%) vs. 37/40 (93%). 
No statistically significant differences in Lachman scores  
in 3 studies [19-21] 
Lachman test (grade 0-1; ranges across studies): 31/43 (72%) to  
74/80 (92.5%) vs. 84/91 (92.3%) to 30/32 (93.8%) 
- 489 
(4 RCTs)  
[19-22] 
⨁◯◯◯ 
VERY LOW 
j,k 
Lachman grade 
0-1 indicates an 
intact ligament. 
Clinical knee stability  
assessed with:  
Pivot shift test 
250 239 s. s. difference in Pivot shift test (Grade 0-1) in 1 study [22]:  
38/43 (88.4%) vs. 40/40 (100%) 
No statistically significant differences in Pivot shift test  
in 3 studies [19-21] 
Pivot shift (grade 0-1; ranges across studies): 38/43 (88.4%) to  
95/95 (100%) vs. 32/32 (100%) to 91/91 (100%) 
- 489 
(4 RCTs)  
[19-22] 
⨁◯◯◯ 
VERY LOW 
j,k 
Pivot shift 
grade 0-1 
indicates an 
intact ligament. 
Clinical knee stability  
(Side-to-side difference) 
assessed with:  
KT arthrometer; better 
indicated by lower values 
250 239 2/4 studies [19, 22] found a statistically significant difference  
in instrumented knee laxity favouring autografts, while the other  
2/4 studies [20, 21] did not find any statistically significant difference 
in side-to-side differences measured with the KT arthrometer  
between treatment groups. 
Mean side-to-side differences (in mm; ranges across studies):  
2.5 ±0.9 to 5.5 ±1 vs. 2.1 ±1.6 to 2.5 ±0.7 
- 489 
(4 RCTs)  
[19-22] 
⨁⨁◯◯ 
LOW h,k 
A lower side-to-
side difference 
indicates less 
knee laxity 
(and more 
stability). 
Clinical knee stability  
assessed with:  
objective IKDC 
250 239 None of the studies found a statistically significant difference  
in objective IKDC scores between treatment groups. 
Objective IKDC scores (normal or nearly normal scores;  
ranges across studies): 38/43 (88.4%) to 75/80 (93.8%) vs.  
29/32 patients (90.6%) to 38/40 (95%) 
- 489 
(4 RCTs)  
[19-22] 
⨁⨁⨁◯ 
MODERATE 
h 
More patients 
with normal and 
nearly normal 
according to 
the objective 
IKDC may 
indicate better 
knee stability. 
Patient satisfaction 
assessed with: NR 
53 53 The instrument used to measure patient satisfaction was not reported. 
Satisfied: 46/53 (86.8%) vs. 47/53 (88.7%) 
Nearly satisfied: 7 (13.2%) vs. 5 (9.4%) 
Diff. n. s., with p>0.05 
- 106 
(1 RCT)  
[17] 
⨁⨁◯◯ 
LOW l 
 
Health-related Quality of Life  - (0 studies) -  
SAFETY 
Graft failure 
follow-up: mean ≥5 years 
92 88 26/92 (28.3%) vs. 7/88 (7.9%) m 
Bottoni et al. [15]: 13/49 (26.5%) vs. 4/48 (8.3%), diff. s. s. with p<0.05 
Tian et al. [22]: 13/43 (30.2%) vs. 3/40 (7.5%), diff. s. s. with p<0.001 
- 180 
(2 RCTs)  
[15, 22] 
⨁⨁⨁◯ 
MODERATE 
c,i,n 
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Outcomes 
№ of analysed 
patients Anticipated absolute effects* 
Relative 
effect 
(95% CI) 
№ of analysed 
participants9  
(studies) 
Certainty of 
the evidence 
(GRADE) 
Comments 
Allograft Autograft 
Re-rupture rate   (0 studies) -  
Re-operations 
follow-up: mean ≥5 years 
  (0 studies) -  
Revisions 
follow-up: mean ≥5 years 
81 80 Bottoni et al. [15]: 13/49 (26.5%) vs. 4/48 (8.3%), diff. s. s. with p<0.05 
Li et al. [19]: No patient needed additional surgery because  
of recurrent or residual symptoms (0/32 vs. 0/32). 
- 161 
(2 RCTs)  
[15, 19] 
⨁⨁◯◯ 
LOW c,i,n,o 
 
Complications 
follow-up: mean >5 years 
- - Overall complication rate: NR 
Arthrofibrosis (reported in 2/6 studies [21, 22];  
269 pts): 0/138 (0%) vs. 0/131 (0%) 
Effusion (0/6 studies): NR 
Tenderness (reported in 1 study [21]; 186 pts): 0/95 (0%) vs. 2/91 (2.1%) 
Infections (reported in 4 studies [19-22]; 489 pts):  
5/250 (2%) vs. 0/239 (0%), range: 0-4.6% vs. 0%. 
Hypoesthesia (reported in 2 studies [21, 22]; 269 pts):  
0/138 (0%) vs. 6/131 (4.6%), range: 0% vs. 3.3-7.5%. 
Synovitis was not reported in any of the included studies. 
Deep venous thrombosis (reported in 3 studies [20-22]; 425 pts): 
2/218 (0.9%) vs. 1/207 (0.5%), range: 0-2.5% vs. 0-1.3% 
Further reported complications: 
Postoperative mean fever time in days (reported in 1 study [20];  
156 pts): 6.8 vs. 4.4 diff. s. s., with p<0.05) 
Arthritic progression (reported in 1 study [22]; 83 pts):  
14/43 (32.6%) vs. 4/40 (10%), diff. s. s. with p<0.05. 
Tibial and femoral tunnel widening in mm (reported in 2 studies; 203 pts): 
Jia et al. [17]: 
Tibial (in mm), mean ±SD: 7.8 ±0.4 vs. 7.61 ±0.22, diff. s. s. with p<0.05 
Femoral (in mm), mean ±SD: 7.64 ±0.35 vs. 7.51 ±0.42,  
diff. s. s. with p<0.05 
Bottoni et al. [15]: 
Tibial (in mm), mean (range): 9.2 (7-10) vs. 8.9 (7-10);  
diff. n. s. with p=0.651 
Femoral (in mm), mean (range): 8.8 (7-10) vs. 8.3 (7-10),  
diff n. s. with p=0.453 
Furthermore, some of the included studies specifically stated that 
there were no cases of pain when kneeling, anterior knee pain, etc. 
- 692 
(6 RCTs)  
[15, 17, 19-22] 
⨁⨁◯◯ 
LOW c,p,q 
 
Procedure-related mortality  - (0 studies) -  
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GRADE Working Group grades of evidence: 
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect. 
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. 
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect. 
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. 
Comments: 
a In 4/5 studies, the risk of bias for blinding the outcome assessors was judged to be high. Therefore, we judged that this may have seriously affected the certainty.  
b None of the studies showed any statistically significant differences postoperatively in the Lysholm score between the allograft and the autograft groups. Results from the non-statistically  
significant differences revealed that in 3/5 studies the Lysholm score was higher in the allograft group, while 2/5 studies reported a lower Lysholm score in the allograft group (comparison: allograft 
vs. autograft). While the general difference is small (e.g., <5-point differences between allografts and autografts), it may still be an indicator for heterogeneity. Calculation of the i-square is further 
needed to adequately assess how heterogeneous the results for this outcome may be.  
c Differences in interventions were present across studies (e.g., irradiated vs. non-irradiated grafts, single-bundle vs. double-bundle, etc.). 
d In 5/5 studies, the risk of bias for blinding the outcome assessors was judged to be high. Therefore, we judged that this may have seriously affected the certainty.  
e None of the studies showed any statistically significant difference postoperatively in the Tegner score between the allograft and the autograft groups. The non-statistical findings in all study groups 
showed slightly higher scores in the autograft group. This may be an indicator that heterogeneity is small. Calculating the i-square may be beneficial to further assess heterogeneity.  
f In 3/3 studies, the lack of blinding significantly increases the risk of bias. Given that this is a subjective outcome score, it was judged to be a very serious limitation.  
g None of the studies showed any statistically significant differences in the Cincinnati Knee scores between treatment groups. The non-statistical findings showed slightly higher scores in allograft 
patients in 2/3 studies, and lower scores in allograft patients in 1/3 study when compared to the autograft groups, respectively. The difference of the mean scores ranged from 1 to -3.  
h The lack of blinding in the study/ies may seriously affect the certainty to believe the evidence of this outcome measure.  
i The overall applicability for the broad population selected in these assessment results may suffer due to the fact that numerous different graft types were used and some studies used a subpopulation 
of the population of interest. Bottoni et al., for instance, solely included highly active military (mostly) men, and Tian et al. used irradiated allografts. It is unclear in how far the generalisability 
suffers due to the aforementioned factors. 
j It was judged that the lack of blinding may have very seriously affected the certainty to believe the evidence for this specific outcome.  
k Heterogeneity was suspected within the included studies. It appears that the studies do not consistently show any difference/differences favouring a treatment group.  
A calculation of the i-square is further needed to elaborate how significant the inconsistency is.  
l There were 2 substantial factors that increased the risk of bias: lack of blinding and selective outcome reporting; the latter was present insofar as it insufficiently described  
how patient satisfaction was measured.  
m Graft failure, however, was defined differently in the studies. Tian et al. defined it as knee laxity >5mm measured with a KT-2000, and Bottoni et al. did not clearly mention  
how graft failure was defined.  
n The lack of blinding for outcome assessors was judged to be less likely to affect this outcome.  
o Bottoni et al. found a considerably large difference in the revision rate, while Li et al. stated that no additional surgeries were needed in either of the treatment groups.  
p The risk of bias for selective outcome reporting was judged high in 2/6 studies, and unclear in the remaining 4/6 studies. Most of the studies, however, did not report  
on an overall complication rate. Instead, they were presented narratively in the studies.  
q The optimal information size may have not been reached for most of the specific complications.  
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Table 7-2: Summary of findings table of allografts for PCLR 
Outcomes 
№ of analysed 
patients Anticipated absolute effects* (95% CI) 
Relative 
effect 
(95% CI) 
№ of analysed 
participants 10 
(studies) 
Certainty of 
the evidence 
(GRADE) 
Comments 
Allograft Autograft 
EFFECTIVENESS 
Patient-reported function, 
activity level and symptoms 
assessed with: Lysholm score 
follow-up: mean ≥2 years  
50 58 None of the studies found a statistically significant difference in 
the Lysholm score between treatment groups postoperatively. 
Li et al. [18]: 85.2 ±3.9 vs. 87.8 ±3.6, diff. n. s. with p>0.05 
Wang et al. [23]: 92.3 ±6.8 vs. 87.8 ±9.6, diff. n. s. with p>0.05 
- 108 
(2 RCTs)  
[18, 23] 
⨁◯◯◯ 
VERY LOW 
1,a,b,c 
Higher scores 
indicate better 
patient-reported 
outcome. 
Patient-reported function, 
activity level and symptoms 
assessed with: Tegner score  
50 58 None of the studies found a statistically significant difference in 
the Tegner score between treatment groups postoperatively. 
Li et al. [18]: 6.2 ±1.7 vs. 6.8 ±1.1, diff. n. s. with p>0.05 
Wang et al. [23]: 4.7 ±1.66 vs. 4.73 ±1.66, diff. n. s. with p>0.05 
- 108 
(2 RCTs)  
[18, 23] 
⨁⨁◯◯ 
LOW a,b 
Higher scores 
indicate better 
patient-reported 
outcome. 
Patient-reported function, 
activity level and symptoms 
assessed with:  
Cincinnati Knee score  
  (0 studies) - Higher scores 
indicate better 
patient-reported 
outcome. 
Patient-reported function, 
activity level and symptoms 
assessed with: SANE score  
  (0 studies) - Higher scores 
indicate better 
patient-reported 
outcome. 
Patient-reported function, 
activity level and symptoms 
assessed with:  
subjective IKDC score 
27 26 Mean postoperative subjective IKDC score:  
80.2 ±6.8 vs. 83.5 ±6.3, diff. n. s. with p>0.05 
- 53 
(1 RCT)  
[18] 
⨁⨁◯◯ 
LOW b,d 
Higher scores 
indicate better 
patient-reported 
outcome. 
Patient-reported function, 
activity level and symptoms 
assessed with: KOOS score  
 - (0 studies) - Higher scores 
indicate better 
patient-reported 
outcome. 
Patient-reported function, 
activity level and symptoms 
assessed with:  
Marx activity scale  
 - (0 studies) - Higher scores 
indicate better 
patient-reported 
outcome. 
                                                             
10 The Number of analysed participants only refers to the number of patients receiving either allografts or autografts. Hybrid grafts were hereby excluded. 
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Outcomes 
№ of analysed 
patients Anticipated absolute effects* (95% CI) 
Relative 
effect 
(95% CI) 
№ of analysed 
participants 10 
(studies) 
Certainty of 
the evidence 
(GRADE) 
Comments 
Allograft Autograft 
Clinical knee stability  
assessed with:  
reverse Lachman test  
23 32 The study did not find a statistically significant difference  
in the reverse Lachman test postoperatively. 
Mean postoperative reverse Lachman test score:  
0.7 ±0.56 vs. 0.75 ±0.67, diff. n. s. with p>0.05 
- 55 
(1 RCT)  
[23] 
⨁⨁◯◯ 
LOW a 
Lachman grade 0-1 
indicates an intact 
ligament. 
Clinical knee stability  
assessed with:  
reverse Pivot shift test  
27 26 Postoperative reverse Pivot shift (Grade 0-1):  
26/27 (96.3%) vs. 26/26 (100%), diff. n. s. with p>0.05 
- 53 
(1 RCT)  
[18] 
⨁⨁⨁◯ 
MODERAT
E b 
Pivot shift grade  
0-1 indicates an 
intact ligament. 
Clinical knee stability  
assessed with:  
KT arthrometer; better 
indicated by lower values  
50 58 1 study found a statistically significant difference favouring 
autografts, while another study did not find any statistically 
significant difference based on the side-to-side difference 
measured with an instrumented knee laxity test. 
Side-to-side difference in mm: 
Li et al. [18]: 3.5 ±1.1 vs. 2.1 ±1, diff. s. s. with p<0.001 
Wang et al. [23]: 2.83 ±1.7 vs. 3.16 ±2.6, diff. n. s. with p>0.05 
- 108 
(2 RCTs)  
[18, 23] 
⨁◯◯◯ 
VERY LOW 
a,b,e 
A lower side-to-side 
difference indicates 
less knee laxity 
(and more stability). 
Clinical knee stability 
assessed with: objective IKDC  
50 58 None of the studies found a statistically significant difference in the 
objective IKDC score between treatment groups postoperatively. 
Objective IKDC score (normal and nearly normal): 
Li et al. [18]: 24/27 (88.9%) vs. 25/26 (96.2%) 
Wang et al. [23]: 14/23 (60.9%) vs. 23/32 (71.9%) 
- 108 
(2 RCTs)  
[18, 23] 
⨁⨁◯◯ 
LOW a,b 
More patients with 
normal and nearly 
normal scores 
according to the 
objective IKDC score 
may indicate better 
knee stability. 
Patient satisfaction    (0 studies) -  
Health-related Quality of Life   (0 studies) -  
SAFETY 
Graft failure    (0 studies) -  
Re-rupture rate    (0 studies) -  
Re-operations  27 26 The study stated that no patient needed additional surgery 
because of recurrent or residual posterior laxity: 0% vs. 0% 
(further information: NR). 
- 53 
(1 RCT) [18] 
⨁⨁◯◯ 
LOW 2,f,g 
 
Revisions    (0 studies) -  
Complications  - - Overall complication rate (reported in 1 study; [23]):  
0/23 (0%) vs. 7/32 (21.9%). 
Arthrofibrosis: NR 
Effusion: NR 
Tenderness: NR 
- 108 
(2 RCTs)  
[18, 23] 
⨁⨁◯◯ 
LOW d 
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Outcomes 
№ of analysed 
patients Anticipated absolute effects* (95% CI) 
Relative 
effect 
(95% CI) 
№ of analysed 
participants 10 
(studies) 
Certainty of 
the evidence 
(GRADE) 
Comments 
Allograft Autograft 
Complications  
(continuation) 
- - Infections: Li et al [18]: no postoperative infection; Wang et al. 
[23]: 0/23 (0%) vs. 2/32 (6.3%; one acute and one late infection) 
Hypoesthesia: NR 
Synovitis: NR 
Deep venous thrombosis (reported in 1 study; [18]):  
0/27 (0%) vs. 0/26 (0%) 
Further reported complications: 
Donor site symptoms in 1 study [23]: 0/23 (0%) vs. 4/32 (12.5%); 
Reflex sympathetic dystrophy in 1 study [23]: 0/23 (0%) vs. 1/32 (3.1%) 
Li et al. [18] further stated narratively that no postoperative infection, 
no deep venous thrombosis, no cases of major neurovascular, 
infectious, vascular, deep venous thrombosis or wound complications 
in any of the 80 analysed patients (of which 27, 26 and 27 received 
allografts, autografts and hybrid grafts, respectively) occurred. 
Tibial and femoral tunnel enlargement in 1 study [23]: 
Tibial: 12 ±20 (range: 0-90) vs. 12 ±14 (range: 0-43), n. s. with p=0.64 
Femoral: 5.3 ±22 (range: 0-50) vs. 13 ±19 (range: 0-55),  
n. s. with p=0.771 
-    
Procedure-related mortality    (0 studies) -  
GRADE Working Group grades of evidence:  
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect. 
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. 
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect. 
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. 
Comments: 
a In Wang et al., there was a high risk of bias for selection bias and an unclear risk of bias whether patients were blinded.  
b In Li et al., it was unclear whether the random sequence generation was adequate (selection bias), and whether patients were blinded.  
c None of the studies showed any statistically significant differences postoperatively in the Lysholm score between the allograft and the autograft groups. The non-statistically significant differences 
were not unanimously higher in 1 treatment group. This may be an indicator for heterogeneity. A calculation of the i-square is further needed to adequately assess how heterogeneous the results  
for this outcome may be.  
d The optimal information size may have not been reached.  
e Heterogeneity may have been present because study results were not unanimous. A further calculation of the i-square is needed to elaborate on the extent of the heterogeneity.  
f The study referred to the patients who did not need additional surgery because of recurrent or residual posterior laxity. It was unclear to the review authors whether this refers  
to the overall re-operations rate or only the patients with recurrent or residual posterior laxity.  
g The optimal information size may have not been reached.  
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Table 7-3: Summary of findings table of allografts for revision ACLR 
Outcomes 
№ of enrolled 
patients Anticipated absolute effects* (95% CI) 
Relative 
effect 
(95% CI) 
№ of enrolled 
participants  
(studies) 
Certainty of 
the evidence 
(GRADE) 
Comments 
Allograft Autograft 
EFFECTIVENESS 
Patient-reported function, 
activity level and symptoms 
assessed with: Lysholm score  
 - (0 studies) -  
Patient-reported function, 
activity level and symptoms 
assessed with: Tegner score  
 - (0 studies) -  
Patient-reported function, 
activity level and symptoms 
assessed with: Cincinnati 
Knee score  
 - (0 studies) -  
Patient-reported function, 
activity level and symptoms 
assessed with: SANE score 
 - (0 studies) -  
Patient-reported function, 
activity level and symptoms 
assessed with: subjective 
IKDC score 
590 583 The study conducted a logistic regression analysis and  
found out that graft choice proved to be a significant predictor  
of 2-year IKDC score (p=0.045; OR =1.31; 95% CI: 1.01-1.70). 
- 1205 
(1 observational 
study) [16] 
⨁⨁◯◯ 
LOW 
 
Patient-reported function, 
activity level and symptoms 
assessed with: KOOS score 
follow-up: 2 years  
590 583 The study conducted a logistic regression analysis and found out that 
graft choice did not predict KOOS symptoms, and KOOS activities 
and daily living. On the contrary, KOOS sports and recreation 
subscale demonstrated higher scores in the setting of an autograft 
when compared to allograft for revision reconstruction (p=0.037; 
OR =1.33; 95%CI: 1.02-1.73). Results from further KOOS subscales 
(KOOS pain from the regression analysis comparing graft types 
was not reported. 
- 1205 
(1 observational 
study) [16] 
⨁⨁◯◯ 
LOW 
 
Patient-reported function, 
activity level and symptoms 
assessed with:  
Marx activity scale 
follow-up: 2 years  
590 583 The study conducted a logistic regression and found out that graft 
choice was a significant predictor of 2-year Marx activity scores 
(p=0.012). Specifically, the use of a combination autograft plus 
allograft for revision reconstruction predicted improved scores on 
the Marx activity scale (p=0.005; OR =3.33; 95%CI: 1.43-7.78). 
- 1205 
(1 observational 
study) [16] 
⨁⨁◯◯ 
LOW 
 
Clinical knee stability  
assessed with: Lachman test  
  (0 studies) -  
Clinical knee stability 
assessed with: Pivot shift test  
  (0 studies) -  
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Outcomes 
№ of enrolled 
patients Anticipated absolute effects* (95% CI) 
Relative 
effect 
(95% CI) 
№ of enrolled 
participants  
(studies) 
Certainty of 
the evidence 
(GRADE) 
Comments 
Allograft Autograft 
Clinical knee stability 
assessed with: KT arthrometer  
  (0 studies) -  
Clinical knee stability 
assessed with:  
objective IKDC score  
  (0 studies) -  
Patient satisfaction    (0 studies) -  
Health-related Quality of Life 590 583 Results from the logistic regression analysis show that the use of 
autografts predicted improved scores on the KOOS quality of life 
subscale (p=0.031; OR: 1.33; 95%CI: 1.03-1.73). 
 1205 
(1 observational 
study) [16] 
⨁⨁◯◯ 
LOW 
 
SAFETY 
Graft failure    (0 studies) -  
Re-rupture rate  Results from the regression analysis: Subjects with an autograft revision were found to 
be 2.78 times less likely of sustaining a subsequent graft rupture compared with subjects 
who received an allograft (p=0.047; 95%CI: 1.01-7.69). 
not 
estimabl
e 
1205 
(1 observational 
study) [16] 
⨁⨁◯◯ 
LOW 
 
Re-operation rate  The study only reported on the overall re-operation rate for all patients including 
allografts, autografts or a combination of these grafts: 150/1112 (13.5%). 
 1205 
(1 observational 
study) [16] 
⨁⨁◯◯ 
LOW 
 
Revisions    (0 studies) -  
Complications    (0 studies) -  
Procedure-related mortality    (0 studies) -  
GRADE Working Group grades of evidence: 
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect. 
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. 
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect. 
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. 
Comments: 
a Selective outcome reporting may have been present for this specific outcome, since the results from the regression analysis were not presented.  
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8 Discussion 
This systematic review identified evidence consisting of 9 studies [15-23] com-
paring allografts to autografts for ACLR, PCLR, or revision ACLR. For revi-
sion PCLR or cruciate ligament reconstruction in patients with multi-ligament 
knee injuries, no evidence was identified to answer the research question.  
In this systematic review, evidence was found indicating that allografts may 
be as effective as autografts in ACLR and PCLR with regard to the selected 
crucial effectiveness outcome of patient-reported function, activity level and 
symptoms (certainty: very low to moderate; evidence base: 6 RCTs with high 
RoB for ACLR, 2 RCTs with unclear to high RoB for PCLR).  
Concerning comparative safety for ACLR, moderate quality evidence was 
found suggesting that allografts may be less safe compared to autografts with 
regard to graft failures. However, with regard to the other selected crucial 
safety outcomes, the evidence was insufficient to clearly prove the inferiority 
of allografts when compared to autografts in ACLR. 
Concerning comparative safety for PCLR, insufficient evidence was found to 
indicate the superiority or inferiority of allografts over autografts. Low-quali-
ty evidence was found that allografts lead to fewer complications related to 
infections, donor site pain, and reflex sympathetic dystrophy in comparison 
to autografts. However, only 1 study reported on an overall complication rate 
(without statistical testing), and it appears that the reported complications are 
related to graft harvesting and, therefore, do not capture all relevant compli-
cations.  
For revision ACLR, insufficient evidence was found to indicate superiority 
or inferiority on the basis of the selected effectiveness and safety outcomes of 
allografts when compared to autografts. The evidence derived from 1 large 
cohort study found that allografts may be inferior on the basis of some pa-
tient-reported outcomes, and may also be inferior with regard to safety due 
to increased risks of graft re-rupture at 2 years FU. 
The results of the present report are in line with other published systematic 
reviews and meta-analyses. 
1 recent systematic review [34] included 8 randomised controlled trials with 
785 combined patients comparing soft-tissue allografts to autografts in ACLR. 
The study meta-analysed subjective and objective outcomes, and concluded 
that soft-tissue allografts are inferior to hamstring tendon autografts with re-
spect to subjective patient evaluation and knee stability. Superiority for allo-
grafts was found on the basis of hypoesthesia for patients undergoing prima-
ry ACL reconstruction. The study noted that, overall, the principal findings 
showed that hamstring tendon autografts had some clinical advantages over 
soft tissue allografts with respect to subjective evaluation and knee laxity. 
Another meta-analysis [78] identified 13 RCTs, comparing allografts to au-
tografts in ACLR with a total sample of 1,636 participants. This review also 
included primary studies with a shorter follow-up. Based on a subgroup-anal-
ysis, the study concluded that autografts are superior, when compared to ir-
radiated allografts for patients undergoing ACLR, concerning knee function 
and laxity. The same study found that there are no significant differences be-
tween autografts and non-irradiated allografts. Due to the lack of blinding of 
the primary studies used in the meta-analysis, these results must be interpret-
ed with caution. 
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ACLR & PCLR: 
vergleichbare 
Wirksamkeit 
Sicherheit:  
ACLR: moderate 
Evidenz, dass weniger 
sicher in Bezug auf 
Transplantatversagen  
& unzureichend  
bei anderen 
Sicherheitsendpunkten  
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unzureichende Evidenz 
Einbettung in 
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Soft Tissue Allograft:  
einige klinische Vorteile 
bei Verwendung von 
Autografts 
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Überlegenheit der 
Autografts bei Vergleich 
mit Irradiated Allo, aber: 
kein Unterschied  
im Vergleich zu  
Non-Irradiated Allo  
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Another meta-analysis [79] compared non-irradiated allografts to autografts 
in ACLR. The review included 12 studies with an overall sample of 1,167 pa-
tients. However, only 5 studies were RCTs. Based on their analysis, the au-
thors concluded that autografts exhibit little clinical advantage over non-irra-
diated allografts on the basis of knee stability, function, and side effects. Due 
to the lack of limited randomised controlled trials, however, the robustness 
of the findings must be further validated.  
Similarly, a systematic review published in 2013 [80] specifically compared 
autografts to non-irradiated, non-chemically treated allografts in ACLR. The 
review included 11 studies (RCTs, NRCTs and retrospective comparative 
studies), and found no statistically significant differences between autografts 
and non-chemically processed, non-irradiated allografts in Lysholm scores, 
International Knee Documentation Committee (IKDC) scores, Lachman ex-
aminations, Pivot shift testing, KT-1000 measurements, or failure rates. How-
ever, the study had less strict inclusion criteria and included – besides ran-
domised controlled trials – prospective and retrospective comparative studies, 
and most of these results refer to short-term to mid-term clinical outcomes. 
For PCLR, 1 recent systematic review [81] published in 2018 included 25 pri-
mary studies, of which 5 studies (RCTs, NRCTs and retrospective studies) 
compared allograft and autografts directly. Based on the identified scientific 
evidence, the study concludes that there would be no significant difference 
in postoperative functional outcomes between patients having undergone al-
lograft and autograft PCLR. Patients with autografts have donor site morbidi-
ties that are not associated with allograft PCLR. On the contrary, some iden-
tified evidence in the review suggests that autograft reconstruction would re-
sult in reduced posterior laxity when compared to allograft PCLR. The review 
[81] also states clearly that the magnitude of these findings may not be clini-
cally significant, and that decision-making based on the currently available 
literature is at high risk of potential bias.  
Another meta-analysis [82] compared the use of allografts to autografts in 
revision ACLR. The review identified 8 primary studies with 3,021 patients. 
Yet, only 2 of these studies directly compared allografts to autografts (1 pro-
spective comparative study and 1 retrospective prognostic study). The meta-
analysis found similar failure rates between allografts and autografts, with 
3.6% (95% CI: 1.4%-6.7%) and 4.1% (95% CI: 2.0%-6.9%) graft failures in 
these treatment groups, respectively. However, the primary aim of this review 
was to compare revision ACLR to autograft or allograft ACLR. Therefore, 
and considering the limited number of primary studies, these results must 
be interpreted with caution. 
 
Limitations 
The results of this review should be interpreted in light of its limitations. 
Firstly, for ACLR we only included RCTs with a long follow-up (more than 
5 years) and more than 50 patients, to assess the best available evidence for 
effectiveness and safety questions. In addition, in the presence of RCTs, we 
excluded prospective, non-comparative cohort studies and retrospective stud-
ies in general, which may have led to excluding several studies with a large 
sample size. However, these studies are – in comparison to randomised con-
trolled trials – more prone to internal validity concerns due to the limited in-
formation on or controlling of confounding variables.  
1 Meta-Analyse: Non-
Irradiated Allo vs. Auto 
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Vorteil zugunsten  
von Auto 
1 rezenter SR 
Auto vs. Non-Irradiated 
Allo: keine stat. 
signifikanten 
Unterschiede, aber: 
Beobachtungsstudien 
eingeschlossen 
PCLR: 
1 SR: kein Unterschied 
bei Funktionalität 
Unterschiede bei 
Morbiditäten, Laxität, 
etc. 
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Limitationen: 
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As mentioned above, for ACLR, 10 publications [83-92] defined as RCTs were 
excluded due to a length of follow-up <5 years. It appears that overlapping 
samples may have been present, and some of these studies were simply re-
published at a later stage and included in this review. These studies suffer 
from similar limitations concerning the evaluation of comparative safety as the 
RCTs included in this review. It seems that the differences in complications 
between allografts and autografts were often not statistically tested. 1 study 
[84], for instance, found a higher re-rupture rate in BPTB allografts (20.6%) 
when compared to BPTB autografts (4.8%), and concluded that, according 
to their data and analysis, allografts may not be suitable for young patients 
who are highly active (in sports), yet the p-value was not reported. Another 
study [83] found a graft failure rate of 8% in the hamstring allograft group 
(n=46) as opposed to 2% in the hamstring autograft group (n=37), yet this 
difference was not statistically significant (p>0.05). Furthermore, 2 publica-
tions [87, 88] that were probably the same study reported on a graft failure 
rate of 34.4%, 6.1%, and 8.8% for irradiated allografts, autografts, and non-
irradiated allografts, respectively (p-value was not reported). However, it 
seems that these publications may refer to a study that was included in this 
assessment and was published at a later stage with a longer follow-up period 
[22]. The remaining publications [85, 86, 89-92] suffered from similar limi-
tations regarding reporting on complications in a standardised, comparative 
manner. Therefore, and while RCTs with shorter FU are available for ACLR, 
it was judged to be unlikely that these RCTs may change the findings/con-
clusions of this review.  
Secondly, numerous different types of grafts within allogenic ligaments are 
available. It was unclear how far these differences (e.g., when it comes to dis-
infection procedures) affect clinical outcomes. The medical literature [93], 
describes the specific graft types to be equipped with unique advantages and 
disadvantages. This may affect the generalisability derived from results that 
were found for one specific graft type and could influence the general com-
parison of allograft versus autograft. Applicability concerns are described in 
the applicability table (see Table A-10).  
Thirdly, the fact that all primary studies had unclear to high RoB (RCTs) or 
moderate RoB (cohort study), combined with a poor reporting on complica-
tions, must be mentioned as another significant limitation. In this context, 
one further main limitation of this work, as evident with all studies investi-
gating ACLR or PCLR, is the lack of an objective assessment of numerous 
outcomes (e.g., rotational knee stability, knee function, etc.) within primary 
research. All of the aforementioned limitations manifested in the GRADE 
assessment, and lead, among other factors, to very low to moderate certainty 
to believe in the evidence of the outcomes selected in this assessment. 
Finally, a minimally clinically relevant difference was not defined. It may be 
worthwhile to define a clinically relevant difference and use quantitative anal-
ysis to evaluate whether the statistically significant differences found within 
a review are also clinically relevant. In our context, most of the crucial out-
comes containing sufficient data did not clearly favour one graft over the 
other (no statistically significant differences in patient-reported function, 
activity level and symptoms in ACLR and PCLR). However, evidence was 
found, suggesting that allografts are inferior with regard to safety for ACLR, 
consisting mainly of 2 studies [15, 22] that were applicable for highly active, 
young patients (1 study [15]), or for irradiated allografts as an intervention 
(1 study [22]). The other ACLR and PCLR studies did not specifically and 
sufficiently report on this safety outcome as mentioned above.  
10 RCTs bei ACLR 
ausgeschlossen, 
gleiche Problematik  
der unzureichenden 
Berichterstattung der 
Sicherheitsendpunkte  
& Doppelpublikationen 
 
 
 
 
 
 
 
 
 
 
 
 
Ausschluss der RCTs mit 
kurzem FU auf Basis der 
“best available evidence” 
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Economic evaluations 
When investigating the benefits of one medical procedure over another, re-
sults from health economic evaluations may provide valuable supplementary 
information. Four economic evaluations [94-97] were identified and procured 
through the abstract screening process. Of those, 1 study was a cost-effective-
ness analysis comparing different graft types, i.e., BPTB autografts, hamstring 
autografts, and allografts (not further specified) in the United States. In this 
analysis, hamstring tendon (HS) autografts were the least costly ($5,375/sur-
gery), but the most effective, with 0.912 quality-adjusted life years (QALYs). 
Allograft ACLR, on the contrary, was the most costly treatment modality 
($1,585/case additional to HS autograft) and least effective (0.912 QALYs). 
The remaining 3 studies [95-97] were simple economic cost comparisons con-
ducted in the United States: 2 studies [96, 97] found that allografts are more 
costly when compared to autografts, while 1 study [95] concluded that auto-
grafts may be the pricier graft choice. Of the 2 cost-comparisons favouring 
autografts, 1 study [94] measured a total mean cost (incl., supply cost, case 
time per min, personnel, and facility cost) of $3,154 ±704 for an autograft 
versus $4,147 ±943 for an allograft. Another cost-comparison [95] measured 
a mean total cost of $5,465 for allograft ACLR and $4,872 for autograft ACLR 
(p=0.009). The latter analysis was based on retrospectively reviewing 155 
patients who underwent ACLR (charges were extracted from itemised bill-
ing records; yet surgeon and anaesthesiologist fees were not included in the 
analysis). The other less-recent cost-comparison [96] conducted in 2005 fa-
voured allografts and based their analysis on hospital charge data solely: the 
study measured a mean hospital charge for ACLR of $4,622 ±524 for allo-
graft ACLR, as opposed to $5,694 ±809 for autografts (p<0.0001). Due to 
the fact that these economic evaluations were conducted in the United States 
and that no critical appraisal of these studies was conducted, these results 
(and its applicability) must be interpreted with caution.  
 
Ongoing studies 
The search for ongoing studies revealed that none of the studies currently be-
ing undertaken may change the evidence base significantly, given that only 2 
ongoing RCTs were identified, of which only 1 was relevant, comparing al-
lografts to autografts in ACLR. The other ongoing RCT compared allografts 
to animal tissues (Z-lig) used in ACLR (see Table A-11, Table A-12, Table 
A-13, and Table A-14 in the Appendix). 
According to information from the manufacturers, 2 studies (incl. 1 RCT) are 
currently being conducted in Austria. However, study protocols are not pub-
licly available. 
 
Conclusion 
For ACLR, the evidence found in this systematic review indicates that allo-
grafts may be equally effective compared to autografts, and moderate evidence 
indicates that it may be less safe in ACLR with regard to graft failure. How-
ever, the evidence for comparative safety was insufficient for the remaining 
safety outcomes.  
Regarding PCLR, the effectiveness of allograft may be comparable to auto-
grafts, yet insufficient evidence was found for comparative safety.  
gesundheitsökonomische 
Evaluationen  
in Ö wesentlich 
Discussion 
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Insufficient evidence was found for revision ACLR, and no evidence was 
found for the remaining indications used in this review (revision PCLR, cru-
ciate ligament reconstruction in multi-ligament knee injuries). 
Further research should focus on more high-quality, randomised controlled 
trials with comprehensive safety reporting. In addition, questions regarding 
differences between types of allografts should be addressed. Evidence-based 
guidelines should clearly state the role of allografts in the management of cru-
ciate ligament reconstruction. 
 
 
weitere Forschung und 
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9 Recommendations 
In Table 9-1 the scheme for recommendations is displayed and  
the according choice is highlighted. 
Table 9-1: Evidence-based recommendations 
 The inclusion in the catalogue of benefits is recommended.  
 The inclusion in the catalogue of benefits is recommended with restrictions. 
X The inclusion in the catalogue of benefits is currently not recommended. 
 The inclusion in the catalogue of benefits is not recommended. 
 
Reasoning: 
The current evidence indicates that allografts may be equally effective, but 
less safe in ACLR with regard to graft failures. Regarding PCLR, effective-
ness may be comparable, but insufficient evidence was found for the compara-
tive safety of allografts when compared to autografts. The evidence is insuf-
ficient for revision ACLR, and no evidence was found for the remaining in-
dications. 
The overall strength of evidence for the effectiveness and safety – based on 
the selected crucial outcomes – of allograft ACLR in comparison to autograft 
ACLR is low. 
The overall strength of evidence for the effectiveness and safety – based on 
the selected crucial outcomes – of allograft PCLR in comparison to autograft 
PCLR is very low.  
The overall strength of evidence for the effectiveness and safety of revision 
allograft ACLR– based on the selected crucial outcomes – in comparison to 
autograft ACLR is low.  
For the remaining indications (e.g., revision PCLR, cruciate ligament recon-
structions in multi-ligament knee injuries), no evidence is available to assess 
the effectiveness and safety of allografts compared to autografts. 
For the comparison of allograft cruciate ligament reconstruction to conserva-
tive management, no evidence is available to assess the effectiveness and 
safety of allografts compared to autografts. 
In the absence of ongoing RCTs providing an answer to the question chosen 
in this assessment, it is unlikely that the evidence will change. A re-evalua-
tion is, therefore, not recommended for the present. 
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7 
Appendix 
Evidence tables of individual studies included for clinical effectiveness and safety 
Table A-1: Allograft versus autograft for anterior cruciate ligament reconstruction: results from randomised controlled trials 
Author, year Bottoni 2015 [15] Sun 2009 [20] Sun 2011 [21] Tian 2016 [22] Li 2015 [19] Jia 2015 [17] 
Country United States of America China China China China China 
Sponsor Arthrex, Inc. and the 
Musculoskeletal 
Transplant Foundation 
Supported by Natural 
Science Foundation of 
China Grant No. 
2004GG2202034 
Research funding was 
provided by the Key 
Project of the Provincial 
Science Foundation of 
Shandong 
NR NR Nil 
Interventions/Products Fresh-frozen,  
non-irradiated tibialis 
posterior tendon allograft 
Fresh frozen,  
non-irradiated BPTB  
hemi-allograft 
Fresh-frozen, non-
irradiated hamstring 
tendon allograft 
Fresh-frozen, irradiated 
hamstring tendon 
allograft 
4-stranded, y-irradiated 
tibialis anterior tendon 
allograft 
Bone‑patellar  
tendon‑bone 
allograft11 
Comparator 4-stranded hamstring 
autograft 
BPTB autograft 4-stranded hamstring 
tendon autograft 
Hamstring tendon 
autograft 
4-stranded gracilis and 
semitendinosus tendon 
autograft 
Hybrid 
graft (y-irradiated tibialis 
anterior tendon allograft 
and semitendinosus 
tendon autograft) 
Hamstring autograft 
Surgical procedure ACLR  
(not further specified) 
Arthroscopic 
ACLR 
Arthroscopic 
ACLR 
Arthroscopic anatomic 
double bundle ACLR 
ACLR  
(not further specified) 
Arthroscopic 
ACLR 
Study design RCT RCT RCT RCT RCT RCT 
Number of pts12 99 pts (100 knees) 
50 vs. 50 (knees) 
17213 
86 vs. 86 
20814 
104 vs. 104 
10715 
53 vs. 54 
10216 
34 vs. 34 vs. 34 
10617 
53 vs. 53 
                                                             
11 Allografts were pre-soaked in gentamicin and dexamethasone. 
12 At time of randomisation. 
13 218 pts underwent ACL reconstruction. Of those, 195 pts were eligible to participate in the study. 172 pts provided written, informed consent  
and were randomised to different treatment groups.  
14 256 pts were assessed for eligibility, of which 208 were randomised to the different treatment groups.  
15 121 pts were assessed for eligibility, of which 107 were eligible and randomised to the different treatment groups.  
16 281 pts were assessed for eligibility, of which 102 patients were randomised to the different treatment groups. 
17 122 pts were assessed for eligibility, of which 106 patients were randomised to the different treatment groups. 
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Author, year Bottoni 2015 [15] Sun 2009 [20] Sun 2011 [21] Tian 2016 [22] Li 2015 [19] Jia 2015 [17] 
Inclusion criteria Patients 18 years  
of age or older with 
symptomatic ACL 
deficiency,  
confirmed by MRI 
Only primary unilateral 
reconstructions of the 
ACL were included in 
the study.18 
Patients with minor 
medial collateral 
ligament sprains (lower 
than grade II), previous 
diagnostic arthroscopy, 
or meniscal tears were 
not excluded from  
the study. 
 Only primary uni-
lateral reconstructions 
of the ACL were in-
cluded in the study18. 
 No previous injury 
or surgery on the 
affected knee, 
 no multiple 
ligamentous injuries 
or malalignment, and 
 ability to complete 
the study protocol. 
Patients with minor 
medial collateral sprains 
(<grade 2), meniscal 
tears and or previous 
diagnostic arthroscopes 
were not excluded. 
Patients with acute or 
chronic ACL ruptures 
Only primary unilateral 
reconstructions of the 
ACL were included in 
the study18. 
Unilateral ACL rupture 
verified clinically by 
positive Lachman test 
and positive Pivot shift 
test findings. 
All patients had 
undergone a 
preoperative MRI scan 
to confirm the ACL 
rupture. All patients 
with normal 
preoperative CRP  
(<10 mg/L) and ESR 
(≤15 mm/h) values 
were included. 
Diagnosis with ACL 
tear by physical 
examination and 
magnetic resonance 
imaging, normal 
alignment, normal 
contralateral knee, and 
willingness to join the 
rehabilitation 
programme 
Exclusion criteria   Multiligamentous 
injuries (concomitant 
grade I or II medial 
collateral ligament 
injuries were not 
excluded), 
 previous knee 
ligament surgery 
(previous knee 
arthroscopic surgery 
was not excluded), 
and 
 time remaining on 
the island of less 
than 6 months 
Patients were excluded 
from the study if they 
had had 
 a previous injury to 
or surgery on the 
affected knee, 
 multiple 
ligamentous injuries, 
or malalignment, or 
 if they lacked the 
ability to complete 
the study protocol. 
Patients undergoing 
revision reconstruction 
and those with associated 
injuries of the posterior 
cruciate ligament or 
posterolateral corner  
or with deficiency or 
reconstruction of the 
ACL in the contralateral 
knee were also  
excluded. 
Revision reconstruction 
and patients with 
associated injuries of 
the posterior cruciate 
ligament or the 
posterolateral corner, 
with deficiency, or a 
reconstruction of the 
ACL in the contra-
lateral knee were 
excluded. 
Pts were excluded if 
they had 
 a previous injury or 
 surgery on the 
affected knee, 
 had open physes 
present, 
 had severe arthritic 
changes in the knee, 
 had multiple 
ligamentous injuries, 
 had malalignment, 
 lacked the ability to 
complete the study 
protocol 
 a revision 
reconstruction, 
 associated injuries of 
the posterolateral cor-
ner, and deficiency or 
 reconstruction of 
the ACL in the  
contralateral knee. 
 Combined multiple-
ligament injuries, 
 previous ACL surgery, 
 contralateral knee 
ligament injury, 
 radiographically 
verified osteoarthritis 
Patients with pre-
existing metabolic 
pathologies such as 
diabetes mellitus or 
uremia were excluded 
from the study. 
Those patients who 
could not finish the 
minimum clinical 
follow-up period of 5 
years were also 
excluded. 
NR 
       
                                                             
18 All pts had an MRI scan obtained preoperatively to exclude combined, complicated ligament injuries to their knees. 
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Author, year Bottoni 2015 [15] Sun 2009 [20] Sun 2011 [21] Tian 2016 [22] Li 2015 [19] Jia 2015 [17] 
Rehabilitation (before or 
after ACLR) 
Physical therapy19 
(Standardised protocol) 
Physical therapy19 
(Same protocol) 
Physical therapy19 
(Same protocol) 
Physical therapy19 
(Same protocol) 
Physical therapy19 
(Standardised protocol) 
Physical therapy19 
(Same programme) 
Age of patients,  
mean ±SD (range), yrs  
29.2 ± 5.5 (20.7-41.5) vs. 
28.9 ± 5.8 (20.6-42.5) 
32.8 ±7.1 (19-65) vs. 
31.7 ±6.3 (20-54)20 
31.2 ±8.3 (18-59) vs. 
29.6 ±6.9 (19-56) 20 
28.6 ±7.2 (18-50) vs. 
29.2 ± 6.9 (18-55)20 
30.5 ±6.1 vs. 29.8 ±7.9 
vs. 31.6 ±8.221 20 
28 vs. 3122 
Sex, n female (%) 6 (12.2) vs. 7 (14.6) 17 (21.3) vs. 15 (20)20 17 (17.9) vs. 20 (22)20 9 (20.9) vs. 8 (20)20 17 (53.1) vs. 15 (46.9) 
vs. 13 (41.9)20 
27 (50.9) vs. 25 (47.2) 
Further relevant patient 
characteristics at baseline  
& co-interventions 
95% of pts were in the 
military (active-duty). 
Concomitant meniscal 
and chondral pathologic 
abnormalities, micro-
fracture, and meniscal 
repair performed at the 
time of reconstruction 
were similar in both 
groups23. 
No statistically 
significant differences 
between treatment 
groups when considering 
arthroscopic findings 
and treatments at time 
of ACLR 
No. of pts with normal 
meniscus (no treatment 
of meniscal tears at time 
of ACL reconstruction): 
36/80 pts (45%) vs. 
36/76 pts (47%)24 
No statistically 
significant differences 
between treatment 
groups when considering 
arthroscopic findings 
and treatments at time 
of ACLR 
No. of pts with normal 
meniscus (no treatment 
of meniscal tears at 
ACL reconstruction): 
48/95 pts (50.5%) vs. 
45/91 pts (49.5%) 
No statistically 
significant differences 
between treatment 
groups when considering 
arthroscopic findings 
and treatments at time 
of ACLR 
No. of pts with normal 
meniscus (no treatment 
of meniscal tears at 
ACL reconstruction): 
18/43 pts (41.9%) vs. 
16/40 pts (40.0%) 
No statistically 
significant differences 
when considering 
associated injuries and 
treatments before 
ACLR 
No. of pts. with no 
treatment of meniscal 
tears: 3/32 pts (9.4%) 
vs. 6/32 pts (18.8%)  
vs. 7/31 pts (22.6%) 
Baseline characteristics 
insufficiently described 
Mean follow-up (in yrs) 10.5, range: 10-1125 5.6, range: 4-8 7.8, range: 6-10 
7.9 (SD: 1.1) vs. 7.6 (SD: 
0.9) 
6.9, range: 5.5-8 
6.8 (SD: 0.8) vs. 7 (SD: 
0.7) 
5.9 (overall mean), 
range: 5-7 
6.1 (SD: 0.3) vs. 5.8 (SD: 
0.9) vs. 5.9, SD: 0.6 
6.75, range:  
2.33–7.1626 
                                                             
19 Physical therapy may have included, but was not limited to, the following: Pre-operative therapy to restore full knee range, normal gait and eliminate knee swelling.  
Post-operative: Full extension range of motion, strengthening exercises, range of motion brace (for 4 weeks post surgery), and a functional brace for sport activities (for 1-2 years 
after surgery). Adaptations for range of motion restriction and weightbearing status applied, with accompanying meniscal and chondral surgery. 2 studies explicitly reported that 
physical therapy provided outside of the institution may have varied and may have been a factor that influenced the outcomes. 
20 The study only described information on the age and sex of the patients who were analysed (as opposed to the number of pts who were originally randomised).  
Therefore, the denominator used to calculate the percentages is the number of patients analysed in the respective treatment group.  
21 The range of the variable age was not reported in the study. 
22 SD and range were not reported. 
23 No statistically significant differences were found when comparing the respective baseline characteristics between allograft and autograft groups,  
except for lateral compartment: grade 0: 43 (87.8%) vs. 35 (72.9%); grade 1: 3 (6.1%) vs. 3 (6.3%); grade 2: 1 (2%) vs. 6 (12.5%); grade 3: 2 (4.1%) vs. 0 (0%);  
grade 4: 0 (0%) vs. 4 (8.3%). Diff. of LC category was s. s. with p=0.034. 
24 Pts with meniscal tears underwent partial meniscectomy or repair. 
25 Converted to yrs by review authors. FU reported in study: 126 months (mean), range: 120-132. 
26 Converted in yrs by review authors. FU reported in study: 81 months (mean), range: 28–86. 
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Author, year Bottoni 2015 [15] Sun 2009 [20] Sun 2011 [21] Tian 2016 [22] Li 2015 [19] Jia 2015 [17] 
Loss to follow-up, n (%)27 Overall: 3 (3) 
1 vs. 228 
Overall: 16 (9.3) 
6 (6.9) vs. 10 (11.6) 
Overall: 22 (10.6) 
9 (8.7) vs. 13 (12.5) 
Overall: 24 (22.4) 
10 (18.9) vs. 14 (25.9) 
Overall: 7 (6.8) 2 (5.9) 
vs. 2 (5.9) vs. 3 (8.8) 
Overall: 0 (0) 
0 (0) vs. 0 (0) 
Pts included in analysis, n 49 vs. 48 (knees29) 80 vs. 76 95 vs. 91 43 vs. 40 32 vs. 32 vs. 31 53 vs. 53 
Outcomes 
Effectiveness 
Patient-reported function, activity level and symptoms 
 Lysholm score,  
mean ±SD (range) 
NR30 Preoperative: 60 ±9 
(32-76) vs. 59 ±11 (33-78) 
At final FU: 91 ±6 vs. 
90 ±8; diff. n. s.,  
with p=0.58631 
Preoperative: 
59 ±10 (33-78) vs.  
60 ±12 (35-79) 
At final FU: 90 ±8 vs. 
89 ±9; diff. n. s., 
p=0.59531 
Preoperative: NR32 
At final FU: 86 ±9  
(50-100) vs. 90 ± 11 
(65-100); diff. n. s., 
with p=0.0727 
Preoperative: NR33 
scores “after surgery”34: 
88.7 ±8.6 vs. 91.3 ±11.5 
vs. 90.5 ±10.2; diff. n. s., 
with p=0.213 
Preoperative: 71.0 ± 3.6 
(66–83) vs. 71.9 ± 4.2 
(69–84)35 
Postoperative score: 
86.8 ± 2.6 (81–90) vs. 
85.2 ± 3.1 (80–95);  
diff. n. s., with p>0.0536 
 Tegner score,  
mean ± SD (range) 
Preoperative: NR 
Postoperative37: 4.5 ± 
2.2 vs. 4.8 ± 2.3; diff. n. 
s, with p=0.505 
Preoperative: 3.0 ±1.7 
(1-6) vs. 3.1 ±1.5 (1-6) 
At final FU: 7.6 ±1.9 vs. 
7.8 ± 1.6, diff. n.s,  
with p=0.87138 
Preoperative: 3.1 ±1.5 
(1-7) vs. 3.0 ±1.3 (1-6) 
At final FU: 7.6 ±1.5 vs. 
7.7 ±1.8, diff. n. s.,  
with p=0.93638 
Preoperative: NR32 
At final FU: 7.3 ± 1.3 (3-
9) vs. 7.8 ± 1.2 (3-9); 
diff. n. s.  
with p=0.0730 
Preoperative: NR33 
Scores “after surgery”34: 
7.0 ±2.1 vs. 7.3 ±1.3 vs. 
7.5 ±1.5; diff. n. s., with 
p=0.416 
NR 
                                                             
27 Due to the fact that calculating the loss to follow-up is sometimes confused in clinical studies, the loss to FU was calculated by the review authors using consistent criteria [98]: 
The follow-up rate was calculated using the number of randomised patients as the denominator and the number of patients analysed as the numerator. The difference between 
randomised and analysed patients was therefore considered to be patients lost to FU.  
28 The review authors judged it to be spurious that the investigators switched constantly between knees and patients when reporting characteristics of patients and results.  
Given that it was only reported that 50 knees were randomised in two groups, the percentage for the loss to FU in each group was not estimable. Of the pts lost to FU,  
2 were deceased, and 1 patient was lost to FU for other reasons. 
29 It was unclear to the review authors whether the presented results refer to 97 knees or patients, because the study did not clearly report it.  
Given that 3 patients were lost to FU, 97 knees must have been considered in the analysis. 
30 The study reported that the Lysholm score was measured and there was no statistically significant difference in the Lysholm score between treatment groups.  
However, no results of the Lysholm score were reported in the publication of the study. 
31 Significant differences were found according to the scores preoperatively and postoperatively (p<0.05). 
32 The study stated that preoperative subjective outcomes were measured preoperatively and at the final FU. However, preoperative scores were not reported. 
33 The study stated that there were no significant differences in the (preoperative) Lysholm score, Tegner activity score, or IKDC evaluation score (subjective, objective). 
34 Data of the subjective evaluation were reported as “after surgery” only. Significant improvements at last follow-up compared with preoperative values. 
35 Difference in baseline score between groups was n. s. (p>0.05). 
36 The study did not report on whether the postoperative score was statistically significantly different when compared to the baseline score. 
37 Specific time point was not mentioned.  
38 Significant differences were found according to the scores preoperatively and postoperatively (p<0.05). 
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Author, year Bottoni 2015 [15] Sun 2009 [20] Sun 2011 [21] Tian 2016 [22] Li 2015 [19] Jia 2015 [17] 
 Cincinnati Knee score, 
mean ±SD (range) 
NR Preoperative: NR 
Postoperative39: 
92 ±11 (62-100) vs. 91 
±12 (59-100); diff. n. s., 
with p=0.949 
Preoperative: NR 
Postoperative39: 
91 ±11 (58-100) vs. 90 
±10 (55-100); diff. n. s. 
(p=0.927) 
Preoperative: NR32 
At final FU: 87 ± 12 
(45-100) vs. 90 ± 10 
(50-100); diff. n. s., 
with p=0.2214 
NR NR 
 SANE score, mean ±SD Preoperative: NR 
10-year follow-up: 
78.8 ± 18.8 vs. 81.5 ±16.4; 
differences n. s.  
with p=0.454 
NR NR NR NR NR 
 IKDC score (subjective), 
mean ±SD (range) 
Preoperative: NR 
Postoperative39:  
73.7 ± 25.9 vs.  
77.2 ± 25.4, n. s.  
with p=0.510 
Preoperative: NR 
Postoperative39: 
88 ±9 (65-100) vs.  
90 ±10 (64-98); 
differences n. s.,  
with p=0.442 
Preoperative: NR 
Postoperative39:  
90 ±14 (65-100) vs.  
89 ± 12 (60-100);  
differences n. s.,  
with p=0.548 
Preoperative: NR32 
At final FU:  
85 ± 11 (60-100) vs.  
89 ± 9 (65-100); 
differences n. s.,  
with p=0.0748 
Preoperative: NR33 
Scores “after surgery”34: 
83.8 ±6.9 vs.  
87.5 ±3.2 vs. 89.8 ±5.7; 
differences n. s.,  
with p=0.353 
Preoperative: 66.1 ± 3.5 
(60–74) vs. 67.3 ± 2.5 
(61–78)35 
Postoperative score40: 
85.6 ± 2.9 (81–91) vs. 
87.8 ± 1.6 (82–90);  
diff. n. s., with p>0.0541 
 KOOS score (e.g., symptoms, 
pain, sports and activity) 
NR NR NR NR NR NR 
 Marx activity scale NR NR NR NR NR NR 
Clinical knee stability 
 Lachman test (grade 0-1), 
n (%)  
NR At final FU: 74 (92.5) 
vs. 71 (93.4) 
Differences n. s.,  
with p=0.06 
At final FU: 87 (91.6) 
vs. 84 (92.3) 
Differences n. s.,  
with p=0.968 
At final FU: 
31 (72) vs. 37 (93) 
Differences s. s.,  
with p<0.001 
At final FU: 28 (87.5) vs. 
30 (93.8) vs. 30 (96.8) 
Differences n. s.,  
with p=0.209 
NR42 
 Pivot shift test (grade 0-1), 
n (%) 
NR At final FU: 80 (100) 
vs. 76 (100) 
differences n. s.,  
with p=0.169 
At final FU: 95 (100) 
vs. 91 (100) 
differences n. s.,  
with p=0.855 
At final FU: 
38 (88.4) vs. 40 (100); 
differences s. s.,  
with p=0.004 
At final FU: 
31 (96.9) vs. 32 (100) vs. 
31 (100) 
Differences n. s.,  
with p=0.249 
NR42 
                                                             
39 The time point was not clearly reported. 
40 The study did not clearly state whether the subjective or objective IKDC score was used. Due to the fact that the objective IKDC variable has 4 distinctive characteristics (nor-
mal, nearly normal, abnormal, and severely abnormal), it was assumed that the extracted numbers referred to the subjective IKDC score. 
41 The study did not report on whether the postoperative score was statistically significantly different when compared to the baseline score. 
42 The study did mention that the Lachman test was measured. Grade 1 scores can be found for the Lachman test (6/53 vs. 7/53) and Pivot shift test (13/53 vs. 11/53), but the rest of 
the patients were classified with a “–”. Given that no explanation was provided whether those patients were negative or grade 0, we did not extract this data. 
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Author, year Bottoni 2015 [15] Sun 2009 [20] Sun 2011 [21] Tian 2016 [22] Li 2015 [19] Jia 2015 [17] 
 Side-to-side difference  
in mm, mean ±SD (range)  
NR Postoperative43 
(measured with the  
KT-2000 arthrometer: 
2.5 ±0.9 (0-5.6) vs.  
2.4 ±0.7 (0-5.4);  
diff. n. s., with p=0.369 
Postoperative44 
(measured with the  
KT-2000 arthrometer): 
2.7 ±0.9 (0-7) vs.  
2.5 ±0.7 (-1-7);  
diff. n. s., with p=0.314 
Postoperative45 
(measured with the  
KT-2000 arthrometer): 
5.5 ±1.0 (0-10) vs.  
2.4 ±0.7 (0-7);  
diff. s. s., with p<0.001 
At final FU  
(measured with the  
KT-1000 arthrometer): 
3.5 ±1.2 (NR46) vs.  
2.1 ±1.6 (NR47) vs.  
2.0 ±1.5 (NR48) 
Diff. s. s. with p=0.025 
NR 
 IKDC score (objective; 
normal and nearly normal), 
n (%)49 
NR At final FU:  
75 (93.8) vs. 72 (94.7); 
diff. n. s., with p=0.285 
At final FU:  
86 (90.5) vs. 85 (93.4) 
Diff. n. s., with p=0.707 
At final FU: 
38 (88.4) vs. 38 (95) 
Difference in objective 
IKDC scores between 
groups n. s., with p=0.435 
At final FU: 
29 (90.6) vs. 29 (90.6) 
vs. 28 (90.3); 
differences n. s.,  
with p=0.880 
NR 
Patient satisfaction NR NR NR NR NR Satisfied: 46/53 
(86.8%) vs. 47/53 
(88.7%) 
Nearly satisfied: 7 
(13.2%) vs. 5 (9.4%) 
Diff. n. s.; p>0.0550 
Health-related Quality of Life NR NR NR NR NR NR 
Safety outcomes 
Graft failure rate, n (%) 13 (26.5) vs. 4 (8.3), 
diff. s. s., with p=0.03151 
NR NR Defined as knee laxity 
>5mm (KT-2000): 
13 (30.2) vs. 3 (7.5),  
diff. s. s., with p<0.001 
NR NR52 
                                                             
43 Unclear time point. 
44 Unclear time point. 
45 Unclear time point. 
46 95%CI was reported instead of the range: 3.1-4.1. 
47 95%CI was reported instead of the range: 1.6-2.6. 
48 95%CI was reported instead of the range: 1.4-2.6. 
49 The overall IKDC score has 4 qualitative characteristics regarding knee functionality: normal, nearly normal, abnormal, and severely abnormal.  
In this assessment, only the number of pts with normal and nearly normal characteristics were extracted and summarised. 
50 The study only stated that patient satisfaction was measured using a questionnaire. The instrument was not reported. 
51 The study stated that 17 patients failed their index operation and sustained graft failure, requiring revision ACL reconstruction.  
The study did not state how graft failure was defined. It appears that revision ACL reconstruction may have been an indicator for graft failure for the investigators.  
The authors of the study were contacted for further information, but no information was provided by them. 
52 The study reported that “(…) graft failure proportions were larger for allografts than for autografts, but after statistical analysis, the differences were not significant”.  
Further information was not reported. 
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Author, year Bottoni 2015 [15] Sun 2009 [20] Sun 2011 [21] Tian 2016 [22] Li 2015 [19] Jia 2015 [17] 
Re-rupture rate NR 53 NR NR NR NR NR54 
Re-operation rate, n (%) NR55 NR NR56 NR57 NR58 NR 
Revisions, n (%) 13 (26.5) vs. 4 (8.3), 
diff. s. s., with p=0.031 
NR NR NR The study stated that 
no patient needed 
additional surgery 
because of recurrent  
or residual symptoms. 
NR 
Overall complications, n (%) NR NR NR NR NR NR 
 Arthrofibrosis, n (%) NR NR 0 (0) vs. 0 (0) 0 (0) vs. 0 (0) NR NR59 
 Effusion, n (%) NR NR NR NR NR NR 
 Tenderness, n (%) NR NR 0 (0) vs. 2 (2.1)60; p=NR NR NR NR 
 Infection, n (%) NR Postoperative infection: 
1 (1.25)61 vs. 0 (0); 
p=NR 
2 (2.1) vs. 0 (0)62; 
p=NR 
2 (4.6) vs. 0 (0)62; 
p=NR 
The study stated  
that no postoperative 
infection occurred. 
NR 
 Hyposthesia, n (%) NR NR 0 (0) vs. 3 (3.3); p=NR 0 (0) vs. 3 (7.5); p=NR NR NR 
 Synovitis, n (%) NR NR NR NR NR NR 
 Deep venous thrombosis,  
n (%) 
NR 2 (2.5) vs. 1 (1.3); p=NR 0 (0) vs. 0 (0) 0 (0) vs. 0 (0) NR NR 
                                                             
53 The 17 patients who failed their index operation sustained graft failure and required revision ACL reconstruction. This number may also represent the re-rupture rate,  
given that the patients needed revision ACL reconstruction.  
54 The study stated that the rate of ligament rupture after primary reconstruction was higher in the allograft group, but the difference was not statistically significant.  
Further information was, however, not reported. 
55 The data only refers to revision ACL reconstruction and may not include other re-operations. 
56 The study did mention that no postoperative complications required reoperation or readmission. The authors judged this information to be insufficient  
to calculate the re-operation rate. 
57 The study did mention that no complications required reoperation. The authors judged this information to be insufficient to calculate the overall re-operation rate. 
58 The study stated that no patient needed additional surgery because of recurrent or residual symptoms. This information was judged insufficient to calculate the re-operation rate. 
59 The study stated that no statistically significant differences were found when comparing the incidence of arthrofibrosis between groups at the final FU.  
However, further information was not reported. 
60 The 2 patients in the autograft group had tenderness or irritation at the graft harvest site. 
61 There was 1 patient (1.25%) in the allograft group with a late infection that required antibiotic treatment. 
62 There were 2 patients with a superficial wound infection in the allograft group at the incision area who needed antibiotic treatment and healed well soon after. 
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Author, year Bottoni 2015 [15] Sun 2009 [20] Sun 2011 [21] Tian 2016 [22] Li 2015 [19] Jia 2015 [17] 
 Other complications Tibial and femoral 
tunnel widening was 
higher, yet not s. s. 
different, in the 
allograft group at final 
follow-up. 
Tibial (in mm),  
mean (range):  
9.2 (7-10) vs. 8.9 (7-10); 
diff. n. s. with p=0.651 
Femoral (in mm), 
mean (range):  
8.8 (7-10) vs. 8.3 (7-10),  
diff n. s. with p=0.453 
The mean postoperative 
fever time (axillary 
temperature >38°C, 
which was taken by 
nurses for 10 minutes) 
in the allograft group 
(mean, 6.8 days;  
range, 4.4 to 9.8 days) 
was 2.4 days longer 
than that in the 
autograft group  
(mean, 4.4 days;  
range, 3.5 to 6.9 days).  
Diff. s. s., with p<0.05 
The study stated that 
there were no cases of 
the following complica-
tions in either treatment 
group during the study: 
 arthrofibrosis, 
 anterior knee pain 
 pain on kneeling, 
 deep infection, 
 deep venous 
thrombosis, 
 failure of fixation, 
 blowout fracture, 
 reoperation issues 
such as removal of 
staples, or 
 failed meniscal repairs. 
There were no cases of 
 deep venous 
thrombosis, 
 deep infection, 
arthrofibrosis, 
 pain when kneeling, 
 anterior knee pain, 
 failure of fixation, or 
 blowout fracture 
in either treatment 
group during the study. 
Arthritic progression:  
14 (32.6%) vs. 4 (10%), 
diff. s. s.,  
with p<0.0563 
Regarding 
complications, the 
study stated that there 
were no cases of  
major neurovascular, 
infectious, vascular, or 
wound complications. 
Tibial and femoral 
widening was s. s. higher 
in the allograft group 
(p<0.05). 
Scores at final follow-up: 
Tibial (in mm),  
mean ±SD:  
7.8 ±0.4 vs. 7.61 ±0.22, 
Femoral (in mm), 
mean ±SD:  
7.64 ±0.35 vs. 7.51 ±0.42 
Procedure-related mortality, 
n (%) 
NR NR NR NR NR NR 
Abbreviations: ACL – anterior cruciate ligament; ACLR – anterior cruciate ligament reconstruction; BPTB – bone-patellar tendon-bone; CI – confidence interval; diff. – difference; FU – follow-up; 
IKDC – International Knee Documentation Committee; KOOS – Knee injury and Osteoarthritis Outcome Score; MRI – magnetic resonance imaging; n. s. – not statistically significant; NR – not 
reported; Pts – patients; RCT – randomised controlled trial; s. s. – statistically significant; SANE – Single Assessment Numerical Evaluation; SD – standard deviation; vs. – versus; yrs – years. 
 
 
                                                             
63 It appears that a typing error occurred in the included study: in the abstract, the study reports that “(…) 32.6% (19/43)” patients had arthritic progression in the allograft group 
(note: wrong calculation, since this should be 44.2% then), while in the text it is written that 14/43 (32.6%) had arthritic progression in the allograft group.  
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Table A-2: Allograft versus autograft for posterior cruciate ligament reconstruction: results from randomised controlled trials 
Author, year Li 2016 [18] Wang 2004 [23] 
Country China Taiwan 
Sponsor NR NR 
Interventions/Products 4-stranded y-irradiated tibialis anterior tendon allograft Allograft (incl. Achilles tendon and anterior tibial tendons) 
Comparator Gracilis and semitendinosus tendon autograft 
Hybrid graft (y-irradiated tibialis anterior tendon allograft  
and semi-tendinosus tendon autograft 
Autograft (incl. quadriceps tendon-patellar bones  
and quadruple hamstrings) 
Surgical procedure Arthroscopic single-bundle PCLR Arthroscopic single-bundle PCLR 
Study design RCT RCT 
Number of pts 9064 
30 vs. 30 vs. 30 
55 
23 vs. 32 
Inclusion criteria  persistent posterior laxity greater than or equal to grade 2, 
 lack of response to conservative treatment (medication and 
physical therapy) for more than 3 months, and 
 objective evidence of PCL rupture by MRI. 
NR65 
Exclusion criteria   concomitant injury to other knee ligaments, 
 previous surgery on the injured knee, or 
 articular cartilage lesions greater than Outerbridge grade II based on 
the preoperative MRI scan and diagnostic arthroscopic examination 
Patients with PCL avulsion fracture and combined ligament injuries 
were not included. 
Rehabilitation (before or after PCLR) The 3 groups of patients followed the same postoperative 
rehabilitation programme. 
Physiotherapy66 
Rehabilitation outside the hospital was not controlled. 
Patients received the same postoperative rehabilitation  
(incl. e.g., exercise, functional knee braces, etc.). 
Physiotherapy: NR 
Age of patients, mean ±SD (range), yrs  32.2 ±7.8 (20-40) vs. 31.3 ±6.2 (20-40) vs. 30.6 ±7.5 (20-40)67 30 ±12 (16-64) vs. 29 ±12 (16-54) 
Sex, n female (%) 11 (40.7) vs. 9 (34.6) vs. 10 (37) 67 7 (30.4) vs. 7 (21.9) 
                                                             
64 116 pts were assessed for eligibility. Of those, 90 pts were randomised in the 3 treatment groups. 
65 The study only reported that it consisted of patients who underwent PCLR. In this context, the study states that the indication for surgery included pain  
and instability because of high-energy posterior cruciate ligament injury with failure of conservative treatments for 3 months. 
66 Post-operative physiotherapy may have included, but was not limited to, the following: a functional brace (6-12 weeks), passive range of motion exercises,  
progressive weight bearing after 2 weeks, and closed kinetic chain exercises. 
67 The study reported on demographic data using the analysed (not the enrolled) patients. Therefore, the denominator(s) are the analysed patients within the groups. 
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Author, year Li 2016 [18] Wang 2004 [23] 
Further relevant patient 
characteristics 
Pts with tears of the meniscus underwent partial meniscectomy  
(if irreparable) or repair. 
No. of pts. with no treatment of meniscal tears:  
10/30 pts (33.3%) vs. 9/30 pts (30%) vs. 9/30 pts (30%); diff. n. s. 
Associated injuries were treated accordingly before PCLR. 
Concomitant treatments68: 
5 meniscectomies 
3 meniscus repairs 
3 debridement for chondral lesions 
Mean follow-up in yrs ±SD Overall69: 5.6  
5.7 ±0.3 vs. 5.5 ±0.2 vs. 5.6 ±0.5 
Overall70: 2.83 
2.83 vs. 2.75 
Loss to follow-up, n (%) Overall: 10 (11) 
3 (10) vs. 4 (13.33) vs. 3 (10) 
NR71 
Pts included in analysis, n 27 vs. 26 vs. 27 23 vs. 32 
Outcomes 
Effectiveness 
Patient-reported function, activity level and symptoms 
 Lysholm score, mean ±SD (range) Pre-operative:  
64.1 ±10.8 vs. 63.8 ±11.2 vs. 62.3 ±12.9; diff. n. s. with p=0.721 
Postoperative72:  
85.2 ±3.9 vs. 87.8 ±3.6 vs. 86.9 ±4.3; diff. n. s., with p=0.193 
Preoperative: NR 
Postoperative73: 
92.3 ±6.8 vs. 87.8 ±9.6; diff. n. s., with p=0.077 
 Tegner score, mean ± SD Pre-operative: 
2.6 ±1.1 vs. 2.7 ±1.2 vs. 2.9 ±1.3; diff. n. s., with p=0.662 
Postoperative 72: 
6.2 ±1.7 vs. 6.8 ±1.1 vs. 6.5 ±1.8; diff. n. s., with p=0.096 
4.70 ±1.66 vs. 4.73 ±1.66; diff. n.s., with p=0.976 
 Cincinnati Knee score, mean ±SD NR NR 
 SANE score, mean ±SD NR NR 
 IKDC score (subjective) , mean 
±SD (range) 
Pre-operative:  
65.9 ±9.3 vs. 66.5 ±10.1 vs. 65.5 ±11.5; diff. n. s., with p=0.586 
Postoperative72  
80.2 ±6.8 vs. 83.5 ±6.3 vs. 82.8 ±5.7; diff. n. s., with p=0.153 
NR 
                                                             
68 Differences between treatment groups were not reported. 
69 The overall mean was calculated by the review authors based on the mean FU time of the respective treatment groups. 
70 The study only reported on the FU time in months. Overall: 34±10 (34 ±11 vs. 33 ±12) 
71 The study did not adequately report on the enrolment process. Therefore, the loss to follow-up rate could not have been calculated. 
72 There were significant differences (p<0.05) between baseline scores and the last follow-up scores after surgery. 
73 The time point was not clearly reported. 
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Author, year Li 2016 [18] Wang 2004 [23] 
 KOOS score (e.g., symptoms, pain, 
sports and activity) 
NR NR 
 Marx activity scale NR NR 
Clinical knee stability 
 Lachman test (grade 0-1), n (%)  NR Reverse Lachman 
Preoperative: NR 
Postoperative74: mean ±SD (range)75: 
0.70 ±0.56 (0-2) vs. 0.75 ±0.67 (0-3); diff. n. s., with p=0.898 
 Pivot shift test (grade 0-1), n (%) Reverse Pivot shift (postoperative at final FU):  
26 (96.3) vs. 26 (100) vs. 27 (100); diff. n. s., with p=0.407 
NR 
 Side-to-side difference in mm, 
mean ±SD (range)  
Measured with Instrumented Anteroposterior Measurements 
Postoperative: 
3.5 ±1.1 (NR76) vs. 2.1 ±1.0 (NR77) vs. 2.6 ±1.2 (NR78);  
diff. s. s., with p<0.001 
Measured with the KT-1000 arthrometer 
Preoperative: NR 
Postoperative79: 
2.83 ±1.70 (1-6) vs. 3.16 ±2.60 (1-10); diff. n. s., with p=0.605 
 IKDC score (objective; normal  
and nearly normal), n (%)80 
Postoperative (at Final FU): 
24 (88.9) vs. 25 (96.2) vs. 25 (92.6); diff. n. s., with p=0.716 
Preoperative: NR 
Postoperative81: 
14 (60.9) vs. 23 (71.9); diff. n. s., with p=0.391 
Patient satisfaction NR NR 
Health-related Quality of Life NR NR 
Safety 
Graft failure rate, n (%) NR NR 
Re-ruptures NR NR 
                                                             
74 The time point was not clearly reported. 
75 The study only reported on the mean and range of the Lachman test. 
76 95%CI was reported: 3.083-3.9200 
77 95%CI was reported: 1.6946-2.4941 
78 95%CI was reported: 2.1028-3.0397 
79 The time point was not clearly reported. 
80 The overall IKDC score has 4 qualitative characteristics regarding knee functionality: normal, nearly normal, abnormal, and severely abnormal.  
In this assessment, only the number of pts with normal and nearly normal characteristics were extracted and summed up. 
81 The time point was not clearly reported. 
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Author, year Li 2016 [18] Wang 2004 [23] 
Re-operation rate, n (%) The study stated that no patient needed additional surgery  
because of recurrent or residual posterior laxity. 
NR 
Revisions, n (%) NR NR 
Overall complications, n (%) NR 0 (0) vs. 7 (21.9) 
 Arthrofibrosis, n (%) NR NR 
 Effusion, n (%) NR NR 
 Tenderness, n (%) NR NR 
 Infection, n (%) The study stated that no postoperative infection occurred. 0 (0) vs. 2 (6.3)82 
 Hyposthesia, n (%) NR NR 
 Synovitis, n (%) NR NR 
 Deep venous thrombosis, n (%) The study stated that no deep venous thrombosis occurred. NR 
 Other complications Regarding complications, the study reported that there were no cases 
of major neurovascular, infectious, vascular, deep venous thrombosis, 
or wound complications. 
Donor site pain: 0 (0) vs. 4 (12.5) 
Reflex sympathetic dystrophy (RSD): 0 (0) vs. 1 (3.1) 
Tibial and femoral tunnel 
Enlargement was comparable between the allograft and autograft 
groups with no significant difference at final follow-up: 
Tibial83: 12 ±20 (range: 0-90) vs. 12 ±14 (range: 0-43), with p=0.64 
Femoral83: 5.3 ±22 (range: 0-50) vs. 13 ±19 (range: 0-55), with p=0.771 
Procedure-related mortality, n (%) NR NR 
Abbreviations: BPTB – bone-patellar tendon-bone; diff. – difference; FU – follow-up; IKDC – International Knee Documentation Committee; KOOS – KOOS – Knee injury and Osteoarthritis 
Outcome Score; MRI – magnetic resonance imaging; n. s. – not statistically significant; NR – not reported; PCL – posterior cruciate ligament; PCLR – posterior cruciate ligament reconstruction; 
pts – patients; RCT – randomised controlled trial; s. s. – statistically significant; SANE – Single Assessment Numerical Evaluation; SD – standard deviation; vs. – versus; yrs – years. 
 
  
                                                             
82 Of the 2 infections, one was an acute infection and the other was a late infection. 
83 Femoral and tibia tunnel enlargements are presented in percentage of the tunnel width at follow-up over the width postoperative in A-P view X-ray. 
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Table A-3: Allograft versus autograft for anterior cruciate ligament revision surgery: results from observational studies 
Author, year MARS Group [16] 
Country United States of America 
Sponsor AOSSM, Smith and Nephew (Andover, Massachusetts) 
National Football League Charities (New York, New York) 
Musculoskeletal Tissue Foundation (MTF; Edison, New Jersey) 
Project was partially funded by a grant from the  
National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIH/NIAMS). 
Interventions/Products Allograft: various specific graft types84 (n=590) 
Comparator Autograft: various specific graft types (n=583) 
Autograft+Allograft: various specific graft types (n=32) 
Surgical procedure Revision anterior cruciate ligament (ACL) reconstruction (not further specified) 
Study design Prospective cohort study 
Number of pts 1205 
Inclusion criteria Patients undergoing revision of a previously failed ACL reconstruction who agreed to participate and filled out  
an informed consent and a series of patient-reported outcome instruments 
Exclusion criteria  Multiligament reconstructions 
Rehabilitation (before or after ACLR) NR 
Age of patients, mean ±SD (range), yrs  Mean age: NR 
26, median (IQR: 20-34) 
Sex, n female (%) 508 (42) 
Further relevant patient characteristics Previous surgery included, n (%): 
Number of previous medial meniscus surgery: 743 (62) 
Number of previous lateral meniscus surgery: 958 (80) 
Number of previous articular cartilage surgeries: 1059 (88) 
Prior revisions ranged from 1 to 3+ (with 1055, 125 and 25 pts, respectively) 
Prior graft type, n (%): 
Autograft: 816 (68) 
Allograft: 348 (29) 
Both autograft + allograft: 29 (2) 
Other/unknown: 12 (<1) 
Follow-up in yrs  2 
                                                             
84 All of the grafts were fresh frozen and had minimal to no irradiation. 
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Author, year MARS Group [16] 
Loss to follow-up, n (%) Questionnaire loss to FU: 216 (17.9) 
FU by telephone: 93 (7.7)85 
Pts included in analysis, n Questionnaire: 989 
FU by telephone: 1112 
Outcomes 
Effectiveness 
Patient-reported function, activity level and symptoms 
 Lysholm score, mean ±SD (range) NR 
 Tegner score, mean ± SD NR 
 Cincinnati Knee score, mean ±SD NR 
 SANE score, mean ±SD NR 
 IKDC score (subjective),  
mean ±SD (range) 
Scores were only reported for all pts: 
Baseline score vs. score at 2 years FU: 52 (median, IQR: 38-63) vs. 77 (median, IQR: 61-86); diff. s. s., with p<0.001 
Results from logistic regression analysis: Graft choice proved to be a significant predictor of 2-year IKDC scores (p=0.017).  
Specifically, the use of an autograft for revision reconstruction predicted an improved score on the IKDC (p=0.045; OR, 1.31; 95% CI: 1.01-1.70). 
 KOOS symptoms Scores were only reported for all pts: 
Baseline score vs. score at 2 years FU: 68 (median; IQR: 54-82) vs. 79 (mean; IQR: 64-89); diff. s. s., with p<0.001 
Results from logistic regression analysis: It is stated that graft choice did not predict the outcome score (no further data reported). 
 KOOS pain Scores were only reported for all pts: 
Baseline score vs. score at 2 years FU: 75 (median; IQR: 58-86) vs. 89 (median; IQR: 75-94); diff. s. s., with p<0.001 
Results from logistic regression analysis: NR 
 KOOS sports and recreation Scores were only reported for all pts: 
Baseline score vs. score at 2 years FU: 45 (median; IQR: 25-65) vs. 75 (median; IQR: 55-90); diff. s. s., with p<0.001 
Results from logistic regression analysis: The KOOS sports and recreation subscale demonstrated higher scores in the setting of an 
autograft compared with allograft for revision reconstruction (p=0.037; OR, 1.33; 95% CI, 1.02-1.73). 
 KOOS activities of daily living Scores were only reported for all pts: 
Baseline score vs. score at 2 years FU: 87 (median; IQR: 69-96) vs. 97 (median; IQR: 88-100); diff. s. s., with p<0.001 
Results from logistic regression analysis: It is stated that graft choice did not predict this outcome score. 
                                                             
85 There was some inconsistency regarding the reporting of the number of patients analysed in the study. It is not clearly stated how many patients were analysed in the respective 
treatment groups. However, the denominator is described narratively for some of the results of the outcomes of interest. That is, regarding re-ruptures, it is stated that 540, 542 and 
29 patients were described as the denominator for re-ruptures, leading to an overall sample of 1,111 analysed patients. Yet, it is also stated that overall 1,112 patients were analysed 
after loss to FU. 
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Author, year MARS Group [16] 
 Marx activity score Scores were only reported for all pts: 
Baseline score vs. score at 2 years FU: 11 (median; IQR: 4-16) vs. 7 (median; IQR: 2-12); diff. s. s., with p<0.001 
Results from logistic regression analysis: Graft choice was a significant predictor of 2-year Marx activity scores (p=.012).  
Specifically, the use of a combination autograft plus allograft for revision reconstruction predicted improved scores on the Marx (p =.005; 
OR, 3.33; 95% CI, 1.43-7.78). No further data were reported. 
Clinical knee stability 
 Lachman test (grade 0-1), n (%) NR 
 Pivot shift test (grade 0-1), n (%) NR 
 Side-to-side difference in mm, 
 mean ±SD (range)  
NR 
 IKDC score (objective;  
normal and nearly normal), n (%)86 
NR 
Patient satisfaction NR 
Health-related Quality of Life KOOS QoL subscale (scores were only reported for all pts): 
Baseline score vs. score at 2 years FU: 31 (median; IQR: 19-44) vs. 56 (median; IQR: 38-75) diff. s. s., with p<0.001 
Results from logistic regression analysis: Use of an autograft predicted improved scores on the KOOS quality of life subscale  
(p=0.031; OR =1.33; 95% CI, 1.03-1.73). 
Safety 
Graft failure rate, n (%) NR 
Re-rupture rate, n (%) Graft re-ruptures: 24 (4.4) vs. 12 (2.2) vs. 1 (3.4) 
Results from logistic regression analysis: Subjects with an autograft revision were found to be 2.78 times less likely  
of sustaining a subsequent graft rupture compared with subjects who received an allograft (p=0.047; 95%CI: 1.01-7.69). 
Re-operation rate, n (%) Overall: 150 (13.5) 
No further data were reported, but it is stated that the multivariate regression analysis showed that graft choice was not  
a predictor of reoperation87 at 2 years FU. 
Revisions, n (%) NR 
Overall complications, n (%) NR 
 Arthrofibrosis, n (%) NR 
 Effusion, n (%) NR 
                                                             
86 The overall IKDC score has 4 qualitative characteristics regarding knee functionality: normal, nearly normal, abnormal, and severely abnormal. In this assessment,  
only the number of pts with normal and nearly normal characteristics were extracted and summed up. 
87 The included re-operations in the analysis were chondroplasty and other articular cartilage treatment procedures, meniscectomy, meniscal repair, and hardware removal. 
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Author, year MARS Group [16] 
 Tenderness, n (%) NR 
 Infection, n (%) NR 
 Hyposthesia, n (%) NR 
 Synovitis, n (%) NR 
 Deep venous thrombosis, n (%) NR 
 Other complications NR 
Procedure-related mortality, n (%) NR88 
Abbreviations: ACL – anterior cruciate ligament; CI – confidence interval; diff. – difference; FU – follow-up; IKDC – International Knee Documentation Committee; IQR – interquartile range; 
KOOS – Knee injury and Osteoarthritis Outcome Score; n. s. – not statistically significant; NR – not reported; QoL – quality of life; SANE – Single Assessment Numerical Evaluation;  
s. s. – statistically significant; SD – standard deviation; vs. – versus; yrs – years. 
 
  
                                                             
88 1 patient died and was not eligible for the analysis. It was deemed unlikely that this patient died due to the procedure, since it was not stated that this death was procedure-related. 
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Risk of bias tables and GRADE evidence profile 
Internal validity of the included studies was judged by two independent researchers. In case of disagreement a third researcher was involved to solve the differences. 
The Cochrane Risk of Bias Tool was used for randomised controlled trials [12], while the Newcastle-Ottawa Scale (NOS) was utilised for the included cohort 
studies[13]. 
  
Figure A-1: Risk of bias summary for studies comparing allografts to autografts in ACLR89 Figure A-2: Risk of bias summary for studies comparing allografts  
to autografts in PCLR89 
 
  
                                                             
89 The figures, summarising the risk of bias of the included studies, were created with the computer program Review Manager (version 5.3). 
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Table A-4: Risk of bias assessment for studies comparing allografts to autografts in ACLR: review authors’ judgements about each risk of bias item for each included study  
(study level: RCTs, see [2]) 
RoB Assessment for  
Bottoni 2015 [15] 
Author’s 
judgement 
Support for judgement 
Random sequence generation  
(selection bias) 
Unclear risk The investigators of the study did not sufficiently describe the random component in the sequence generation process.  
They did state that participating patients were randomised by study design, but it was unclear to the review authors what 
kind of sequence generation process is meant hereby. Therefore, the review authors judged the risk of bias to be unclear. 
Allocation concealment  
(selection bias) 
Low risk The investigator stated that sealed envelopes were used. Therefore, the review authors judged it to be unlikely  
that patient assignment could have somehow been foreseen. 
Blinding of participants and personnel 
(performance bias) 
Unclear risk Although the authors stated that patients were, once randomised, not blinded as to their graft type, the personnel  
(e.g., the physical therapists) seemed to have been blinded to the graft type. Overall, the review authors judged it to be 
unclear whether the outcomes may be influenced by the lack of blinding of personnel or participants. 
Blinding of outcome assessment 
(detection bias) 
High risk It was not clearly stated whether the outcome assessors were blinded to the graft type that was used. It was reported that 
the participants, once randomised, were not blinded to their graft types. The physical therapist was, on the contrary, blinded 
to their graft types. Given that subjective outcome measurements were also used in the study and the patients were not 
blinded, the review authors judged this to be potentially increasing the risk of bias in the study. 
Incomplete outcome data (attrition bias) Low risk The percentage of patients lost to FU was considerably small. 
Selective reporting (reporting bias) High risk The review authors did not find a protocol or supplementary material showing the full spectrum of measured outcomes. 
Therefore, it was not possible to adequately assess whether reporting bias occurred. 
However, numerous outcomes were insufficiently reported (for the Lysholm score, e.g., it was only written narratively that 
no statistically significant differences were found between treatment groups without reporting on the respective scores). 
Overall, the review authors judged the risk of selective outcome reporting to be increased, since outcomes of interest  
(e.g., the Lysholm score) are reported incompletely so that they cannot be entered in a meta-analysis, or adequately 
considered in a qualitative evidence synthesis. 
Other bias Unclear risk The study was funded by Arthrex Inc. and the Musculosceletal Transplant Foundation. In addition, the primary investigator 
of the study was a consultant for Arthrex Inc. However, it was unclear to which degree funding bias may have been present 
due to the consultant role of the primary investigator. 
RoB Assessment for  
Jia 2015 [17] 
Author’s 
judgement 
Support for judgement 
Random sequence generation  
(selection bias) 
Low risk The investigators of the study describe an adequate random component in the sequence generation process.  
That is, the investigators state that 106 patients were randomised into two groups using computer-generated,  
randomised numbers which were put in sealed opaque envelopes. 
Allocation concealment (selection bias) Low risk The investigator described that sealed opaque envelopes were used. Therefore, the review authors judged it to be unlikely 
that patient assignment could have somehow been foreseen. 
Blinding of participants and personnel 
(performance bias) 
Unclear risk The investigator did not report on whether participants and personnel were blinded. The participants and personnel  
may have had knowledge of the allocated interventions. 
Blinding of outcome assessment 
(detection bias) 
Unclear risk No information on whether outcome assessors had knowledge on the allocated intervention was found. 
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RoB Assessment for  
Jia 2015 [17]  (continuation) 
Author’s 
judgement 
Support for judgement 
Incomplete outcome data (attrition bias) Low risk Once randomised, all patients were considered in the analysis and no patient was lost to FU. 
Selective reporting (reporting bias) High risk The review authors did not find a protocol or supplementary material showing the full spectrum of measured outcomes. 
Therefore, the review authors could not adequately assess whether reporting bias occurred. 
Some outcomes of interest (e.g., complications) were reported incompletely, so that they could not be entered  
in a meta-analysis or considered in the evidence synthesis. Therefore, the review authors judged the risk of  
selective outcome reporting to be increased. 
Other bias Low risk The review authors could not find any other potential sources of bias that may have distorted the results. 
RoB Assessment for  
Li 2015 [19] 
Author’s 
judgement 
Support for judgement 
Random sequence generation  
(selection bias) 
Unclear risk The investigators did not report on the random component in the sequence generation process. Therefore,  
the risk of selection bias is unclear. 
Allocation concealment (selection bias) Unclear risk The investigators did not report on the concealment of allocations prior to assignment. Therefore, the risk of selection bias is unclear. 
Blinding of participants and personnel 
(performance bias) 
Unclear risk The participants were not blinded to the received graft type. It is unclear to which extent this may have biased the results. 
Blinding of outcome assessment 
(detection bias) 
High risk The investigator described that “(...) all of the examinations were performed by the senior physicians (...) twice at  
each time point, neither of whom was the operating surgeon, and both of whom were blinded to the clinical findings”. 
Therefore, the review authors judged the risk of detection bias for objective outcomes and complications to be low. 
However, and given that there were also subjective outcome measurements used in the study and the patients  
were not blinded, the review authors judged this to be potentially increasing the risk of bias in the study, leading  
to a high risk of bias for the likelihood of a detection bias for the subjective outcome scores. 
Incomplete outcome data (attrition bias) Low risk Although some patients were lost to FU, the review authors judged the risk of attrition bias to be low due to the  
relatively small number of patients that were not considered in the analysis after randomisation and the fact that  
loss to FU was judged to be not related to differences between treatment groups. 
Selective reporting (reporting bias) Unclear risk The review authors did not find a protocol or supplementary material showing the full spectrum of measured outcomes. 
Therefore, the review authors could not adequately assess whether reporting bias occurred. 
Other bias Low risk The review authors could not find any other potential sources of bias that may have distorted the results. 
RoB Assessment for  
Sun 2009 [20] 
Author’s 
judgement 
Support for judgement 
Random sequence generation  
(selection bias) 
Low risk The investigators of the study describe an adequate random component in the sequence generation process.  
That is, a computer was used to generate a random component in the sequence generation: 
“Written informed consent to participate in the study was provided by 172 patients. These 172 patients were randomised on 
the day of surgery by use of a computer to either BPTB autograft (number 1 to 86) or BPTB allograft (number 87 to 172)”. 
Allocation concealment (selection bias) Unclear risk It was unclear to the review authors whether the investigators of the study used a concealed allocation schedule  
(a list of random numbers). 
  
A
llo
graft fo
r an
terio
r an
d
 p
o
sterio
r cru
ciate lig
am
en
t reco
n
stru
ctio
n
 
10
6
 
LB
I-H
T
A
| 20
19
 
RoB Assessment for  
Sun 2009 [20]  (continuation) 
Author’s 
judgement 
Support for judgement 
Blinding of participants and personnel 
(performance bias) 
Unclear risk The study reported that the participants had knowledge of the allocated interventions and the personnel could have guessed 
the type of intervention due to the incisions. However, the review authors judged it to be unclear in how far the risk of bias 
increased due to the lack of blinding participants and personnel. 
Blinding of outcome assessment 
(detection bias) 
High risk The likelihood of detection bias is high in the study due to the fact that data were collected in an unblinded fashion by 1 fellow-
ship-trained surgeon at 1 institution. The investigators themselves mention that observer bias was a limitation of the study: 
“The data were collected by only 1 fellowship-trained surgeon at 1 institution and were not collected in a blinded fashion. 
Patients were informed as to the type of surgery by the surgeon postoperatively, so the data collector may also have been 
aware at the time of follow-up”. 
In addition, subjective outcome measurements were also used in the study, and the patients were not blinded, so the review 
authors judged this to be potentially increasing the risk of bias in the study. 
Incomplete outcome data (attrition bias) Low risk While not all randomised patients were analysed (172 randomised patients; 156 analysed patients), the review authors judged 
the risk of attrition bias to be low due to the fact that loss to FU was judged to be comparable between treatment groups. 
Moreover, the review authors judged it to be unlikely that missing data were somehow related to treatment groups. 
Selective reporting (reporting bias) Unclear risk The review authors did not find a protocol or supplementary material showing the full spectrum of measured outcomes. 
Therefore, it was not possible to adequately assess whether reporting bias occurred. 
Other bias Low risk The review authors could not find any other potential sources of bias that may have distorted the results. 
RoB Assessment for  
Sun 2011 [21] 
Author’s 
judgement 
Support for judgement 
Random sequence generation  
(selection bias) 
Low risk The investigators of the study describe an adequate random component in the sequence generation process. That is, a computer 
was used to generate a random component in the sequence generation: patients “(...) were randomised on the day of surgery 
using a computer to either the hamstring tendon autograft group (numbers 1 to 104) or allograft group (numbers 105 to 208)”. 
Allocation concealment (selection bias) Unclear risk It was unclear to the review authors whether the investigators of the study used a concealed allocation schedule  
(the list of random numbers). 
Blinding of participants and personnel 
(performance bias) 
Unclear risk The study reported that neither the participants nor the personnel had knowledge of the allocated interventions. However, the 
review authors judged it to be unclear in how far the risk of bias increased due to the lack of blinding participants and personnel. 
Blinding of outcome assessment 
(detection bias) 
High risk The likelihood of detection bias is high in the study due to the fact that data were collected in an unblinded fashion by 1 fellow-
ship-trained surgeon at 1 institution. The investigators themselves mention that observer bias was a limitation of the study: 
“These data were collected by only 1 fellowship-trained surgeon at 1 institution and were not collected in a blinded fashion. 
Patients were informed as to the type of surgery by the surgeon after surgery, so the data collector may also have been 
aware at the time of the follow-up. Additionally the incisions could also tip off the observer to the type of surgery”. 
In addition, subjective outcome measurements were also used in the study and the patients were not blinded, so the review 
authors judged this to be potentially increasing the risk of bias in the study. 
Incomplete outcome data (attrition bias) Low risk The review authors judged it to be unlikely that missing data were somehow related to treatment groups. 
Selective reporting (reporting bias) Unclear risk The review authors did not find a protocol or supplementary material showing the full spectrum of measured outcomes. 
Therefore, it was not possible to adequately assess whether reporting bias occurred. 
Other bias Low risk The review authors could not find any other potential sources of bias that may have distorted the results. 
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RoB Assessment for  
Tian 2016 [22] 
Author’s 
judgement 
Support for judgement 
Random sequence generation  
(selection bias) 
Low risk The investigators of the study describe an adequate random component in the sequence generation process. That is,  
the investigators state that a computer software programme was used to generate the random allocation sequence. 
Allocation concealment (selection bias) Low risk The investigator described that the random allocation sequence remained concealed from those enrolling patients into  
the study to minimise the effect of bias. Therefore, the review authors judged it to be unlikely that patient assignment  
could have somehow been foreseen. 
Blinding of participants and personnel 
(performance bias) 
Unclear risk The study reported that the participants had knowledge of the allocated interventions and the personnel could have guessed 
the type of intervention due to the incisions. However, the review authors judged it to be unclear in how far the risk of bias 
increased due to the lack of blinding of participants and personnel. 
Blinding of outcome assessment 
(detection bias) 
High risk Detection bias may have occurred in the study due to the fact that the outcome assessor was not blinded: “(...) the data  
were collected by only 1 surgeon at 1 institution and were not collected in a blinded fashion. Patients were informed as to  
the type of surgical procedure that they underwent by the surgeon after surgery, so the data collector may also have  
been aware at the time of the follow-up”. 
In addition, there were also subjective outcome measurements used in the study and the patients were not blinded, so the 
review authors judged this to be potentially increasing the risk of bias in the study as well. 
Incomplete outcome data (attrition bias) Low risk The risk of attrition bias was judged to be low. 83 out of 107 enrolled patients (77.5%) were analysed. 14/54 (25.9%) and 
10/53 (18.9%) of patients were lost to FU in the autograft and allograft groups, respectively. However, the reported reasons 
for missing outcome data were judged unlikely to be systematically related to differences of treatment groups. 
Selective reporting (reporting bias) Unclear risk The review authors did not find a protocol or supplementary material showing the full spectrum of measured outcomes. 
Therefore, it was not possible to adequately assess whether reporting bias occurred. 
Other bias Low risk The review authors could not find any other potential sources of bias that may have distorted the results. 
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Table A-5: Risk of bias assessment for studies comparing allografts to autografts in PCLR: review authors’ judgements about each risk of bias item for each included study  
(study level: RCTs, see [2]) 
RoB Assessment  
for Li 2016 [18] 
Author’s 
judgement 
Support for judgement 
Random sequence generation  
(selection bias) 
Unclear risk The investigators of the study did not sufficiently describe the random component in the sequence generation process. 
Therefore, the review authors judged the risk of bias to be unclear. 
Allocation concealment (selection bias) Low risk The investigators stated that all patients were randomly allocated by sealed envelopes into 1 of 3 groups: autograft group, 
hybrid graft group, or y-irradiated allograft group. Therefore, the review authors judged the risk of bias to be low. 
Blinding of participants and personnel 
(performance bias) 
Unclear risk The investigators did not report on whether participants or personnel were adequately blinded.  
The review authors judged the risk of performance bias to be unclear. 
Blinding of outcome assessment 
(detection bias) 
Unclear risk No information was found on whether outcome assessors had knowledge on the allocated intervention. 
Incomplete outcome data (attrition bias) Low risk Although some patients were lost to FU, the review authors judged the risk of attrition bias to be low due to the relatively 
small number of patients who were not considered in the analysis after randomisation, and the comparable loss to FU 
between groups. It was judged to be unlikely that missing data were somehow related to treatment groups. 
Selective reporting (reporting bias) Unclear risk The review authors did not find a protocol or supplementary material showing the full spectrum of measured outcomes. 
Therefore, it was not possible to adequately assess whether reporting bias occurred. 
Other bias Low risk The review authors could not find any other potential sources of bias that may have distorted the results. 
RoB Assessment for  
Wang 2004 [23] 
Author’s 
judgement 
Support for judgement 
Random sequence generation  
(selection bias) 
High risk It appears to the review authors that there was a lack of randomisation process in the study.  
The study described a randomisation according to hospital admission. Therefore, the review authors judged  
the randomisation to be solely quasi-randomised, increasing the risk of selection bias considerably. 
Allocation concealment (selection bias) High risk It appears that the allocation was not concealed. We, therefore, judged the risk of selection bias to be high. 
Blinding of participants and personnel 
(performance bias) 
Unclear risk Insufficient information was provided to judge whether performance bias occurred. 
Blinding of outcome assessment 
(detection bias) 
Unclear risk The study did not report on (whether) a blinding process was present. 
Incomplete outcome data (attrition bias) Unclear risk The loss to follow-up rate was not reported in the included study.  
It was unclear to the review authors whether attrition bias occurred. 
Selective reporting (reporting bias) Unclear risk Insufficient information to judge the risk of reporting bias (no protocol available). 
Other bias Low risk No other potential bias was detected according to the information of the study’s publication. 
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Table A-6: Risk of bias – study level (observational studies) using the Newcastle-Ottawa Scale (NOS) [13] 
Study  
reference/ID 
Selection Comparability Outcome Comments 
Representativeness 
of the exposed 
cohort 
Selection of the 
non-exposed 
cohort 
Ascertainment 
of exposure 
Demonstration that out-
come of interest was not 
present at start of study 
Comparability of 
cohorts on the basis of 
the design or analysis 
Assessment 
of outcome 
Was follow-up 
long enough for 
outcomes to occur? 
Adequacy  
of follow-up  
of cohorts 
Overall  
risk of bias 
MARS Group 
2014 [16] 
190 1 0 1 2 0 191 0 Moderate 
* A study can be awarded a maximum of 1 point (=star) for each numbered item within the Selection and Outcome categories. A maximum of 2 points (star)s can be given for Comparability. 
 
                                                             
90 While the baseline characteristics were not homogenous (e.g., prior graft type, presence of other prior surgery such as meniscus surgery), it was still judged that the subjects  
derived from groups are representative of patients with re-ruptures of the ACL who need a revision ACL reconstruction.    
91 While it is important to see the long-term benefits of each graft type, it was argued that 2 years FU are long enough for outcomes to occur in this patient population. 
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Table A-7: Evidence profile: efficacy and safety of allografts for ACLR  
Certainty assessment 
№ of analysed 
patients92 93 
Effect Certainty Importance 
№ of 
studies 
Study 
design 
Risk  
of bias 
Incon-
sistency 
Indirect-
ness 
Impre-
cision 
Other con-
siderations 
Allo-
graft 
Auto-
graft 
EFFECTIVENESS 
Patient-reported function, activity level and symptoms (follow-up: mean ≥5 years; assessed with: Lysholm score) 
5  
[17, 19-
22] 
randomised 
trials 
serious,a serious b not 
serious c 
not 
serious 
none 303 292 None of the studies found a statistically significant 
difference in Lysholm scores between treatment  
groups postoperatively. 
Postoperative mean Lysholm scores (ranges):  
86 ±9 to 91 ±6 vs. 85.2 ±3.1 to 91.3+11.5 
⨁⨁◯◯ 
LOW 
CRITICAL 
Patient-reported function, activity level and symptoms (follow-up: mean ≥5 years; assessed with: Tegner score) 
5  
[15, 19-
22] 
randomised 
trials 
serious d not  
serious e 
not 
serious c 
not 
serious 
none 299 287 None of the studies found a statistically significant 
difference when comparing the Tegner activity score 
between treatment groups postoperatively. 
Postoperative mean Tegner scores (ranges):  
4.5 ±2.2 to 7.6 ±1.9 vs. 4.8 ±2.3 to 7.8 ±1.2 
⨁⨁⨁◯ 
MODERATE 
CRITICAL 
Patient-reported function, activity level and symptoms (follow-up: mean ≥5 years; assessed with: Cincinnati Knee score) 
3  
[20-22] 
randomised 
trials 
serious f not  
serious g 
not 
serious c 
not 
serious 
none 218 207 None of the studies found a statistically significant 
difference when comparing the Cincinnati Knee score 
between treatment groups postoperatively. 
Postoperative mean Cincinnati Knee scores (ranges):  
87 ±12 to 92 ±11 vs. 90 ±10 to 91 ±12 
⨁⨁⨁◯ 
MODERATE 
CRITICAL 
Patient-reported function, activity level and symptoms (follow-up: mean 10.5 years; assessed with: SANE score) 
1 [15] randomised 
trials 
serious h not  
serious 
serious i not 
serious 
none 49 48 The postoperative mean score was 2.7 points lower in the 
allograft group when compared to the autograft group. 
Postoperative mean SANE score: 78.8 ±18.8 vs. 81.5 ±16.4 
⨁⨁◯◯ 
LOW 
CRITICAL 
Patient-reported function, activity level and symptoms (follow-up: mean ≥5 years; assessed with: subjective IKDC score) 
6 
[15, 17, 
19-22] 
randomised 
trials 
serious h not  
serious 
not 
serious c 
not 
serious 
none 352 340 None of the studies found a statistically significant difference 
in subjective IKDC scores between groups postoperatively. 
Postoperative mean subjective IKDC scores (ranges): 
73.7 ±25.9 to 90 ±14 vs. 77.2 ±25.4 to 90 ±10 
⨁⨁⨁◯ 
MODERATE 
CRITICAL 
                                                             
92 The reader is reminded that in Bottoni et al. the number of patients actually refers to the number of knees. 
93 Excluding patients with hybrid grafts. 
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Certainty assessment 
№ of analysed 
patients92 93 
Effect Certainty Importance 
№ of 
studies 
Study 
design 
Risk  
of bias 
Incon-
sistency 
Indirect-
ness 
Impre-
cision 
Other con-
siderations 
Allo-
graft 
Auto-
graft 
Patient-reported function, activity level and symptoms (assessed with: KOOS score) 
0         - CRITICAL 
Patient-reported function, activity level and symptoms (assessed with: Marx activity scale) 
0         - CRITICAL 
Clinical knee stability (assessed with: Lachman test) 
4  
[19-22] 
randomised 
trials 
very 
serious j 
serious k not 
serious 
not 
serious 
none 250 239 s. s. difference in Lachman scores (grade 0-1)  
in 1 study [22]: 31/43 (72%) vs. 37/40 (93%). 
No statistically significant differences in Lachman scores 
in 3 studies [19-21] 
Lachman test (grade 0-1; ranges across studies): 31/43 (72%) 
to 74/80 (92.5%) vs. 84/91 (92.3%) to 30/32 (93.8%) 
⨁◯◯◯ 
VERY LOW 
IMPORTANT 
Clinical knee stability (follow-up: mean ≥5 years; assessed with: Pivot shift test) 
4 
[19-22] 
randomised 
trials 
very 
serious j 
serious k not 
serious 
not 
serious 
none 250 239 s. s. difference in Pivot shift test (Grade 0-1)  
in 1 study [22]: 38/43 (88.4%) vs. 40/40 (100%) 
No statistically significant differences in Pivot shift test 
in 3 studies [19-21] 
Pivot shift (grade 0-1; ranges across studies): 38/43 (88.4%) 
to 95/95 (100%) vs. 32/32 (100%) to 91/91 (100%) 
⨁◯◯◯ 
VERY LOW 
IMPORTANT 
Clinical knee stability (follow-up: mean ≥5 years; assessed with: KT arthrometer; better indicated by lower values) 
4  
[19-22] 
randomised 
trials 
serious h serious k not 
serious 
not 
serious 
none 250 239 2/4 studies [19, 22] found a statistically significant difference 
in instrumented knee laxity favouring autografts, while 
the other 2/4 studies [20, 21] did not find any statistically 
significant difference in side-to-side differences measured 
with the KT arthrometer between treatment groups. 
Mean side-to-side differences (in mm; ranges across 
studies): 2.5 ±0.9 to 5.5 ±1 vs. 2.1 ±1.6 to 2.5 ±0.7 
⨁⨁◯◯ 
LOW 
IMPORTANT 
Clinical knee stability (follow-up: mean ≥5 years; assessed with: objective IKDC score) 
4  
[19-22] 
randomised 
trials 
serious h not  
serious 
not 
serious 
not 
serious 
none 250 239 None of the studies found a statistically significant difference 
in the objective IKDC score between treatment groups. 
Objective IKDC score (normal or nearly normal scores; 
ranges across studies): 38/43 (88.4%) to 75/80 (93.8%) 
vs. 29/32 patients (90.6%) to 38/40 (95%) 
⨁⨁⨁◯ 
MODERATE 
IMPORTANT 
  
A
llo
graft fo
r an
terio
r an
d
 p
o
sterio
r cru
ciate lig
am
en
t reco
n
stru
ctio
n
 
112 
LB
I-H
T
A
| 20
19
 
Certainty assessment 
№ of analysed 
patients92 93 
Effect Certainty Importance 
№ of 
studies 
Study 
design 
Risk  
of bias 
Incon-
sistency 
Indirect-
ness 
Impre-
cision 
Other con-
siderations 
Allo-
graft 
Auto-
graft 
Patient satisfaction (assessed with: NR) 
1 [17] randomised 
trials 
very 
serious l 
not  
serious 
not 
serious 
not 
serious 
none 53 53 Patient satisfaction was analysed in 106 patients from  
1 study. The study found no statistically significant 
difference between patients undergoing allograft ACLR 
(n=53) or autograft ACLR (n=53). The instrument used 
to measure patient satisfaction was not reported. 
Satisfied: 46/53 (86.8%) vs. 47/53 (88.7%) 
Nearly satisfied: 7 (13.2%) vs. 5 (9.4%) Diff. n. s.; p>0.05 
⨁⨁◯◯ 
LOW 
IMPORTANT 
Health-related Quality of Life 
0         - IMPORTANT 
SAFETY 
Graft failure (follow-up: mean ≥5 years) 
2  
[15, 22] 
randomised 
trials 
not 
serious m 
not  
serious 
serious c i not 
serious 
none 92 88 26/92 (28.3%) vs. 7/88 (7.9%) n 
Bottoni et al. [15]: 13/49 (26.5%) vs. 4/48 (8.3%),  
diff. s. s. with p<0.05  
Tian et al. [22]: 13/43 (30.2%) vs. 3/40 (7.5%),  
diff. s. s. with p<0.001 
⨁⨁⨁◯ 
MODERATE 
CRITICAL 
Re-rupture rate 
0         - CRITICAL 
Re-operations 
0         - CRITICAL 
Revisions (follow-up: mean ≥5 years) 
2 
[15, 19] 
randomised 
trials 
not 
serious m 
seriouso serious c i not 
serious 
none 81 80 Bottoni et al. [15]: 13/49 (26.5%) vs. 4/48 (8.3%),  
diff. s. s. with p<0.05 
Li et al. [19]: no patient needed additional surgery 
because of recurrent or residual symptoms (0/32 vs. 0/32) 
⨁⨁◯◯ 
LOW 
CRITICAL 
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Certainty assessment 
№ of analysed 
patients92 93 
Effect Certainty Importance 
№ of 
studies 
Study 
design 
Risk  
of bias 
Incon-
sistency 
Indirect-
ness 
Impre-
cision 
Other con-
siderations 
Allo-
graft 
Auto-
graft 
Complications (follow-up: mean ≥5 years) 
6  
[15, 17, 
19-22] 
randomised 
trials 
serious p not  
serious 
not 
serious c 
serious q none 352 340 Overall complication rate: NR 
Arthrofibrosis (reported in 2/6 studies [21, 22]; 269 pts): 
0/138 (0%) vs. 0/131 (0%) 
Effusion (0/6 studies): NR 
Tenderness (reported in 1 study [21];  
186 pts): 0/95 (0%) vs. 2/91 (2.1%) 
Infections (reported in 4 studies [19-22]; 489 pts):  
5/250 (2%) vs. 0/239 (0%), range: 0-4.6% vs. 0% 
Hypoesthesia (reported in 2 studies [21, 22]; 269 pts): 
0/138 (0%) vs. 6/131 (4.6%), range: 0% vs. 3.3-7.5%. 
Synovitis was not reported in any of the included studies. 
Deep venous thrombosis (reported in 3 studies [20-22]; 
425 pts): 2/218 (0.9%) vs. 1/207 (0.5%),  
range: 0-2.5% vs. 0-1.3% 
Further reported complications: 
Postoperative mean fever time in days (reported in  
1 study [20]; 156 pts): 6.8 vs. 4.4 diff. s. s., with p<0.05) 
Arthritic progression (reported in 1 study [22]; 83 pts): 
14/43 (32.6%) vs. 4/40 (10%), diff. s. s. with p<0.05. 
Tibial and femoral tunnel widening in mm  
(reported in 2 studies; 203 pts): 
Jia et al. [17]: 
Tibial (in mm), mean ±SD:  
7.8 ±0.4 vs. 7.61 ±0.22, diff. s. s. with p<0.05 
Femoral (in mm), mean ±SD:  
7.64 ±0.35 vs. 7.51 ±0.42, diff. s. s. with p<0.05 
Bottoni et al. [15]: 
Tibial (in mm), mean (range):  
9.2 (7-10) vs. 8.9 (7-10); diff. n. s. with p=0.651 
Femoral (in mm), mean (range):  
8.8 (7-10) vs. 8.3 (7-10), diff n. s. with p=0.453 
Furthermore, some of the included studies specifically 
stated that there were no cases of pain when kneeling, 
anterior knee pain, etc. 
⨁⨁◯◯ 
LOW 
CRITICAL 
Procedure-related mortality 
0         - IMPORTANT 
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MD: Mean difference 
Comments: 
a In 4/5 studies, the risk of bias for blinding the outcome assessors was judged to be high. Therefore, we judged that this may have seriously affected the certainty.  
b None of the studies showed any statistically significant differences postoperatively in the Lysholm score between the allograft and the autograft groups. Results from the non-statistically significant 
differences revealed that in 3/5 studies the Lysholm score was higher in the allograft group, while 2/5 studies reported a lower Lysholm score in the allograft group (comparison: allograft vs. autograft). 
While the general difference is small (e.g., <5 point differences between allografts and autografts), it may still be an indicator for heterogeneity. A calculation of the i2 is further needed to 
adequately assess how heterogenous the results for this outcome may be.  
c Differences in interventions were present across studies (e.g., irradiated vs. non-irradiated grafts, single-bundle vs. double-bundle, etc.).  
d In 5/5 studies, the risk of bias for blinding the outcome assessors was judged to be high. Therefore, we judged that this may have seriously affected the certainty.  
e None of the studies showed any statistically significant difference postoperatively in the Tegner score between the allograft and the autograft groups. The non-statistical findings in all  
study groups showed slightly higher scores in the autograft group. This may be an indicator that heterogeneity is small. Calculating the i2 may be beneficial to further assess heterogeneity.  
f In 3/3 studies, the lack of blinding significantly increases the risk of bias. Given that this is a subjective outcome score, it was judged to be a very serious limitation.  
g None of the studies showed any statistically significant differences in Cincinnati Knee scores between treatment groups. The non-statistical findings showed slightly higher scores in allograft patients 
in 2/3 studies, and lower scores in allograft patients in 1/3 study/studies when compared to the autograft groups, respectively. The difference of the mean scores ranged from 1 to -3.  
h The lack of blinding in the study/studies may seriously affect the certainty to believe in the evidence of this outcome measure.  
i The overall applicability for the broad population selected in these assessment results may suffer due to the fact that numerous different graft types were used and that some studies used  
a subpopulation of the population of interest. Bottoni et al., for instance, only included highly active military (mostly) men, and Tian et al. used irradiated allografts. It is unclear in how far  
the generalisability suffers due to the aforementioned factors. 
j It was judged that the lack of blinding may have very seriously affected the certainty to believe this specific outcome.  
k Heterogeneity was suspected within the included studies. It appears that the studies do not consistently show any difference/difference favouring a treatment group.  
A calculation of the i2 is further needed to elaborate how significant the inconsistency is.  
l There were 2 substantial factors that increased the risk of bias: lack of blinding and selective outcome reporting; the latter was present insofar as it was insufficiently described  
how patient satisfaction was measured. In addition, no scores were reported, but it was stated that no statistically significant differences between treatment groups was found.  
m Lack of blinding for outcome assessors was judged to be less likely to affect this outcome.  
n Graft failure, however, was defined differently in the studies. Tian et al. defined it as knee laxity >5mm measured with a KT-2000, and Bottoni et al. did not clearly mention  
how graft failure was defined.  
o Bottoni et al. found a considerably large difference in the revision rate, while Li et al. stated that no additional surgeries were needed in either of the treatment groups.  
p The risk of bias for selective outcome reporting was judged high in 2/6 studies, and unclear in the remaining 4/6 studies. Most of the studies, however, did not report on an overall complication rate. 
Instead, they were presented narratively in the studies.  
q The optimal information size may have not been reached for most of the specific complications.  
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Table A-8: Evidence profile: efficacy and safety of allografts for PCLR  
Certainty assessment 
№ of analysed 
patients94 
Effect Certainty Importance 
№ of 
studies 
Study 
design 
Risk  
of bias 
Incon-
sistency 
Indirect-
ness 
Impre-
cision 
Other con-
siderations 
Allo-
graft 
Auto-
graft 
EFFECTIVENESS 
Patient-reported function, activity level and symptoms (follow-up: mean >2 years; assessed with: Lysholm score) 
2 1,2 
[18, 23] 
randomised 
trials 
very 
serious 
1,a,b 
serious c not 
serious 
not 
serious 
none 50 58 None of the studies found a statistically significant 
difference in the Lysholm score between treatment 
groups postoperatively. 
Li et al. [18]: 85.2 ±3.9 vs. 87.8 ±3.6, diff. n. s. with p>0.05 
Wang et al. [23]: 92.3 ±6.8 vs. 87.8 ±9.6,  
diff. n. s. with p>0.05 
⨁◯◯◯ 
VERY LOW 
CRITICAL 
Patient-reported function, activity level and symptoms (follow-up: mean >2 years; assessed with: Tegner score) 
2 1,2 
[18, 23] 
randomised 
trials 
very 
serious 
a,b 
not  
serious 
not 
serious 
not 
serious 
none 50 58 None of the studies found a statistically significant 
difference in the Tegner score between treatment 
groups postoperatively. 
Li et al. [18]: 6.2 ±1.7 vs. 6.8 ±1.1, diff. n. s. with p>0.05 
Wang et al. [23]: 4.7 ±1.66 vs. 4.73 ±1.66,  
diff. n. s. with p>0.05 
⨁⨁◯◯ 
LOW 
CRITICAL 
Patient-reported function, activity level and symptoms (assessed with: Cincinnati Knee score) 
0         - CRITICAL 
Patient-reported function, activity level and symptoms (assessed with: SANE score) 
0         - CRITICAL 
Patient-reported function, activity level and symptoms (follow-up: mean 5.6 years; assessed with: subjective IKDC score) 
1 2[18] randomised 
trials 
serious b not  
serious 
not 
serious 
serious d none 27 26 Mean postoperative subjective IKDC score:  
80.2 ±6.8 vs. 83.5 ±6.3, diff. n. s. with p>0.05 
⨁⨁◯◯ 
LOW 
CRITICAL 
Patient-reported function, activity level and symptoms (assessed with: KOOS score) 
0         - CRITICAL 
Patient-reported function, activity level and symptoms (assessed with: Marx activity scale) 
0         - CRITICAL 
                                                             
94 Excluding patients with hybrid grafts. The number of patients refers to the analysed patients, not the enrolled ones. 
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Certainty assessment 
№ of analysed 
patients94 
Effect Certainty Importance 
№ of 
studies 
Study 
design 
Risk  
of bias 
Incon-
sistency 
Indirect-
ness 
Impre-
cision 
Other con-
siderations 
Allo-
graft 
Auto-
graft 
Clinical knee stability (follow-up: mean 2.8 years assessed with: Reverse Lachman test) 
1 [23] randomised 
trials 
very 
serious a 
not  
serious 
not 
serious 
not 
serious 
none 23 32 The study did not find a statistically significant 
difference in the reverse Lachman test postoperatively. 
Mean postoperative reverse Lachman test score:  
0.7 ±0.56 vs. 0.75 ±0.67, diff. n. s. with p>0.05 
⨁⨁◯◯ 
LOW 
IMPORTANT 
Clinical knee stability (assessed with: Reverse Pivot shift test) 
1 [18] randomised 
trials 
serious 
b 
not serious not 
serious 
not 
serious 
none 27 26 Postoperative reverse Pivot shift (Grade 0-1):  
26/27 (96.3%) vs. 26/26 (100%), diff. n. s. with p>0.05 
⨁⨁⨁◯ 
MODERATE 
IMPORTANT 
Clinical knee stability (follow-up: mean >2 years; assessed with: KT arthrometer; better indicated by lower values) 
2  
[18, 23] 
randomised 
trials 
very 
serious 
a,b 
serious e not 
serious 
not 
serious 
none 50 58 1 study found a statistically significant difference 
favouring autografts, while another study did not find 
any statistically significant difference based on the side-
to-side difference measured with an instrumented knee 
laxity test. 
Side-to-side difference in mm: 
Li et al. [18]: 3.5 ±1.1 vs. 2.1 ±1, diff. s. s. with p<0.001 
Wang et al. [23]: 2.83 ±1.7 vs. 3.16 ±2.6, diff. n. s. with p>0.05 
⨁◯◯◯ 
VERY LOW 
IMPORTANT 
Clinical knee stability (follow-up: mean >2 years; assessed with: objective IKDC) 
2  
[18, 23] 
randomised 
trials 
very 
serious 
a,b 
not  
serious 
not 
serious 
not 
serious 
none 50 58 None of the studies found a statistically significant 
difference in the objective IKDC score between 
treatment groups postoperatively. 
Objective IKDC (normal and nearly normal): 
Li et al. [18]: 24/27 (88.9%) vs. 25/26 (96.2%) 
Wang et al. [23]: 14/23 (60.9%) vs. 23/32 (71.9%) 
⨁⨁◯◯ 
LOW 
IMPORTANT 
Patient satisfaction 
0         - IMPORTANT 
Health-related Quality of Life 
0         - IMPORTANT 
SAFETY 
Graft failure 
0         - CRITICAL 
Re-rupture rate 
0         - CRITICAL 
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Certainty assessment 
№ of analysed 
patients94 
Effect Certainty Importance 
№ of 
studies 
Study 
design 
Risk  
of bias 
Incon-
sistency 
Indirect-
ness 
Impre-
cision 
Other con-
siderations 
Allo-
graft 
Auto-
graft 
Re-operations (follow-up: mean 5.6 years) 
1 [18] randomised 
trials 
not 
serious 
not  
serious 
serious 2,f serious g none 27 26 The study stated that no patient needed additional 
surgery because of recurrent or residual posterior 
laxity: 0% vs. 0% (further information: NR). 
⨁⨁◯◯ 
LOW 
CRITICAL 
Revisions 
0         - CRITICAL 
Complications (follow-up: mean >2 years) 
2  
[18, 23] 
randomised 
trials 
serious not  
serious 
not 
serious 
serious d none 50 58 Overall complication rate (reported in 1 study; [23]): 
0/23 (0%) vs. 7/32 (21.9%). 
Arthrofibrosis: NR 
Effusion: NR 
Tenderness: NR 
Infections: Li et al [18]: no postoperative infection; 
Wang et al. [23]: 0/23 (0%) vs. 2/32 (6.3%;  
one acute and one late infection) 
Hypoesthesia: NR 
Synovitis: NR 
Deep venous thrombosis (reported in 1 study; [18]): 0/27 
(0%) vs. 0/26 (0%) 
Further reported complications: 
Donor site symptoms in 1 study [23]:  
0/23 (0%) vs. 4/32 (12.5%); 
Reflex sympathetic dystrophy in 1 study [23]:  
0/23 (0%) vs. 1/32 (3.1%) 
Li et al. [18] further stated narratively that no post-
operative infection, no deep venous thrombosis, no cases 
of major neurovascular, infectious, vascular, deep venous 
thrombosis or wound complications in any of the 80 
analysed patients (of which 27, 26 and 27 received allo-
graft, autografts and hybrid grafts respectively) occurred. 
Tibial and femoral tunnel enlargement in 1 study [23]: 
Tibial: 12 ±20 (range:  
0-90) vs. 12 ±14 (range: 0-43), n. s. with p=0.64 
Femoral: 5.3 ±22 (range:  
0-50) vs. 13 ±19 (range: 0-55), n. s. with p=0.771 
⨁⨁◯◯ 
LOW 
CRITICAL 
Procedure-related mortality 
0        - IMPORTANT 
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CI: Confidence interval; MD: Mean difference 
Comments: 
a In Wang et al., there was high risk of bias for selection bias and unclear risk of bias whether patients were blinded.  
b In Li et al., it was unclear whether the random sequence generation was adequate (selection bias), and whether patients were blinded.  
c None of the studies showed any statistically significant differences postoperatively in the Lysholm score between the allograft and the autograft groups.  
The non-statistically significant differences were not unanimously higher in one treatment group. This may be an indicator for heterogeneity.  
A calculation of the i-square is further needed to adequately assess how heterogeneous the results for this outcome may be.  
d The optimal information size may have not been reached.  
e Heterogeneity may have been present because study results were not unanimous. Further calculation of the i-square is needed to elaborate on the extent of the heterogeneity.  
f The study referred to the patients who did not need additional surgery because of recurrent or residual posterior laxity.  
It was unclear to the review authors whether this refers to the overall re-operations rate or only the patients with recurrent or residual posterior laxity.  
g The optimal information size may have not been reached.  
 
Table A-9: Evidence profile: efficacy and safety of allografts for revision ACLR  
Certainty assessment 
№ of analysed 
patients95 
Effect Certainty Importance 
№ of 
studies 
Study 
design 
Risk  
of bias 
Incon-
sistency 
Indirect-
ness 
Impre-
cision 
Other con-
siderations 
Allo-
graft 
Auto-
graft 
EFFECTIVENESS 
Patient-reported function, activity level and symptoms (assessed with: Lysholm score) 
0         - CRITICAL 
Patient-reported function, activity level and symptoms (assessed with: Tegner score) 
0         - CRITICAL 
Patient-reported function, activity level and symptoms (assessed with: Cincinnati Knee score) 
0         - CRITICAL 
Patient-reported function, activity level and symptoms (assessed with: SANE score) 
0         - CRITICAL 
                                                             
95 Excluding patients with a combination of allografts and autografts. 
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Certainty assessment 
№ of analysed 
patients95 
Effect Certainty Importance 
№ of 
studies 
Study 
design 
Risk  
of bias 
Incon-
sistency 
Indirect-
ness 
Impre-
cision 
Other con-
siderations 
Allo-
graft 
Auto-
graft 
Patient-reported function, activity level and symptoms (follow-up: 2 years; assessed with: subjective IKDC score) 
1 [16] observational 
studies 
not 
serious 
not  
serious 
not 
serious 
not 
serious 
none 590 583 The study conducted a logistic regression analysis and 
found that graft choice proved to be a significant 
predictor of 2-year IKDC score. 
Specifically, the use of an autograft for revision 
reconstruction predicted improved score on the IKDC 
(p=0.045; OR =1.31; 95% CI: 1.01-1.70). 
⨁⨁◯◯ 
LOW 
CRITICAL 
Patient-reported function, activity level and symptoms (follow-up: 2 years; assessed with: KOOS ) 
1 [16] observational 
studies 
not 
serious 
not  
serious 
not 
serious 
not 
serious 
none 590 583 The study conducted a logistic regression analysis and 
found that graft choice did not predict KOOS symptoms, 
and KOOS activities of daily living. On the contrary, 
KOOS sports and recreation subscale demonstrated higher 
scores in the setting of an autograft when compared to 
allograft for revision reconstruction (p=0.037; OR =1.33; 
95%CI: 1.02-1.73). Results from further KOOS subscales 
(KOOS pain, from the regression analysis comparing 
graft types, was not reported. 
⨁⨁◯◯ 
LOW 
CRITICAL 
Patient-reported function, activity level and symptoms (follow-up: 2 years; assessed with: Marx activity scale) 
1 [16] observational 
studies 
not 
serious 
not serious not 
serious 
not 
serious 
none 590 583 The study conducted a logistic regression and found that 
graft choice was a significant predictor of 2-year Marx 
activity scores (p=0.012). Specifically, the use of a 
combination autograft plus allograft for revision 
reconstruction predicted improved scores on the Marx 
(p=0.005; OR =3.33; 95%CI: 1.43-7.78). 
⨁⨁◯◯ 
LOW 
CRITICAL 
Clinical knee stability (assessed with: Lachman test) 
0         - IMPORTANT 
Clinical knee stability (assessed with: Pivot shift test) 
0         - IMPORTANT 
Clinical knee stability (assessed with: KT arthrometer) 
0         - IMPORTANT 
Clinical knee stability (assessed with: objective IKDC) 
0         - IMPORTANT 
Patient satisfaction 
0         - IMPORTANT 
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Certainty assessment 
№ of analysed 
patients95 
Effect Certainty Importance 
№ of 
studies 
Study 
design 
Risk  
of bias 
Incon-
sistency 
Indirect-
ness 
Impre-
cision 
Other con-
siderations 
Allo-
graft 
Auto-
graft 
Health-related Quality of Life 
1 [16] observational 
studies 
not 
serious 
not  
serious 
not 
serious 
not 
serious 
none 590 583 Results from the logistic regression analysis show  
that the use of an autograft predicted improved scores 
on the KOOS quality of life subscale  
(p=0.031; OR: 1.33; 95%CI: 1.03-1.73). 
⨁⨁◯◯ 
LOW 
IMPORTANT 
SAFETY 
Graft failure 
0         - CRITICAL 
Re-rupture rate (follow-up: 2 years) 
1 [16] observational 
studies 
not 
serious 
not  
serious 
not 
serious 
not 
serious 
none 24/540 
(4.4%) 
12/542 
(2.2%) 
Results from regression analysis: Subjects with an 
autograft revision were found to be 2.78 times less likely 
of sustaining a subsequent graft rupture compared with 
subjects who received an allograft  
(p=0.047; 95%CI: 1.01-7.69) 
⨁⨁◯◯ 
LOW 
CRITICAL 
Re-operation rate (follow-up: 2 years) 
1 [16] observational 
studies 
not 
serious 
not  
serious 
not 
serious 
not 
serious 
none The study only reported on the overall re-operation rate for all patients 
including allografts, autografts or a combination of these grafts:  
150/1112 (13.5%) 
⨁⨁◯◯ 
LOW 
CRITICAL 
Revisions 
0         - CRITICAL 
Complications 
0         - CRITICAL 
Procedure-related mortality 
0         - IMPORTANT 
CI: Confidence interval; OR: Odds ratio 
Comments: 
a Selective outcome reporting may have been present for this specific outcome, since the results from the regression analysis were not presented.  
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Applicability table 
Table A-10: Summary table characterising the applicability of a body of studies 
Domain Description of applicability of evidence 
Population The target population in this review included all patients of any age receiving allografts.  
Age and activity level of the patients may affect the applicability of the results: 
For ACLR, the mean age of the patients receiving allografts and autografts ranged from  
28 to 32.8 years and 28.9 to 31.8 years, respectively.  
For PCLR, the mean age between allograft and autograft groups was 32.2 vs. 31.3 years,  
and 30 vs. 29 years in these studies, respectively.  
For revision ACLR, the median age of all patients was 26 (IQR: 20-34).  
508 of all patients (42%) were female. 
In addition, there were (most likely highly active) predominantly military men enrolled in 1/6 studies.  
The applicability is restricted insofar as some outcomes were only measured by the study that only 
enrolled (mostly) military men. 
Intervention All of the included studies (9/9 studies) used allograft cruciate ligament reconstruction as an 
intervention. Differences were present with specific graft types, e.g., some studies used 4-stranded 
grafts, others used tibialis anterior tendons or Achilles tendons, and the allograft (processing) 
techniques varied between the included studies as well (e.g., irradiated or not, fresh-frozen or not). 
Within allografts, there are numerous different graft types with unique advantages and 
disadvantages.  
Given that the evidence base is sometimes dominated by a specific graft type (for ACLR,  
for instance, graft failure rate was measured by 2/6 studies of which 1 had only irradiated allografts  
as an intervention), the applicability may be limited. Concerns regarding specific applicability of the 
evidence were highlighted in text and in the GRADE evidence tables. 
Comparators All of the included studies used autograft cruciate ligament reconstruction as a comparator.  
Some additional comparators were hybrid grafts (i.e., a combination of allograft and autograft;  
2/9 studies had 3 treatment groups, of which 1 group received hybrid grafts). Within autografts,  
there are numerous different graft types with unique advantages and disadvantages.  
These further differences may limit conclusions in this context. 
None of the included studies used conservative management as a comparator of allograft 
 cruciate ligament reconstruction. 
Outcomes All of the included studies (ACLR: 6/6 studies; PCLR: 2/2 studies; revision reconstruction: 1/1 study) 
reported on the crucial outcomes of patient-reported function, activity level and symptoms.  
The important outcome of clinical knee stability was reported in 4/6 studies for ACLR, in 2/2 studies 
for PCLR, and 0/1 studies for revision reconstruction. Other important outcomes, such as HRQoL or 
patient satisfaction, were hardly reported (1/9 included studies, respectively). 
Regarding safety outcomes, no standardised reporting of complications or graft failure was available. 
Therefore, it may be that different definitions were present and different complications were judged 
worthwhile to be reported. As a result, the applicability for safety is limited and must be interpreted 
with caution. 
Setting It is not expected that the applicability of the results are limited by geographic settings. However,  
the setting of the patients may reduce the applicability of the results. As such, patients in settings 
that require highly active behaviour may be differently affected by allografts/autografts when 
compared to environments in which less activity is required. 
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List of ongoing randomised controlled trials 
Table A-11: List of ongoing trials of allografts for ACLR 
Identifier/ 
Trial name 
Patient  
population 
Study  
design 
Number  
of patients Intervention Comparison Primary Outcome 
Primary 
completion date Sponsor 
NCT00510848 Rupture of the 
Anterior Cruciate 
Ligament with 
Instability of the 
Knee Joint 
Randomised 
controlled trial: 
parallel assignment, 
open label 
40 Reconstruction 
with an autograft 
tendon 
(hamstrings) 
Reconstruction 
with an allograft 
tendon (tibialis 
posterior) 
X-ray, CT-scan, KT1000 
[Time frame: 12 months] 
July 2015 University 
Hospital, 
Ghent 
NCT01245400 Patients with 
Ruptured Anterior 
Cruciate Ligaments 
Randomised 
controlled trial: single 
group assignment, 
quadruple masking 
(participant, care 
provider, investigator, 
outcome assessor 
60 Z-Lig Anterior 
Cruciate Ligament 
Reconstruction 
(ACLR) graft 
implantation 
performed under 
anesthesia during 
an arthroscopic 
procedure. 
Allograft bone/ 
tendon graft 
implantation 
performed under 
anaesthesia 
during an 
arthroscopic 
procedure. 
KT-1000 [Time 
frame: baseline, 3,6, 12 &  
24 months ] 
April 2014 Aperion 
Biologics, 
Inc. 
NCT00975845 Patients with 
Anterior Cruciate 
Ligament Rupture 
Prospective cohort 
study 
43 BioCleanse Tibialis 
Tendon Allograft 
- Objective International Knee 
Documentation Committee 
(IKDC) Exam [Time frame: 
pre-op, 2 months, 4 months, 
6 months, 12 months,  
24 months] 
November 2017 RTI 
Surgical 
 
Table A-12: List of ongoing trials of allografts for PCLR 
Identifier/ 
Trial name Patient population Study design 
Number  
of patients Intervention Comparison Primary outcome 
Primary 
completion date Sponsor 
NCT00991588 Complete ruptures to 
the posterior cruciate 
ligament (PCL) and 
posterolateral 
structures of the  
knee joint 
Prospective cohort 
study 
20 Procedure: PCL, 
posterolateral 
reconstruction 
- Elimination of knee giving-
way [Time frame: Minimum 
2 years postoperatively] 
December 2019 Sue Barber-
Westin 
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Table A-13: List of ongoing trials of allografts in multi-ligament knee injuries 
Identifier/ 
Trial name Patient population Study design 
Number  
of patients Intervention Comparison Primary outcome 
Primary 
completion date Sponsor 
NCT01440348 Rupture of 
Posterior Cruciate 
Ligament|Rupture 
of Anterior Cruciate 
Ligament 
Intervention Model: 
Single Group 
Assignment|Masking: 
None (Open 
Label)|Primary 
Purpose: Treatment 
51 Procedure: cruciate 
ligament 
reconstruction 
- circumference and length of the 
Achilles allograft [Time frame: 
day 1] 
September 2011 National 
Police 
Hospital 
 
Table A-14: List of ongoing trials of allografts in revision cruciate ligament reconstruction  
Identifier/ 
Trial name 
Patient  
population 
Study  
design 
Number  
of patients Intervention Comparison Primary outcome 
Primary 
completion date Sponsor 
UMIN000003599 Re-injury after the 
anterior cruciate 
ligament 
reconstruction 
Single arm, non-
randomised open 
label uncontrolled 
study 
196 Re-reconstruction 
of ligament with 
allogenic graft 
- Knee function and safety NR Department 
of Ortho-
paedic 
Surgery, 
Shimane 
University 
ACTRN126120006
31808 
Patients 
undergoing ACL 
reconstruction 
Prospective 
uncontrolled 
longitudinal study 
100 Anterior Cruciate 
Ligament (ACL) 
reconstruction with 
Live Donor 
Allograft 
- Clinical and subjective outcome as 
assessed by the International Knee 
Documentation Committee 
(IKDC) Evaluation, KT1000 
arthrometer, Lysholm 
Knee Score, effusion, and kneeling 
pain (time point: 2 years) 
NR Friends of 
the Mater 
Foundation 
 
 
                                                             
96 The number of patients may have been incorrectly entered in the database. The description of the study leads to the impression that this study is not a case report. 
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Literature search strategies 
Search strategy for Cochrane 
ID Search 
#1 (cruciate ligament*) (Word variations have been searched) 
#2 MeSH descriptor: [Anterior Cruciate Ligament Injuries] explode all trees 
#3 MeSH descriptor: [Posterior Cruciate Ligament] explode all trees and with qualifier(s): [injuries – IN] 
#4 ((knee* NEAR ligament* NEAR (defect* or injur* or lesion* or rupture* or rerupture* or re-rupture* or tear* 
or dislocat* or damage*))) (Word variations have been searched) 
#5 (multiligament* knee*) (Word variations have been searched) 
#6 (multi*ligament* knee*) (Word variations have been searched) 
#7 #1 OR #2 OR #3 OR #4 OR #5 OR #6 (Word variations have been searched) 
#8 MeSH descriptor: [Allografts] explode all trees 
#9 (Allograft*) (Word variations have been searched) 
#10 MeSH descriptor: [Transplantation, Homologous] explode all trees 
#11 ("allogeneic transplant*") (Word variations have been searched) 
#12 #8 OR #9 OR #10 OR #11 (Word variations have been searched) 
#13 MeSH descriptor: [Anterior Cruciate Ligament Reconstruction] explode all trees 
#14 MeSH descriptor: [Posterior Cruciate Ligament Reconstruction] explode all trees 
#15 (ligament* NEAR reconstruct*) (Word variations have been searched) 
#16 ((ACL or PCL) NEAR (repair* or reconstruct*)) (Word variations have been searched) 
#17 (ACLR):ti,ab,kw (Word variations have been searched) 
#18 (PCLR):ti,ab,kw (Word variations have been searched) 
#19 #13 OR #14 OR #15 OR #16 OR #17 OR #18 (Word variations have been searched) 
#20 #12 AND #19 (Word variations have been searched) 
#21 (allograft* NEAR (ligament* NEAR (repair* or reconstruct*))) (Word variations have been searched) 
#22 (allograft* NEAR (repair* or reconstruct*)) (Word variations have been searched) 
#23 #20 OR #21 OR #22 
#24 #7 AND #23 
Total: 117 Hits 
 
 
Search strategy for CRD 
ID Search 
1 MeSH DESCRIPTOR Allografts EXPLODE ALL TREES 
2 (allograft*) 
3 MeSH DESCRIPTOR Transplantation, Homologous EXPLODE ALL TREES 
4 (allogeneic) 
5 (allogenic) 
6 #1 OR #2 OR #3 OR #4 OR #5 
7 MeSH DESCRIPTOR Anterior Cruciate Ligament Reconstruction EXPLODE ALL TREES 
8 MeSH DESCRIPTOR Posterior Cruciate Ligament Reconstruction EXPLODE ALL TREES 
9 (ligament* NEAR reconstruct*) 
10 ((ACL or PCL) NEAR (repair* or reconstruct*)) 
11 (ACLR) 
12 (PCLR) 
Appendix 
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13 #7 OR #8 OR #9 OR #10 OR #11 OR #12 
14 #6 AND #13 
15 (allograft* NEAR (ligament* NEAR (repair* or reconstruct*))) 
16 (allograft* NEAR (repair* or reconstruct*)) 
17 #14 OR #15 OR #16 
Total: 22 Hits 
 
 
Search strategy for Embase 
Session Results 
No. Query Results  Results Date 
#31. #28 OR #30 181 18 Dec 2018 
#30. #27 AND #29 162 18 Dec 2018 
#29. 'crossover procedure':de OR 'double-blind procedure':de OR 'randomized 
controlled trial':de OR 'single-blind procedure':de OR random*:de,ab,ti OR 
factorial*:de,ab,ti OR crossover*:de,ab,ti OR ((cross NEXT/1 over*):de,ab,ti) OR 
placebo*:de,ab,ti OR ((doubl* NEAR/1 blind*):de,ab,ti) OR ((singl* NEAR/1 
blind*):de,ab,ti) OR assign*:de,ab,ti OR allocat*:de,ab,ti OR volunteer*:de,ab,ti 
2,331,671 18 Dec 2018 
#28. #8 AND #26 AND ([controlled clinical trial]/lim OR [randomized controlled 
trial]/lim) 
87 18 Dec 2018 
#27. #8 AND #26 1,443 18 Dec 2018 
#26. #23 OR #24 OR #25 4,091 18 Dec 2018 
#25. (allograft* NEAR/5 (repair* OR reconstruct*)):ti,ab,de 3,328 18 Dec 2018 
#24. (allograft* NEAR/5 ligament* NEAR/5 (repair* OR reconstruct*)):ti,ab,de 672 18 Dec 2018 
#23. #14 AND #22 1,574 18 Dec 2018 
#22. #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 16,394 18 Dec 2018 
#21. 'knee ligament surgery'/exp 8,975 18 Dec 2018 
#20. pclr:ti,ab 43 18 Dec 2018 
#19. aclr:ti,ab 1,078 18 Dec 2018 
#18. ((acl OR pcl) NEAR/1 (repair* OR reconstruct*)):ti,ab,de 8,442 18 Dec 2018 
#17. (ligament* NEAR/1 reconstruct*):ti,ab,de 14,38 18 Dec 2018 
#16. 'posterior cruciate ligament reconstruction'/exp 543 18 Dec 2018 
#15. 'anterior cruciate ligament reconstruction'/exp 8,221 18 Dec 2018 
#14. #9 OR #10 OR #11 OR #12 OR #13 135,928 18 Dec 2018 
#13. 'allogenic transplant*':ti,ab,de 724 18 Dec 2018 
#12. 'allogeneic transplant*':ti,ab,de 7,823 18 Dec 2018 
#11. 'allotransplantation'/exp 35,383 18 Dec 2018 
#10. 'allograft*':ti,ab,de 102,644 18 Dec 2018 
#9. 'allograft'/exp 38,808 18 Dec 2018 
#8. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 28,634 18 Dec 2018 
#7. 'multiligament knee*':ti,ab,de 89 18 Dec 2018 
#6. 'multi-ligament knee*':ti,ab,de 27 18 Dec 2018 
#5. 'multiligament knee injury'/exp 11 18 Dec 2018 
#4. ('cruciate ligament*' NEAR/5 (defect* OR injur* OR lesion* OR rupture* OR 
rerupture* OR 're-rupture*' OR tear* OR dislocat* OR damage*)):ti,ab,de 
13,794 18 Dec 2018 
#3. 'cruciate ligament*':ti,ab,de 28,57 18 Dec 2018 
#2. 'posterior cruciate ligament injury'/exp 238 18 Dec 2018 
#1. 'anterior cruciate ligament injury'/exp 8,189 18 Dec 2018 
Allograft for anterior and posterior cruciate ligament reconstruction 
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Search strategy for Medline 
Database: Ovid MEDLINE(R) <1946 to December Week 1 2018>, Ovid MEDLINE(R) Epub Ahead of Print  
<December 17, 2018>, Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations <December 17, 2018>,  
Ovid MEDLINE(R) Daily Update <December 17, 2018> 
Search Strategy: 
1 cruciate ligament*.mp. (22511) 
2 exp Anterior Cruciate Ligament Injuries/ (8582) 
3 exp *Posterior Cruciate Ligament/in [Injuries] (567) 
4 (knee* adj5 ligament* adj5 (defect* or injur* or lesion* or rupture* or rerupture* or re-rupture* or tear* or 
dislocat* or damage*)).mp. (2154) 
5 multi* ligament* knee*.mp. (58) 
6 multiligament* knee*.mp. (117) 
7 1 or 2 or 3 or 4 or 5 or 6 (23447) 
8 exp Allografts/ (6321) 
9 allograft*.mp. (66706) 
10 exp Transplantation, Homologous/ (83841) 
11 allogen?ic transplant*.mp. (4932) 
12 8 or 9 or 10 or 11 (128836) 
13 exp Anterior Cruciate Ligament Reconstruction/ (3818) 
14 exp Posterior Cruciate Ligament Reconstruction/ (44) 
15 (ligament* adj reconstruct*).mp. (10356) 
16 ((ACL or PCL) adj (repair* or reconstruct*)).mp. (7019) 
17 ACLR.ti,ab. (844) 
18 PCLR.ti,ab. (43) 
19 13 or 14 or 15 or 16 or 17 or 18 (12772) 
20 12 and 19 (1172) 
21 (allograft* adj5 (ligament* adj5 (repair* or reconstruct*))).mp. (365) 
22 (allograft* adj5 (repair* or reconstruct*)).mp. (2528) 
23 (surg* adj reconstruct*).mp. (4678) 
24 20 or 21 or 22 or 23 (7796) 
25 7 and 24 (1467) 
26 limit 25 to clinical trial, all (120) 
27 ((randomized controlled trial or controlled clinical trial).pt. or randomi#ed.ab. or placebo.ab. or drug 
therapy.fs. or randomly.ab. or trial.ab. or groups.ab.) not (exp animals/ not humans.sh.) (3765350) 
28 25 and 27 (359) 
29 26 or 28 (384) 
30 remove duplicates from 29 (384) 
31 (knee* adj5 ligament* adj5 (defect* or injur* or lesion* or rupture* or rerupture* or re-rupture* or tear* or 
dislocat* or damage*)).mp. (2154) 
32 1 or 2 or 3 or 5 or 6 or 31 (23447) 
33 24 and 32 (1467) 
34 limit 33 to clinical trial, all (120) 
35 27 and 33 (359) 
36 34 or 35 (384) 
Search date: 18.12.2018 
 
 

  
 
